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Abstract 
 
Nephrotic syndrome is a heterogeneous group of disorders characterised by renal and 
extra-renal manifestations. Classic symptoms of nephrotic syndrome include severe 
proteinuria, hypoalbumiaemia, oedema and hyperlipidaemia.  
Genetic studies of hereditary forms of nephrotic syndrome have led to the identification 
of proteins playing a crucial role in slit diaphragm signalling, regulation of actin 
cytoskeleton dynamics and cell-matrix interactions.  
The laminin α5 chain is a 404 kDa protein essential for embryonic development and, in 
association with laminin β2 and laminin γ1, it is a major component of the glomerular 
basement membrane. Mutations in LAMB2 are associated with Pierson’s syndrome and 
mutations in LAMA5 have recently been identified in paediatric patients affected by 
nephrotic syndrome.  
As part of the MRC Harwell Ageing Screen, a large-scale ENU mutagenesis screen, a 
novel missense mutation (E884G) was identified in the gene Lama5. Homozygous mice 
showed a nephrotic phenotype including a severe proteinuria that preceded histological 
and ultrastructural changes. Further investigation using in vitro studies, extensive 
proteomics analysis and investigation of integrin activation, revealed a possible impact 
of the causative mutation on protein folding. Data suggest that changes in protein 
structure lead to a reduced secretion, integrin β1 activation, and agrin expression 
ultimately resulting in possible instability of the podocyte actin cytoskeleton.   
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Introduction  
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1. Introduction 
1.1 The Kidney 
The kidneys have essential roles in keeping the chemical-physical components of the 
interior milieu (plasma and interstitial fluid) constant, including the removal of 
catabolites and exogenous substances from the circulation, the control of the 
extracellular fluid and regulation of the pH of the blood and of the concentration of the 
ions.  
The functional unit of the kidney is the nephron composed of: a blood-filtering 
component, the renal corpuscle, consisting of the glomerulus (a capillary network) and 
a capsule (Bowman’s capsule) that encapsulates the capillary tuft; and a tubular network 
(divided in the segments proximal convoluted tubule, loop of Henle, distal convoluted 
tubule and connecting tubule) containing the tubular fluid filterated in the glomerulus 
(Figure 1.1). 
 
Figure 1.1. A schematic representation of the nephron. In black the glomerulus, the filtering unit of the 
kidney. In red the proximal tubule, in blue the loop of Henle, in green the distal tubule and in yellow the 
collecting duct: in these structures, the pre-urine is concentrated based on the needs of the bodies. The 
collecting duct terminates in the bladder where urine is collected. 
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Blood enters the glomerulus via the afferent arteriole and flows into the glomerulus 
where it is filtered, producing the ultrafiltrate that accumulates in the Bowman’s space. 
Filtered blood exits the glomerulus via the efferent arteriole while the ultrafiltrate 
progresses through the tubular network where it is modified and concentrated 
becoming urine. In a healthy human kidney, the average nephron number is 
approximately 900,000 to 1 million per kidney[1] and about 20% of the total cardiac 
output (filtration fraction) will enter the kidneys to undergo filtration[2]. 
Additionally, the kidneys also have important endocrine functions, secreting hormones 
with systemic actions such as renin and erythropoietin and activating calcitriol. Renin is 
involved in the renin-angiotensin-aldosterone signalling axis that controls blood 
pressure. Calcitriol, the active metabolite of vitamin D, is involved in the reabsorption of 
calcium in the intestine and the kidney and the release of calcium from the bone, 
increasing the blood calcium levels. Erythropoietin stimulates erythropoiesis in the bone 
marrow. Impairment of the kidney function during disease compromises all these vital 
processes.  
 
1.1.2 The glomerular Filtration Barrier: constituents and function 
The glomerular filtration barrier (GFB) is a layered structure between the vasculature 
and Bowman’s space that functions as a barrier between the bloodstream and the urine. 
Small solutes (e.g. urea, mineral ions) and water can easily traverse the highly 
permselective GFB whilst high molecular weight components of the plasma, like albumin 
and circulating cells, are retained in the blood, making the resulting urine virtually free 
of protein[2].  
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Three layers form the GFB (Figure 1.2): the two cellular layers, fenestrated endothelial 
cells and epithelial podocyte, are separated by a specialized extracellular matrix (ECM), 
the glomerular basement membrane (GBM), with the properties of a viscous gel, 
originating from the fusion of a basement membrane synthesized by the podocytes and 
the one synthesized by the endothelial cells [3-5]. 
 
 
 
Figure 1.2. A diagram representing the three different layers of the GFB. From the capillary lumen to the 
urinary space (or Bowman space), the blood is filtered passing through the endothelium, the GBM 
(produced by both endothelial cells and podocytes and composed primarily of type IV collagen and 
laminin) and the space between interdigitating podocyte foot processes. Figure adapted from Suh et al.[6]. 
 
1.1.2.1 Glomerular Endothelial cells 
The glomerular endothelium is the first layer of the GFB to act as a barrier to the passage 
of fluid and macromolecules. The glomerular endothelium has the peculiar aspect of 
being perforated with transcellular pores, fenestrae, of ~60 nm in diameter that allow 
the passage of fluid across the cell layer [2, 5] and constitute 20-50% of the entire 
5 
 
endothelial surface [7]. The fenestrations are too large to influence blood filtration as 
albumin, which is restricted by the glomerular wall, is only 3.6 nm in diameter [5]. 
However, the glomerular endothelium still plays an active role in renal filtration due to 
the presence of the glycocalyx on their luminal face, a 200 nm thick extracellular 
structure consisting of glycosaminoglycans, sialic acids and hyaluronan [8]. It has 
previously been hypothesised that the negative charge of the glycocalyx would 
electrically repel the negatively charged albumin [8], however, more recent studies have 
since challenged this hypothesis [9]. More likely, the glycocalyx components 
(glycosaminoglycans or GAGs), form a broader coat called the endothelial surface layer 
and bind plasma proteins, creating steric hindrance to protein filtration [8] and making 
the pores narrower and more restrictive.  
 
1.1.2.2 Glomerular Basement Membrane 
The ECM is a non-cellular component that provides structural and biochemical support 
to cell layers (in organs and tissues) in the form of a basement membrane, and single 
cells as substrate for cell mobility [10]. In the glomerulus, the GBM is synthesized by both 
podocytes and endothelial cells, with mesangial cells playing a role in turnover [11]. 
Unlike the other basement membranes, GBM is thicker and constantly exposed to flow 
and pressure, hence it needs to maintain its structural integrity [12]. The main 
components are the same as found in all the other basement membranes, but some of 
the isoforms of its macromolecules are specific to individual types of basement 
membrane [3]. The GBM contains: 
Type IV Collagen. The collagen IV family is the major structural component of basement 
membranes and consists of six homologous α-chains (α1-α6) encoded by six different 
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genes COL4A1-COL4A6 [13]. Each α-chain contains a long collagenous region of repeated 
Gly-Xaa-Yaa amino acid triplets, which give the chains stability, but with numerous 
interruptions that provide flexibility to the protomers. The protomers are linked to each 
other by cysteine and lysine-rich 7S domain (non-collagenous NH2-terminal domain) 
and NC1 (non-collagenous COOH-terminal domain) [3]. The six α-chains can create only 
three types of network because of the information present within the NC1 domain 
sequence [14]: α1α1α2, α3α4α5 and α5α5α6. The distribution of the networks differs 
according to the developmental stage and organ: during embryogenesis the α1α1α2 
network is ubiquitous and expressed in all basement membranes of immature nephrons 
[15] but in infancy it is replaced by the α3α4α5 network in kidney (glomerular basement 
membranes), cochlea, eye, lung and testis, and by α5α5α6 in skin, smooth muscle, 
oesophagus and Bowman’s capsule[16].  
Mutations in any of the genes that encode for a chain of the α3α4α5 network (COL4A3, 
COL4A4, COL4A5) arrest its normal maturation resulting in the incorrect assembly of the 
monomers and the related pathological condition arising from it is known as Alport’s 
syndrome. This disease is characterised by a renal component consisting of haematuria, 
proteinuria, progressive kidney failure, and extrarenal phenotypes, primarily hearing 
loss and ocular disorders [17, 18].  
Laminin. Laminins are a family of self-assembling glycoproteins made up of at least 15 
different αβγ heterometric macromolecules [4]. The major laminin heterotrimer in the 
mature GBM is laminin α5β2γ1 and it is secreted by podocytes and endothelial cells [3]. 
Most laminin heterotrimers are cross-shaped macromolecules; the “long arm” is formed 
by the association of the α, β and γ chains via coiled-coil interaction and disulphide 
bonding [3], the three “short arms” contain LN domains (NH2-terminal globular domains) 
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which mediate the trimer-trimer interactions [3]. The α-subunit is largely responsible for 
the cell surface adhesion and receptor interaction as well as contributing to self-
assembly, while the β- and γ- subunits play a structural role and modulate receptor-
binding [19]. Laminins serve as major adhesive proteins and mediate cell adhesion to 
basement membranes [20].  
Mutations in the LAMB2 gene, encoding the laminin β2 chain, cause disorders with a 
vast clinical spectrum. Truncating mutations lead to Pierson syndrome, characterized by 
microcoria, congenital nephrotic syndrome, muscular hypotonia and 
neurodevelopmental defects [21-23], whilst missense variants cause a much milder variant 
of Pierson syndrome or isolated congenital nephrotic syndrome [24].  
Additional components. Laminin and collagen IV are linked in an indirect fashion via 
heparin sulphate proteoglycans (HSPGs) [25] and nidogens [26]. The matrix consists of a 
protein core with covalently linked glycosaminoglycan side chains that are frequently 
modified by sulfation, giving an anionic charge to the proteoglycan and consequently to 
the basement membrane [3]. Unlike all the other basement membranes where the most 
common HSPG is perlecan, the human GBM contains primarily agrin [27], deletion of 
which in mice significantly reduces the negative charge in the GBM but does not cause 
proteinuria, suggesting that the GBM has a limited role in charge selection during 
filtration [28]. Nidogen-1 and nidogen-2 are two proteins bound to the laminin γ1 chain 
short arm as well as to type IV collagen [26]. Double nidogen knock-out causes perinatal 
lethality in mice [29], however, it does not lead to defects of the GBM suggesting that 
nidogens are not crucial for its formation, but might increase its strength against 
mechanical stress.  
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Basement membranes self-assemble in a multi-step process that is initiated by the 
binding of laminin to a competent cell surface through the anchoring of the laminin LG 
domains to integrins and dystroglycan. This interaction promotes laminin 
polymerization through its LN domain[19]. The initial laminin-cell interaction enables the 
accumulation of other ECM components with nidogens binding and forming a stabilizing 
bridge between laminins and type IV collagen and giving input for the polymerization of 
the latter [19].  In the kidney, an in vivo Stochastic Optical Reconstruction Microscopy 
(STORM) study showed the presence of two layers of laminin-521, one on the 
endothelium side and one on the podocyte side. In each layer, the proteins are oriented 
with their C-terminal LG domains close to the cell membrane, while the LN domains and 
short arm are localised toward the middle of the GBM as is type IV collagen [30].  
 
1.1.2.3 Podocytes  
As highly specialized epithelial cells, podocytes encapsulate the outer aspect of the 
glomerular capillaries facing the Bowman’s capsule. The cell body is detached from the 
underlying GBM and is made of an actin-cytoskeleton organised into stress fibres that 
control mobility and contraction. From the cell body start long primary processes (major 
processes) reinforced by microtubules and intermediate filaments [2, 31], and the 
secondary foot processes which emerge at right angles to the primary processes and 
mediate the adhesion with the GBM [32].  
Foot processes are actin-rich projections that are embedded into and bind the GBM via 
cell surface focal adhesion proteins, like α3β1 integrin and α-/β-dystroglycans, to 
guarantee the stability of the podocyte [2, 33]. The foot process cytoskeleton is structured 
so it can oppose the high pressure in the capillary wall; the actin network is made of 
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contractile, highly ordered parallel filament bundles that change the morphology of the 
foot processes modulating the permeability of the GFB [34] and are regulated by 
synaptopodin[35].  
Actin stress fibres of the cell body and actin filament bundles of the foot process are 
regulated respectively by tropomyosin and synaptopodin and are both modulated by 
small GTPases protein of the Rho family and calcium levels [35]. 
Adjacent podocytes foot processes interdigitate with those of neighbouring podocytes 
and form a tight junction, called the slit diaphragm, that maintains a specific pore size 
such that only molecules smaller than 50 kDa can traverse the filtration barrier and enter 
the urinary space [36]. The extracellular segment of the slit diaphragm is made up of rod-
like units connected to the central linear bar so to form a zipper-like substructure with 
pores [34]. In addition to the slit diaphragm, the foot processes have two other functional 
membrane domains; the apical membrane domain and the basal membrane domain, or 
sole plate, which associates with the GBM. As with the slit diaphragm, these other two 
domains are also physically associated with the foot process actin bundles [34]. 
Any interference with any of the membrane domains perturbs the actin cytoskeleton, 
actively changing the organised parallel and contractile bundles into a dense network. 
The manifestation of these modifications is foot process effacement and related 
proteinuria. 
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1.1.3 Other Cells of the Glomerulus 
1.1.3.1 Mesangial Cells 
The mesangial cells are specialised pericytes, contractile cells that wrap around the 
endothelial cells, which constitute ∼30% of all glomerular cells,  and play a central role 
in stabilizing and maintaining the structural architecture of the glomerulus forming a 
central stalk [37]. They are embedded in their own extracellular matrix, the mesangium 
that differs in composition from the glomerular basement membrane. The main 
constituents of the mesangium are α1α1α2 type IV collagen, α5β1γ1 laminin, 
fibronectin, HSPGs and nidogen. The glomerular vascular structure is maintained with a 
cross-talking between mesangial cells and endothelial cells via platelet-derived growth 
factor (PDGF) signalling as indicated by the lack of mesangial cells and abnormal 
glomerular structure in knock-out mice of PDGF and its receptor PDGFR-β [38-40]. 
Given their contractile proprieties, mesangial cells can regulate capillary flow and 
ultrafiltration surface and, consequently, glomerular filtration rate [41] producing factors 
like vascular endothelial growth factor (VEFG) [42], transforming growth factor β1 (TGF-
β1) [43] and connective tissue growth factor  (CTGF) [44].  
In a number of glomerulopathies, the mesangial cells tend to proliferate and the 
mesangium expands as is typically seen during diabetic nephropathy [45]. A similar 
finding is also seen during lupus nephritis and mesangioproliferative glomerulonephritis 
[46] like IgA nephropathy, a disease caused by the deposition of aberrant glycosylated IgA 
in the mesangium causing proteinuria [47].  
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1.1.4 Filtration models 
In a lifetime, humans produce more than 4 million litres of virtually protein-free urine 
thanks to the sieving process of the glomeruli. How the GFB manages to clear more than 
250,000 kg of plasma proteins without clogging even in old age is still unknown [48]. 
Understanding the filtration mechanism is necessary to understand the pathogenesis of 
proteinuria, the hallmark of glomerular diseases.  
Several hypotheses have been suggested to explain the sieving function of the 
glomerulus. The main models are the pore model, the gel permeation hypothesis and 
the albumin retrieval hypothesis. 
 
1.1.4.1 The pore model 
It is well established that for neutral solutes, the glomerular sieving coefficients become 
smaller with increasing molecular size [5]. The simplest model, the “pore model”, 
describes the GFB as a passive mechanical sieve consisting in a series of pores, with the 
podocyte slit diaphragm acting as the main size excluding layer, given the small size of 
its pores [49]. However, it was further observed that when the renal plasma flow is 
arrested, albumin is found in the Bowman space, but the glomerular architecture is 
preserved [50]. Since it was then clear that haemodynamics plays a role in glomerular 
filtration, the pore model included convection as a major force responsible for albumin 
sieving. The convective flux is driven by the drag of the flow of water across the GFB and 
it is proportional to the hydraulic pressure difference [48]. When the flow stops, diffusion 
of albumin is driven by the concentration difference within the capillary and the primary 
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filtrate in the Bowman’s space [48]. However, the pore model does not explain why the 
GFB does not clog.  
 
1.1.4.2 The gel permeation hypothesis 
In this model, the GBM is assumed to be very similar to a gel and it is almost exclusively 
acting as the selectively filtrating layer of the kidney [51]. As in the pore model, 
convection and diffusion are the two main forces responsible for the albumin flux, and 
proteinuria occurs when the filtration rate of water is reduced, while the diffusive flux 
of albumin remains constant [48]. However, this model does not explain why 
podocytopathies and/or endothelial alterations lead to proteinuria. 
 
1.1.4.3 The albumin retrieval hypothesis 
Some researchers have suggested that the GFB is more permeable to albumin than 
previously proposed [52]. The larger amounts of albumin (about 8% instead of 0.02-
0.06%) would actually pass the filter and be reabsorbed (i.e. retrieved) by tubular cells 
[48, 53]. Proteinuria would, therefore, be considered a symptom of tubulopathy. This 
hypothesis is very controversial and not widely accepted [48]. 
 
1.1.4.4 The electrokinetic model 
Based on the measurement of an electric field of –0.045 mV per 10 cm water cross the 
GFB of Necturus maculosus (common mudpuppy) [54], this recently proposed model 
suggests the existence of an electric field (also called filtration-dependent potential or 
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streaming potential), generated across the GFB. This electric field is produced by the 
forced filtration of plasma, which is an ionic solution containing small cations (sodium, 
potassium and calcium) and anions (chloride and bicarbonate), through an electrically 
charged barrier such as the GFB [48]. The streaming potential, that has an extrapolated 
measurement of 0.1-0.5 mV at 5mmHg effective filtration pressure in mammalian 
kidneys [55], influences the passage of albumin (negatively charged) across the GFB, 
dragging it towards the capillary lumen by electrophoresis, preventing the clogging [48]. 
Any insult that impairs homogeneous filtration will interfere with the generation of a 
homogeneous streaming potential and result in proteinuria [56].    
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1.2 Nephrotic Syndrome 
Nephrotic syndrome is a heterogeneous group of disorders characterized by renal and 
extrarenal manifestations. Of all the symptoms, a severe proteinuria (greater than 3.5 
g/24h) is the cornerstone reflecting a dysfunction of the normally highly permselective 
GFB. The other cardinal alterations of nephrotic syndrome include hypoalbuminemia, 
oedema, hyperlipidemia and lipiduria. Hypercoagulability is also frequently associated 
with nephrotic syndrome. 
 
1.2.1 Pathophysiology of Nephrotic Syndrome 
Proteinuria. Under normal circumstances, the GFB of the glomerular capillary wall 
prevents the passage of larger plasma components, in particular albumin, into the urine. 
A proteinuric disease is usually associated with a structural or functional defect of this 
barrier; in most nephrotic diseases, the major defect is associated with podocyte injury 
and dysfunction and/or loss of anionic charge in the GBM (loss of charge selectivity).  
Hypoalbuminemia. Hypoalbuminaemia is predominantly due to the of loss protein in the 
urine. In response, the liver increases albumin production, but this is insufficient to 
prevent the fall in serum albumin concentration. The liver also responds by increasing 
the hepatic protein production in a non-specific way (producing proteins other than 
albumin) and therefore the serum concentration of total proteins in patients with 
nephrotic syndrome may be normal or increased. The consequences of this non-specific 
protein production include other typical alterations of nephrotic syndrome, 
hypercholesterolaemia and hypercoagulability. 
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Oedema. The physiopathology of oedema in nephrotic syndrome is not clear yet. There 
are two main theories, the “underfill model” and the “overfill model”. In the underfill 
model, the hypoalbuminaemia results in reduced plasma oncotic pressure and promotes 
the translocation of fluid from the vascular compartment into the extracellular fluid 
compartment. The activation of the renin-angiotensin-aldosterone system and the 
inhibition of secretion of the atrial natriuretic peptide (ANP), leads to secondary renal 
sodium retention that complicates oedema. According to the “overfill model”, the 
oedema is due to an intrinsic defect of the kidney affected by nephrotic syndrome 
leading to a primary renal sodium retention, which in turn causes expansion in plasma 
volume. 
Hyperlipidaemia. The plasma levels of cholesterol, triglycerides and different 
lipoproteins (very low-density lipoproteins – VLDL, low-density lipoproteins – LDL, high-
density lipoproteins – HDL) can be elevated in nephrotic patients. These abnormal 
concentrations result from impaired clearance of cholesterol and lipoproteins due to the 
increased expression and activity of acyl-CoA cholesterol acyltransferase-2 in the liver. 
This results in enhanced esterification of cholesterol and reduction of intracellular free 
cholesterol and by a deficiency of LDL receptor leading to a reduction in cholesterol 
uptake [57].   
 
1.2.2 Classification of Nephrotic Syndrome 
Nephrotic syndrome is a nonspecific kidney disorder caused by a damage to the 
glomeruli and has many causes, which can be limited to the kidney (primary nephrotic 
syndrome), or a systemic condition that affects the kidney (secondary nephrotic 
syndrome). Among secondary causes, type I and II diabetes are the most frequent 
16 
 
aetiology in adults. Other systemic diseases such as lupus erythematosus, amyloidosis, 
hepatitis B and C, HIV and systemic amyloidosis can also be associated with glomerular 
disorders causing nephrotic syndrome [58]. 
It is possible to classify nephrotic syndrome using several methodologies such as 
histopathological criteria, time of onset and response to pharmacological therapy. 
Based on histopathological criteria, nephrotic syndrome is classified by the three most 
common histopathological patterns:  
Minimal change disease (MCD). MCD is characterised by the presence of normal-
appearing glomeruli on light microscopy whilst electron microscopy shows effacement 
and detachment of the foot processes [59]. It is the most common cause of primary 
nephrotic syndrome in children accounting for 70-90% of nephrotic syndrome cases in 
patients under 10 years old and 50% in children older than 10 years [60]. However, MCD 
is also an important cause of disease in adults, accounting for 10-15% of all nephrotic 
syndrome in older patients [60].  
Focal Segmental Glomerulosclerosis (FSGS). FSGS is characterised by involvement of less 
than 50% of the glomeruli (focal) with sclerotic segments that affect only part of the 
glomerulus (segmental) and usually contain IgM and C3 deposits [59]. Primary FSGS is 
usually idiopathic although 20% of cases are familial with a significant racial/ethnic 
predilection. In the USA incident rates, expressed as patients per million, were 6.8 in 
African Americans, 3.7 in Hispanics, and 1.9 in Caucasians [61]. Secondary FSGS can have 
several causes including HIV infection, heroin use or obesity.  
Idiopathic Membranous Glomerulopathy (IMN). IMN is characterised by 
histopathological features of subepithelial immune-complex deposits and subsequent 
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thickening of glomerular basement membrane with IgG and C3 deposits.  [62]. It is more 
common in males with an incidence that peaks at 30-50 years of age [59].  
Based on the age of disease onset, nephrotic syndrome can be classified as congenital 
(if the disease manifests itself within the first 3 months of life), infantile (if the 
presentation occurs between 4 or 12 months of age) and late-onset (or acquired, when 
the onset is after the first year of life, more frequently during adolescence or adulthood). 
Although the majority of congenital and infantile nephrotic syndrome cases are due to 
genetic defects in the components of the GFB, the disease could also be secondary to 
viral infection, maternal systemic lupus erythematosus or maternal steroid-
chlorpheniramine treatment [63].  
Based on the response to pharmacological therapy based on glucocorticoids, nephrotic 
syndrome can be classified as steroid-sensitive (the most common eventuality, the use 
of glucocorticoids will induce disease remission, hence the prognosis for the patient is 
favourable) or steroid-resistant (patients are more prone to complications and more 
likely to progress to ESRD). 
 
1.2.3 Genetics of Nephrotic Syndrome 
Genetic studies of hereditary forms of nephrotic syndrome have led to the identification 
of a number of proteins playing a crucial role in slit diaphragm signalling, regulation of 
actin cytoskeleton dynamics and cell-matrix interactions. A genetic cause is often found 
in cases of congenital, infantile and steroid-resistant nephrotic syndrome, but more 
rarely found in steroid-sensitive forms. The causative mutations are high-penetrance 
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variants that manifest with either Mendelian inheritance, for nuclear genes, or maternal 
inheritance, for genes encoded by mitochondrial DNA (Figure 1.3). 
 
Figure 1.3. Genes known to be the cause of nephrotic syndrome in humans and distribution of their 
encoded proteins in the GFB. These include components of the GBM and ECM adhesion, proteins that 
regulate F-actin network, transcription factors and components of the slit diaphragm. Image adapted from 
Lennon et al. [64]. 
 
The majority of causative mutations responsible of congenital or infantile nephrotic 
syndrome occur in one of these five genes: nephrin (NPHS1), podocin (NPHS2), Wilms’ 
tumour 1 (WT1), laminin β2 chain (LAMB2) and phospholipase C epsilon-1 (PLCE1). Of 
these main genes, NPHS1 is the most commonly implicated in congenital nephrotic 
syndrome and it is the cause of autosomal recessive of the Finnish type, a very 
aggressive form that manifests with massive proteinuria and rapid deterioration of 
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kidney function leading to end stage renal disease (ESRD) [65]. Rarer hypomorphic 
mutations in this gene are associated with a milder phenotype and later onset [66]. 
Mutations in NPHS2 are the most common cause of autosomal recessive nephrotic 
syndrome in older paediatric patients, with an average age of onset of 6 years old. [67, 
68]. Mutations in PLCE1 are also a relatively common cause of infantile nephrotic 
syndrome, presenting severe proteinuria and rapid progression to ESRD [66].  
Autosomal dominant mutations in α-actinin 4 (ACTN4,) inverted formin 2 (INF2,) and 
transient receptor potential cation channel (TRPC6) are the main causes of late-onset 
FSGS [66].  
Mutations in other genes associated with nephrotic syndrome can also result in extra-
renal manifestations. WT1 is a gene relatively commonly involved in congenic and 
infantile nephrotic syndrome, but mutations resulting in splice insertion and missense 
variants in exons 8 and 9, lead respectively to Frasier syndrome and Denys-Drash 
syndrome (nephrotic syndrome associated with male-to-female sex reversal, 
gonadoblastoma) [69]. Mutations in LIM homebox transcription factor 1 β (LMX1B) are 
responsible for isolated nephrotic syndrome as well as Nail-Patella syndrome (poor 
development of nails, kneecaps, elbows and pelvis) [70, 71]. Nephrotic syndrome can also 
be a manifestation of mutations in mitochondrial or nuclear-encoded mitochondrial 
proteins as part of a wider symptomatology like MELAS (myopathy, encephalopathy, 
lactic acidosis and stroke-like episodes) caused by mutations in mitochondrially encoded 
tRNA leucine 1 (MTTL1),. Coenzyme Q10 deficiency caused by mutations in coenzyme 
Q2 and Q6 polyprenyltransferase (COQ2 and COQ6), or Leigh syndrome caused by 
mutations in PDSS2, can result in nephrotic syndrome also as an isolated phenotype [66]. 
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Lastly, some patients are associated with variants in susceptibility genes, the most 
common of which being apolipoprotein L1 (APOL1) [72, 73]. Two risk alleles in the coding-
region of APOL1, called G1 and G2, have been indicated as being FSGS-associated and 
are common in countries with individuals of West African descent, who have a 3–5-fold 
increased risk of developing chronic kidney disease (CKD) and ESRD [72]. 
 
1.3 Diseases of the glomerular basement membrane 
Inherited abnormalities of the GBM proteins often result in renal diseases 
demonstrating the importance of the GBM in maintaining the health of the kidney.  
Different diseases affect the GBM directly or indirectly. Type III collagen accumulates in 
the GBM in rare glomerulopathies such as nail-patella syndrome and collagenofibrotic 
glomerulopathy [74], and in Goodpasture syndrome, a rare autoimmune disease where 
the type IV collagen α3 chain is the target of antibodies in lung and kidneys [75, 76]. Very 
rarely, abnormal deposition of fibronectin occurs in fibronectin glomerulopathy [77]. 
However, the better characterised GBM diseases are probably Alport syndrome and 
Pierson syndrome “spectrum”.  
 
1.3.1 Alport Syndrome 
Described for the first time in 1927 by Cecil Alport, Alport syndrome is a hereditary 
progressive nephropathy associated with ocular disorders (anterior lenticonus, 
abnormal pigment of the retina, cataracts), deafness (caused by abnormalities of the 
cochlea) and rarely with mental retardation and leiomyomatosis [16, 18].  
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In patients affected by Alport syndrome, one of the genes that encode for a chain of the 
α3α4α5 network, COL4A3, COL4A4, COL4A5, carries a mutation that arrests its normal 
maturation, resulting in the incorrect assembly of the monomers. The α3α3α5 network 
is then rapidly degraded, and the normal “isotype switching” between the normal 
network and the embryonic α1α1α2 network cannot take place in Alport patients.  
The syndrome is classified into three types depending on the gene affected by the 
mutation. Approximately 85% of Alport patients are affected by X-linked Alport 
Syndrome (XLAS) and carry a mutation in the X-linked COL4A5 gene that encodes for the 
α5(IV) chain of type IV collagen. About 500 mutations affecting COL4A5 have been 
described in humans [78] and include missense mutations, splice variants, deletions and 
nonsense mutations. The effects on the α5(IV) chain vary and can result in a reduction, 
distortion or loss of the α3α4α5 network. In female patients, the penetrance of the 
disease is variable and depends also on the degree of mosaicism following lyonization 
of the X chromosome [16]. If a mutation in the COL4A6 gene encoding the α6 type IV 
chain occurs simultaneously, leiomyomatosis could be associated [79].  
The remaining 15% of patients are affected by the autosomal recessive or, very 
infrequently, by a dominant type of Alport syndrome and carry a mutation in either 
COL4A3 or COL4A4. In the recessive form, homozygous or compound heterozygous 
nonsense mutations, missense mutations, frameshifts, small deletions or splice variants 
that lead to a loss of the α3α4α5 network [16]. In the dominant form, which has only been 
described in a few families, the mutations produce aberrations in the α3α4α5 network 
and are missense mutations carried on COL4A4 or shortened signal-peptide sequences 
in the COL4A3 gene [80].  
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Missense mutations in the COL4A3 and COL4A4 genes are also related to the thin 
glomerular basement membrane nephropathy: approximately 40% of patients with thin 
glomerular basement membrane nephropathy carry heterozygous missense mutation 
in COL4A3 and COL4A4, producing aberrations in the α3α4α5 network (while autosomic 
AS is caused by homozygous or compound heterozygous mutations) [81, 82].  
 
1.3.2 Pierson Syndrome 
Identified for the first time in the 1960s in two patients from the same family with a 
microcoria and congenital nephrotic syndrome by M. Pierson, Pierson syndrome is a rare 
genetic disorder resulting from mutations in the LAMB2 gene encoding the laminin β2 
chain found in the GBM, structures of the eye and neuromuscular junction [21-23]. 
Truncating and nonsense mutations leading to Pierson syndrome result in the lack of 
laminin β2 chain and, consequently, of the whole laminin-521 network. 
Lamb2 knockout mice recapitulate the human phenotype exhibiting congenital 
nephrotic syndrome and die at about three weeks of age with severe proteinuria and 
neuromuscular defects [83, 84]. Interestingly, at earlier time points the mice still exhibit 
proteinuria, but without foot process damage [85]. This observation suggests that the 
GBM is a key filtration barrier for albumin. Moreover, Lamb2-/- mice show accumulation 
of ectopic laminins in the GBM such as laminin β1, laminin α1 and α2 as an attempt to 
compensate the lack of laminin-521, but it is not sufficient to restore a normal renal 
function [85].  
Missense mutations, primarily in the LN domain, result in a much milder disease and 
patients normally exhibit a later onset nephrotic syndrome, with or without extra-renal 
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symptoms like microcoria [24, 86-88]. The milder phenotype is also recapitulated by mouse 
models [89-91]. A study of two mutations found in humans (R246Q [89] and C321R [90]) 
through the creation of transgenic mice, showed a reduced secretion of LAMB2 with 
consequent endoplasmic reticulum (ER) stress in podocytes resulting in ER distention 
and podocyte injury [89, 90]. The use of chemical chaperones rescued the in vitro 
phenotype [90].  
The laminin β2-associated phenotype can also result from defective polymerization but 
normal secretion, like in the case of the mutation S80R [92]. An in vitro study by Purvis et 
al. showed how the mutation S68R in the β1 chain (which corresponds to the S80R 
mutation in the closely related β2 chain that causes Pierson syndrome) affected laminin 
polymerization without perturbing the LN domain structure and the chain secretion [93]. 
 
1.4 The Laminin α5 Chain  
Among the major basement membrane proteins, laminins have been shown to be 
essential for the formation of the basement membrane itself by regulating cell adhesion, 
migration and differentiation [94]. Identified in 1979 as a large molecular weight non-
collagenous glycoprotein isolated from Engelbreth-Holm-Swarm sarcoma, there are 
currently ﬁve α, four β, and three γ chain genes that have been described in vertebrates 
and the chains can assemble into at least 16 different heterotrimers [95-97].   
The laminin α5 chain was first cloned in a study by Miner and colleagues in 1995 [98]. 
Using polymerase chain reaction (PCR), the group was able to identify 3610 amino acids 
of the full 3718. The sequence was eventually completed in 2002 [99]. Based on predicted 
secondary structure and homology with the already known laminin α1, eight different 
24 
 
domains were identified, including a large G domain on the C-terminal half of the 
protein, three sets of epidermal growth factor (EGF)-like repeats and two globular 
regions on the N-terminal half that are peculiar of the laminin α chains. A study of 
laminin α5 expression by Nothern Blot analysis with a α5 cDNA, showed a high level of 
mRNA expression in heart, lung and kidney but also in brain, muscle, testis, liver, gut and 
skin suggesting that laminin α5 is a major α chain of adult epithelial and/or endothelial 
basal laminae.  
The α5 chain combines with the β chains 1 and 2, and the γ chain 1 and 3, to form three 
different cross-shaped trimers: laminin-511 (α5β1γ1) in the basement membrane of 
epithelia, endothelia and smooth muscle, laminin-523 (α5β2γ3) in the retina and the 
central nervous system, and laminin-521 (α5β2γ1) in epithelia, endothelia, smooth 
muscle, neuromuscular junctions and glomeruli [94]. Laminin trimerization occurs in the 
endoplasmic reticulum and involves association of the three chains along their α-helical 
laminin coiled-coil domains to form the long arm [89]. Once trimers are secreted into the 
extracellular space, they polymerize to form a supramolecular network via interaction 
among the α, β and γ short arm end [89].  
Unlike most of the other basement membranes of the body, the GBM changes its 
composition as the kidney develops [100]. During murine embryonic development, the 
renal vesicles of the metanephric nephron form at E12.5 [101] and during this stage there 
is a burst of laminin α1 chain expression [102]. As development proceeds and the renal 
vesicle starts to proliferate, laminin α5 becomes detectable in the basement membrane, 
and at the S-shape stage, both laminin α1 and laminin α5 are found in the developing 
GBM adjacent to the differentiating podocytes [100]. Eventually, as the capillaries begin 
to form, laminin α1 is eliminated by an unknown mechanism and laminin α5 remains 
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the only α chain of the GBM [100]. Likewise, laminin β1 and the collagen type IV α1α2α1 
network are replaced by the mature forms laminin β2 and collagen α3α4α5 network [102] 
(Figure 1.4).  
 
 
Figure 1.4. Diagram showing the stages and changes of the GBM assembly and the origin of the collagen 
type IV and laminin isoforms.  At the beginning of renal vesicles development, both podocytes and 
endothelial cells produce laminin-111 and collagen IV α1α2α1 (A). As the renal fascicles proliferate and 
develop, laminin-511 and laminin-521, as well as collagen IV α1α2α1 and α3α4α5, are present in the 
glomerulus (B). Finally, in fully mature glomeruli, podocytes and endothelium cells produce exclusively 
laminin-521, while collagen IV α3α4α5 is produced by podocytes only (C). Image adapted from 
Abrahamson et al.  [102]. 
 
Of all the mature components of the GBM, laminin α5 chain is the only one that is 
essential for a normal embryonic development as shown by the lethality of the mouse 
Lama5 knockout. Mice lacking laminin α5 die at 14 -17 days of gestation of placental 
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insufficiency and incomplete neural tube closure; also present is digit septation, 
placentation and a small percentage of mice (20%) lacked one or both kidneys [103]. In 
the kidneys with normal nephrogenesis, the effect of the lack of laminin α5 resulted in 
aborted glomerulogenesis. As the glomerular constriction progresses, the cells are 
forced out the interior, leaving a cluster of podocytes adjacent to a group of endothelial 
and mesangial cells [103]. The result is a complete lack of vascularised glomeruli. Since 
the substitution of laminin α1 with laminin α5 could not occure in Lama5-/- embryos, 
none of these proteins were present in the GBM resulting in its breakdown. 
Consequently, endothelial cells and mesangial cells could not maintain their position in 
the glomerulus while podocytes failed to maintain a normal single layer arrangement 
and lacked foot processes and slit diaphragm [103].  
Other murine models include a hypomorphic Lama5 mutation, created by inserting a 
PGKneo cassette inserted into a KpnI site in intron 21, which results in proteinuria, 
haematuria and polycystic kidney disease (PKD). This is the first evidence that a primary 
defect in an extracellular matrix component can cause PKD [104]. A podocyte-specific 
deletion Lama5 resulted in nephrotic syndrome with a variable rate of diseases 
progression (from few weeks to 8 months) possibly due to the mixed genetic background 
(C57BL/6J-CBA/J-129) [105].  
Like in kidneys, laminin α5 is essential for the development and function of several 
tissues. Given the lethality of the Lama5 null mice, studying the role in different organs 
has been proven to be challenging and has led to the production of conditional or 
transgenic murine models. In the lung, LAMA5 is required for complete lobar septation 
and visceral pleural basement membrane production, but not for morphogenesis [106]. 
Moreover, mice lacking Lama5 in lung epithelial cells survived birth but presented 
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dilated airspaces, reduction or absence of alveolar cells and decrease proliferation [107]. 
Interestingly, mice showed increased mRNA levels of integrin α3, one of LAMA5’s main 
binding partner, suggesting that the cells were trying to compensate the lack of 
interaction with laminin α5 producing more ligand [107]. In the intestine, a lack of Lama5 
leads to morphological defects of the smooth muscle layer. Conditional deletion of 
Lama5 in the intestine after embryogenesis, resulted in villi fusion and increased goblet 
cell numbers, altering the morphology of mature cryptic-villus architecture [108, 109]. 
Laminin α5 also promotes cell proliferation in the developing tooth and regulates 
keratinocyte proliferation and migration [110-112], suggesting a role of LAMA5 in general 
epithelial replacement and possibly in wound healing.  
In humans, two mutations have been described as causing syndromes [113, 114]. The 
mutations are localised in one of the C-terminal LG domains (V3140M [113]) and in the 
coiled-coil (R2659W [114]) and lead to a plethora of symptoms such as myopia, muscle 
weakness, skin anomalies and failure of neuromuscular transmission. None of the 
patients, however, had any signs of kidney impairment. The two mutations described 
seem to have a different mechanism in disease. In the study by Maselli et al, in vitro 
expression and adhesion assay showed reduced cell adhesion power and reduced 
binding with SV2A. In the study described by Sampaolo et al, cell binding is conserved 
but most of the genes shown to be deregulated in patients are involved in tissue 
inflammatory response, repair and ECM remodelling, hence the authors hypothesise a 
master regulatory role of LAMA5. 
In respect to kidney disease, the mutation G3685R has been reported in two 
independent studies in patients affected by FSGS [115, 116], however, a mouse model 
carrying the same mutation and created by CRISPR/Cas9 gene editing, did not show any 
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phenotype (personal correspondence [117]). More recently, three different genetic 
variants have been identified in three families with nephrotic syndrome [118]. The 
variants are positioned in different domains of the protein: R747W in the LEa EGF-like 
domain, E1001G in the L4a domain and G2948 in the second LG domain. The patients, 
all homozygous for one of the mutations, exhibit early onset nephrotic syndrome 
between 18 months and 4 years of age. Only the children carrying the mutation E1001G 
underwent renal biopsy and were diagnosed with FSGS.  
 
1.4.1 Laminin α5 Structure  
As previously stated, the structure of the laminin α5 chain can be described as having a 
short and a long arm. As in most laminins, the short arm of laminin α5 begins with an N-
terminal globular LN domain, followed by repeated rod-like region consisting of multiple 
EGF-like domains (LEa, LEb and LEc domains) in combination with two additional 
globular domains (L4a and L4b domains). The long arm starts with a long coiled-coil 
domain that joins the α5 chain to the β and γ chains and ends with LG domain which 
includes five similar but not identical modules with a hinge-like region between LG3 and 
LG4 [119] (Figure 1.5).  
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Figure 1.5. A schematic representation of laminin α5 chain structure with its main domains and binding 
sites for its major receptors.  
 
Described as having a crystal structure that resembles a flower, the LN domain 
(previously known as VI domain) is a Swiss roll fold composed of eight beta strands, β1-
β8, with β5-β6 being the loop involved in the network interaction and spontaneous 
heterotrimers polymerization with other laminins [120]. The LN domain is a minor binding 
site of LAMA5 [121, 122]. Experiments using integrin-blocking antibodies indicated integrin 
α3β1 as a potential major receptor. Other potential receptors were found in HSPG as 
suggested by the fact that heparin could inhibit cellular binding to the LN domain by 90% 
[123]. Additionally, the first 40 residues of the domain represent the signal peptide 
cleavage site for normal laminin secretion [99].  
The L4a and L4b domains are probably the least well characterized LAMA5 domains. In 
vitro studies did not show any cell-binding proprieties of L4a domain, but active 
sequences within this region have been proved to promote neurite elongation [124]. The 
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L4b domain (previously known as domain IVa) contains two Arg-Gly-Asp (or RGD) 
sequences in both the human and murine protein. RGD sequences are often found in 
extracellular proteins and are known to be able to bind various integrins. Studies in vitro 
showed the capacity of the RGD sequences to bind β1 and αVβ3 indicating that they 
work as cryptic sites, but it is not clear if this function is maintained in vivo [125]. 
The C-terminal LG domain appears to be the major binding site of LAMA5 as 
demonstrated in both in vivo and in vitro. Yu et al used antibody-inhibition assays 
performed on LG1-LG2-LG3 and LG4-LG5 modules to understand which subdomains is 
specific for which receptor: the study showed how binding of integrins α3β1 and α6β1 
was localised to the LG1-3 modules, while α-dystroglycan, binding was localised to the 
LG4-5 modules [126]. A follow up study by Ido et al showed how LG3 module is 
indispensable for integrin binding. However, when the modules were expressed 
individually, only LG4 was able of binding to α-dystroglycan, whereas neither LG3 nor 
any of the other LG modules retained the ability to bind to the integrins [127].  
The same binding site for integrin on LG1-3 modules appear also to bind Lu/BCAM, but 
just in presence of the laminin coiled coil [128]. Lutheran (Lu) adhesion glycoprotein/basal 
cell adhesion molecule (BCAM) is expressed in different tissues and it is localised on the 
basal surface of many epithelial cells, adjacent to basement membranes containing 
laminin α5 [129]. To support the hypothesis that Lu/BCAM is strictly associated with 
LAMA5, it was shown that Lu/BCAM expression is drastically reduced in tissues from 
Lama5 knockout mice and increased in transgenic mice that overexpress Lama5 [130]. 
Mice with a genetic inactivation of Lu/BCAM showed irregular thickening of the GBM, 
reduction of the glomerular capillary lumens and enlargement of the smooth muscle 
layers of the intestine. However, they were still viable, fertile and did not show any 
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defect in development or into the function of organs [131]. It is still not clear though if the 
different integrins compete for the binding sites and therefore Lu/BCAM could inhibit 
integrin-mediated cell adhesion to LAMA5. 
In the kidney, from different studies, it emerged that the LG1-LG2 domains are the most 
involved during development, while LG3-LG4-LG5 domains are more involved in 
maintaining the integrity of the GFB [132, 133].  
 
1.4.2 Integrins as Laminin α5 Receptors 
Integrins are transmembrane heterodimeric receptors containing non-covalently 
associated α and β subunits and play an important role in cell adhesion to ECM proteins, 
certain cell-cell interactions, and also the transduction of intracellular signals to the ECM 
[134]. The eighteen α subunit and the eight β subunits can form 24 different dimers [135] 
and although some subunits appear only in a single heterodimer, twelve integrins 
contain the β1 subunit, and five contain αV [136].  
Each integrin can bind several different ligands, with ligand-binding specificity being 
dictated by both subunits. Laminins can potentially bind with a number of integrins: 
α1β1, α2β1, α3β1, α6β1, α7β1, α10β1, αVβ3 and α6β4 [136] and, in most cases, they have 
a preference for the laminin α5 chain as their ligand [20]. Integrin α1β1, α2β1, α10β1, 
α11β1 and αXβ2 can bind collagen, with α1β1 having a higher affinity for type IV collagen 
and α2β1 having a higher affinity for type I collagen [136-138].  
Integrin activity is regulated by conformational changes [139]. They can adopt three 
different conformational states; inactive (low affinity) active or primed (with high 
affinity) and ligand occupied state [140]. The passage between inactive and active state 
depends on the signals transduced from the integrin cytoplasmic tail to the extracellular 
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ligand-binding pocket (“inside-out signalling”). The conformational change leads to 
ligand binding and transducing the signal from the ECM to the interior of the cell 
(“outside-in signalling”) so that it can sense the extracellular environment and respond 
accordingly [141, 142]. 
In the kidney, podocytes express high levels integrin α3β1 that plays a crucial role in the 
link between these cells and the GBM [143]. Mouse models have been generated to study 
the role of β1 in development and disease. The lack of Itgb1 leads to peri-implantation 
lethality and embryonic death at E6.5 [144, 145]. Its role in the GFB has been studied using 
a podocyte Itgb1 specific deletion, where glomerular morphogenesis was conserved 
despite the defective GFB present at birth. The resulting proteinuria and progressive 
podocyte loss lead to renal failure by 3 weeks of age [146, 147]. In the same way, the α3 
subunit has been shown to play a crucial role in development, with knock-out mice dying 
within the first day of birth from abnormal morphogenesis of lungs and kidneys, 
including a disorganised and thickened GBM [148]. A similar phenotype was observed in 
a murine model with a podocyte-specific deletion of Itga3, where mice showed severe 
proteinuria from the first week of age, complete foot process effacement, with 
widespread lamination and protrusions of the GBM [149]. Patients with homozygous 
mutations in integrin α3 gene (ITGA3) showed a multi-organ disorder that included 
congenital nephrotic syndrome, interstitial lung disease, and epidermolysis bullosa [150]. 
Moreover, a mutation causing a gain of glycosylation in ITGA3 caused severe nephrotic 
syndrome and lethal lung disease [151]. 
Integrin α3β1 binds tightly to Cluster of Differentiation 151 (CD151, also known as Raph 
blood group), a tetraspanin member of the transmembrane four superfamilies (TM4SF) 
which is largely expressed in different cell types. It contributes fundamentally towards 
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integrin-dependent adhesion/signalling and functions as a signalling switch to balance 
Ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras homolog gene family member 
A (RhoA) activities, leading to cell stability regulating the forces of cell adhesion and 
cytoskeletal tension  [33, 152, 153]. In the kidneys, CD151 is expressed at the base of the 
podocytes and colocalises with integrin α3 [149, 154]. In vitro experiments show that 
Cd151-deficient podocytes resulted in lower shear stress tolerance when cultured in 
laminin [149]. CD151 is needed for the correct assembly of of skin and kidneys. A human 
mutation resulting in the lack of CD151 integrin binding domain leads to haematuria, 
proteinuria and end-stage kidney disease (ESKD) associated with sensorineural 
deafness, pretibial epidermolysis bullosa, and β-thalassemia minor [155]. Cd151-null mice 
recapitulate the progressive kidney disease observed in humans but did not show any 
extra-renal phenotype [149]. Interestingly, the renal phenotype is strictly dependent on 
the genetic background of the mice, with FVB/N Cd151-/- mice displaying a similar 
pathology to humans, but C57BL/6J Cd151-/- mice retain normal kidney function but 
have defective keratinocyte migration and T lymphocyte hyperproliferation [156, 157].  
This strongly suggests that integrin α3β1 is a crucial component of the GFB and that its 
interaction with CD151 increases the strength of podocyte integrin-laminin interaction 
necessary to resist the mechanical forces in the glomerulus. 
 
1.4.2 Focal Adhesion Complexes  
The binding of integrin and laminin triggers integrin clustering and the formation of 
multiprotein complexes called focal adhesions, located at the end of actin stress fibres. 
Depending on the protein they make contact with, cells form thick actin stress fibres, 
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with prominent focal adhesions on collagen or fibronectin, and thin stress fibres and 
smaller and fewer focal adhesions on laminin [158].  
Focal adhesion complexes evoke both mechanical and chemical signals to regulate the 
cytoskeleton. In podocytes, mechanical signals are mediated by proteins such as talin, 
kindlin, α-actinin4 and vinculin that physically bind the cytoskeleton to the ECM, while 
chemical signals like paxillin, integrin-linked kinase (ILK) and focal adhesion kinase (FAK) 
regulate the activities of enzymes like GTPases (Figure 1.6).  
Regulation of the podocyte actin network is essential to GFB integrity, as actin 
reorganisation is possibly the cause of foot process effacement, a common feature of 
glomerular diseases.  
 
Figure 1.6. Molecular components of the focal adhesion complexes that form the podocyte-ECM 
interface and the interaction between components forming the ECM network. Laminin-521 and collagen 
IV α3α4α5 interact thanks the presence of nidogen and HSPGs (percalan). Podocyte foot processes highly 
express integrin α3β1, and its associated tetraspannin CD151, that binds laminin α5 chain of the GBM. 
Activated integrins recruit talin-vinculin-paxillin and ILK-PINCH-parvin to link to the actin cytoskeleton. 
Image adapted from Lennon et al. [64]. 
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1.4.2.1 Talin 1 
Talin 1, encoded by the gene TLN1, is a large protein, which is critical for integrin function 
in focal adhesion. It comprises a globular N-terminal domain (talin head) which contains 
the binding sites for β integrin tails [159], and a flexible rod domain, which contains 
additional binding sites for integrins, actin and vinculin [160, 161].  
Talin 1 is involved in the first step of integrin activation “inside-out”: when talin 1 head 
binds the cytoplasmatic domain of β integrins, it triggers a conformational change in the 
extracellular domain of integrins which activates the ligand binding function of integrins 
to the ECM [142]. Cells lacking talin 1 have reduced cell adhesion, spreading and migration 
[162]. 
In podocytes, talin 1 is required is required to keep the actin cytoskeleton morphology 
of the foot processes stable. Conditional podocyte-specific Tln1-/- mice developed 
proteinuria, podocyte effacement and reached ESRD around 8 weeks of age due to a 
dramatic disorganization of the actin network [163]. 
 
1.4.2.2 Kindlin-2 
Proteins of the kindlin (or fermintin) family are indispensable to enable integrin 
activation through binding of β-integrin tails, and necessary for the integrin inside-out 
signalling in cooperation with talin-1 [164]. The kindlin family includes three proteins, 
kindlin-1 (FERMT1), kindlin-2 (FERMT2) and kindlin-3 (FERMT3), all with a FERM domain 
on the C-terminal end that mediates the integrin bindings. Kindlin-1 is mainly expressed 
in epithelial cells and mutations in FERMT1 lead to Kindler syndrome (an autosomal 
recessive disease characterized by blistering, poikiloderma and photosensitivity in 
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childhood). Kindlin-3 is found in hematopoietic cells and mutations in FERMT3 cause 
leukocyte adhesion deficiency. Kindlin-2 is ubiquitously expressed. No mutations in 
FERMT2 have been reported and global deletion of Fermt2 in mice results in peri-
implantation lethality due to extensive detachment of the endoderm [165].  
In the kidney, kindlin-2 is expressed in podocytes. In an in vitro study, Qu et al. showed 
its expression in cultured human podocytes and how its depletion impacted cell-matrix 
adhesion and reduced the deposition of fibronectin matrix [166]. Further in vitro studies 
proved that kindlin-2 stabilises podocyte morphology functionally linking cortical actin 
structures, plasma membrane tension and interactions with the ECM [167]. Podocyte-
specific knockout of Fermt2 results in alteration of the actin cytoskeleton organization 
leading to very severe proteinuria and kidney failure [168]: this phenotype is likely due to 
the activation of Rac1 in response of the reduction of Rho GDP-Dissociation Inhibitor α 
(RhoGDIα) that seems to be a kindlin-2 associated protein [168].  
 
1.4.2.3 α-Actinin 4 
The members of the α-actinin family are rod-shaped proteins with an N-terminal domain 
that binds actin, four spectrin-like repeats and C-terminal EF hands. The proteins form 
head-to-tail homodimers [169]. Of the four proteins that are part of the α-actinin family 
(ACTN1-4), α-actinin 4 is highly expressed in podocytes where it is involved in cell 
adhesion binding directly to β1-integrin and vinculin thus linking the actin network to 
the ECM. It also plays a role in creating cell junctions by serving as a linker between actin 
and proteins of the SD. α-Actinin 4 also contributes to cell signalling, interacting with 
proteins of the p13kinase pathway, and acts as a nuclear transcription activator [170].  
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Gain of function mutations in ACTN4 have been reported to be the cause of a dominant 
form of FSGS, a common form of nephrotic syndrome affecting adults. All the mutations 
affect the N-terminal actin-binding domain and are associated with an increased binding 
of actin to F-actin forming abnormal cellular cytoskeletal protein aggregates within the 
cells that are rapidly degraded [171-173].  
Although affected families show autosomal dominant inheritance disease, knockout 
mice recapitulate the human phenotype developing albuminuria and foot process 
effacement. Podocytes isolated from Actn4-/- mice showed reduced phosphorylation of 
β-integrin and weaker integrin-cytoskeleton linkages  [174]. Homozygous mice for the 
knock-in mutation K228E developed a similar phenotype to the Actn4-/- mice, but 
Actn4K228E/- mice, that are closer genetically to the affected human patients, did not 
show any phenotype [172]. 
 
1.4.2.4 Vinculin 
Vinculin is an adapter protein recruited by talin 1 that localises at the focal adhesions, 
binding the actin cytoskeleton, and at cell-cell junction [175]. It comprises an N-terminal 
head domain that binds talin 1, a proline-rich neck and a C-terminal tail that binds 
paxillin and F-actin bundles [176]. Vinculin assumes an inactive conformation before talin 
binds to its adhesion sites. This recruitment triggers a conformational change and 
vinculin is extended revealing an open active state [177] and allows the interaction of 
vinculin with several proteins like actin, paxillin and α-actinins [178].  
In the kidney, vinculin is required to maintain glomerular barrier integrity. Patients 
affected by nephrotic syndrome showed differences in vinculin expression and 
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distribution [179]. Additionally, mice with a podocyte-specific vinculin knock out develop 
proteinuria and foot process effacement following injury in vivo [179].   
 
1.4.2.5 Paxillin 
Paxillin is a scaffolding protein that recruits enzymes and proteins involved in the 
intracellular signalling that ultimately results in the reorganization of the actin 
cytoskeleton and the assembly/disassembly of focal adhesions through the presence of 
docking sites for focal adhesion kinase (FAK), Src and vinculin on the N-terminal domains  
[180]. It localises to focal adhesions when phosphorylated on specific tyrosine and/or 
serine residues [181]. Moreover, paxillin also coordinates the spatiotemporal activation 
of signalling molecules, including Cdc42, Rac1, and RhoA GTPases, by recruiting guanine 
nucleotide exchange factors (GEFs), GTPase-accelerating proteins (GAPs) and G protein-
coupled receptor kinase- interacting proteins (GITs) to focal adhesions [181]. 
Although its presence is crucial for the assembly and signalling of the focal adhesions 
and its phosphorylation is increased during glomerular immune injury [182], paxillin’s role 
in the glomerulus has not been studied yet. 
 
1.4.2.6 Integrin-Linked Kinase 
Integrin-linked kinase (ILK) is a scaffold protein able to interact with the cytoplasmatic 
tail domain of β integrins [183]. It has three main domains with five ankyrin repeats 
towards the N-terminus that mediate the interaction with particularly interesting new 
cysteine-histidine-rich protein (PINCH) proteins forming a complex called PINCH-ILK-
parvin, followed by a pleckstrin homology-like domain, and a C-terminal kinase domain 
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that mediates protein-protein interaction at focal adhesions, including with parvin 
proteins [184, 185].  
ILK is necessary for normal embryonic development: Ilk-/- mice die during peri-
implantation stage due to failure to organise the actin network in epiblast cells [186]. 
Specific Ilk deletion in podocytes resulted in an increased GBM thickness that preceded 
foot process effacement and proteinuria with re-localization of integrin α3 into a 
granular pattern along the GBM [187]. In humans, ILKI mRNA is overexpressed in children 
affected by nephrotic syndrome and patients affected by diabetic nephropathy [188, 189]. 
 
1.4.2.7 Focal Adhesion Kinase 
FAK is a scaffold and a non-receptor tyrosine kinase involved in cellular adhesion and 
cell spreading. It binds to itself and cellular partners through four-point-one, ezrin, 
radixin, moesin (FERM) domain with integrin inducing its auto-phosphorylation at 
tyrosine 397 resulting in activation of signalling pathways required for focal adhesion 
turnover [190-192].  
FAK is necessary for normal development: global deletion in mice is embryonic lethal 
due to profound migration defects [193]. In mice with induced glomerular injury, FAK is 
robustly activated at Tyr 397, and, vice versa, inhibition of FAK protects from podocyte 
experimental injury [192]. Interestingly, podocyte-specific deletion of FAK in mice did not 
affect renal function and did not produce proteinuria [192]. 
FAK inhibition also ameliorated the proteinuric phenotype in a model of Alport 
syndrome, where the abnormal accumulation of laminin α2 chain caused the 
upregulation of FAK at Tyr 397 [194]. 
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1.4.2.8 Rho GTPases Family 
The Ras homologue (Rho) GTPases family is a group of small G coupled proteins (guanine 
nucleotide-binding proteins) which belongs to the Ras superfamily, consisting of over 
150 members in mammals. Proteins of this family play important roles in the regulation 
of cell polarity, gene expression and cell survival, but their main involvement in 
eukaryotic cells is to regulate actin cytoskeleton and all the actin-dependent processes 
such as migration, adhesion and morphogenesis [195]. Rho GTPases have two states, an 
inactive form bound to GDP, and an active GTP bound form. The passage between states 
is strictly regulated. The exchange of GDP for GTP, and therefore activation of Rho 
GTPase proteins, is catalysed by guanine nucleotide exchange factors (GEFs), while the 
passage to their inactive form is mediated by GTPase activating protein (GAPs) [195]. 
Additionally, guanine nucleotide dissociation inhibitors (GDIs) act as inhibitors 
preventing the GDP dissociation from the inactive state [195]. 
The Rho GTPases family consists of 20 members that are divided into eight subfamilies, 
Rho, Rnd, RhoD/F, RhoH, Rac, Cdc42, RhoU/V and RhoBTB [196], however most research 
focuses on the three most common members; Rac1 (Rac subfamily), RhoA (Rho 
subfamily) and Cdc42. These three proteins act in complex activation cascades with the 
antagonistic regulatory mechanism. Rac1 can be activated by Cdc42, and Rac1 and RhoA 
operate antagonistically [197]. Laminins activate Rac1 and Cdc42 promoting the 
formation of lamellipodia and filopodia, respectively. Their activation of RhoA is less 
pronounced and results in thinner actin stress fibres and smaller focal adhesions [158].  In 
vivo and in vitro studies have revealed that all three proteins are involved in kidney 
disease in various degrees. Mice lacking Cdc42 in the podocytes developed collapsing 
glomerulopathy and extensive foot process effacement leading to renal failure by 2 
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weeks of age which was associated with in vivo impaired actin polymerization by nephrin 
clustering [198]. Rac1 podocyte-knock out mice did not show any phenotype during the 
three months of study, but misregulation of their expression or their balance can 
influence the renal podocytes. Increased Rac1 activity is associated with proteinuric 
kidney disease and has been demonstrated to be harmful to podocytes in many studies 
[199-203]. Interestingly, treatment with a Rac1 inhibitor or glucocorticoid reduced 
proteinuria and the severity of the kidney damage [202, 204, 205]. Likewise, the 
overexpression of RhoA in podocytes induces kidney injury: in vitro enhanced RhoA 
activity stimulated actin polymerization as well as reduced glomerular nephrin 
expression and caused apoptosis of cultured podocytes [206]. In vivo, the impact of RhoA 
activation on podocyte health has been tested in two studies using doxycycline-
inducible and podocyte-specific expression in mice. Both studies resulted in glomerular 
sclerosis and foot process effacement associated with albuminuria [206, 207]. The study of 
Wang et al, the expression of dominant negative RhoA in podocytes also induced foot 
process effacement and proteinuria. This result strongly suggests that, in addition to the 
lack of expression, is the basal activity of RhoA is also important for the integrity of 
podocytes. 
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1.5 ENU Mutagenesis  
Since Russell’s lab discovered in the late 1970s that N-Ethyl-N-nitrosourea (ENU) was a 
potent mutagen [208], it has been shown to be an effective tool to identify novel genes, 
pathways or functions of the gene in disease pathogenesis and progression. ENU is an 
alkylating agent that acts transferring a methyl or ethyl group to the oxygen or nitrogen 
sites on the nucleotide bases. The resulting DNA adduct creates a mismatch in the 
sequence that, if not corrected, during cell proliferation and DNA replication will convert 
in most cases in a hereditable point mutation (or more rarely, in a small deletion) [209]. 
ENU is usually administrated by a sequence of injections to an adult male mouse: it is 
estimated that an optimal dosage would result in one mutation every 1-1.5 Mb with a 
mutation rate that varies according to the gene size (larger genes have a higher chance 
of being mutated) [210]. The most common ENU induced mutations are A-T to T-A 
transversions or A-T to G-C transitions, while G-C to C-G transversions are rarely seen 
[210]. The preference for specific substitutions is a limiting factor of ENU mutagenesis 
because some amino acid changes will be underrepresented while genes or specific 
domains containing easily targeted amino acid will be more frequently mutated [210]. In 
spite of this limitation, ENU has been widely used to create mouse models of human 
disease.  
 
1.5.1 Phenotype Driven Approach  
Large-scale mutagenesis programs were launched back in 1997 in the UK (MRC Harwell) 
[211] and Germany (GBMH)[212, 213] and they are now performed all around the world [214]. 
43 
 
ENU-based phenotype-driven screening (forward genetics) has been proved to be an 
effective methodology to study gene involvement in disease pathogenesis.  
Forward genetics makes no assumption about the genetic basis and the models are 
identified just based on the expression of particular phenotypes, which is more likely to 
uncover a novel gene function. Another advantage is given by the production of 
mutations that can modify gene function in various ways in addition to the production 
of null alleles resulting in a total loss of gene function. The ENU-induced mutations could 
result in hypomorphs (partial loss of function), hypermorphs (increased of normal 
function), neomorphs (new gene function) and splice variants that better represent 
what happens in human patients.  
Breeding schemes have been implemented to propagate the mutation and permit gene 
mapping (Figure 1.7). The ENU-treated males (G0), after an initial period of sterility, are 
crossed to wild-type females. The offspring resulting from this mating (G1) can be used 
to screen for dominant mutations. If a recessive screen is needed, the G1 males are 
mated to wild-type females and their offspring (G2) can then be intercrossed or the G2 
females can be backcrossed to their G1 father. In both cases, the resulting G3 offspring 
will carry both recessive and dominant mutations and can, therefore, be screened (G3 
screen). To assist in the mapping, wild-type females are usually from a different inbred 
strain [210].  
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Figure 1.7. Breeding plan used for the recessive ENU mutagenesis screen, the Harwell ageing 
screen. Figure adapted from Goldsworthy et al. [215]. 
 
ENU-mutagenesis has been a useful tool also to identify novel models of kidney disease. 
As part of the Munich ENU mouse mutagenesis project [216], C3Heb/FeJ inbred mice were 
screened specifically for increased plasma urea levels. The project involved the 
screening of both G1 offspring (15,000 mice in total) and G3 (500 mice in total) collecting 
plasma and urine at three months of age [217]. The screen led to the identification of five 
mutant lines and causative mutations in genes such as Pou3f3 (POU Class 3 Homeobox 
3)[218] and Kctd1 (potassium channel tetramerization domain containing 1)[219].  
Other mutant lines derived from ENU-mutagenesis screens and used as models of 
glomerular basement membrane disease and/or nephrotic syndrome are Col4a4Aoba, 
model of Alport syndrome (from the Scripps Research Institute), Lamb2nephertiti (from the 
Australian Phenomics Facility) and Ampd2A341S models of nephrotic syndrome (from the 
McLaughlin Research Institute)[91, 220, 221]. 
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1.5.2 Gene Driven Approach  
Genome-wide association studies in the human population have become a common 
approach to study the effect of genes on common and rare diseases. In the UK, the 
100,000 Genome Project (https://www.genomicsengland.co.uk/the-100000-genomes-
project/) aims to sequence more than 70,000 patients affected by cancer and rare 
disease, including renal pathologies. ENU can be a useful tool also in gene-drive screens 
(reverse genetics) using libraries of DNA and sperm derived from ENU-treated G1 males.  
After the identification of the gene of interests, the DNA library can be screened for 
mutations the same specific gene. Once a mutation is identified, the line can be 
recovered by in vitro fertilization (IVF) [210, 214]. Alternatively, embryonic stem (ES) cells 
can be treated and, therefore, mutated using ENU. The ES cells are then screened for 
mutations in a gene of interest. If the mutation is found, a parallel frozen cell archive 
can be microinjected into a murine blastocyst to create a chimeric mouse that carried 
the ENU-induced mutation [210].  
 
 
1.6 Project Aims and Objectives 
The aim of this project is to characterise a novel model of nephrotic syndrome resulting 
from an ENU-induced point mutation in the gene Lama5, encoding laminin α5 chain, a 
crucial component of the GBM recently associated with nephrotic syndrome in humans. 
The study will involve the following: 
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 Phenotypic analysis: 
o Urinalysis and clinical chemistry analysis to assess renal function 
o Histological study to examine the renal morphology. 
o Ultrastructural study using transmission electron microscopy (TEM) and 
scanning electron microscopy (SEM) to study the structure of the GFB. 
 Gene identification using: 
o Whole genome mapping 
o Whole genome sequencing 
 Functional characterisation studies using: 
o In silico analysis to predict the effect of the ENU-induced missense 
variant on the protein structure and/or function. 
o In vitro study of the impact of the ENU-induced missense variant on 
laminin α5 chain expression and secretion. 
o Gene expression, protein expression, immunofluorescence and 
proteomics analysis to investigate possible mechanisms involved in the 
pathogenesis of Lama5-dependent nephrotic syndrome. 
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CHAPTER 2 
Experimental Methods 
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2. Experimental Methods 
2.1 Mice  
C57BL/6J and C3H-C3pde6b+ inbred mice were maintained in the Mary Lyon Centre in 
Harwell UK, in specific pathogen-free conditions. All animal procedures were carried out 
under the guidance issued by the Medical Research Council in “Responsibility in the Use 
of Animals for Medical Research” (July 1993) and in accordance with Home Office 
regulations (Home Office Project Licence No. 30/3070, “‘New mouse models of human 
disease”). 
The MUTA-PED-C3pde-205 mouse line was derived from a G3 pedigree produced in the 
MRC Harwell ENU mutagenesis screen as described previously [222]. Briefly, male 
C57BL/6J mice were mutagenized with ENU with three injections with one at 120mgkg-
1 and two at 100mgkg-1 with 7 days between each dose. They were then mated to female 
C3H.Pde6b+ mice to generate G1 founder males, heterozygous for ENU induced 
mutations. G1 males were subsequently bred to female C3H.Pde6b+ mice to generate 
G2 offspring. Lastly, G2 females were mated back to the original G1 founder to generate 
two G3 cohorts of approximately 50 animals 3 months apart, with homozygous or 
heterozygous offspring. G3 animals entered a high-throughput phenotyping pipeline 
screened throughout their lifetimes (18 months).  
To generate one backcross C3H-C3pde6b+ Lama5E884G mutant mice (C3pde-Lama5E884G), 
MUTA-PED-C3pde-205+/E884G mice were crossed with inbred C3H-C3pde6b+ for one 
generation and then intercrossed to create phenotyping cohorts. 
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To generate congenic C57BL/6J Lama5E884G mutant mice (B6-Lama5E884G), MUTA-PED-
C3pde-205+/E884G mice were crossed with inbred C57BL/6J mice for a total of ten 
generations and then intercrossed to create phenotyping cohorts. 
For gene validation, Lama5-tm1b mice were obtained from the international mouse 
phenotyping consortium (IMPC - http://www.mousephenotype.org/).  This mouse line 
was created deleting the critical exons four, five and six. Lama5-tm1b-/- mice showed 
complete penetrant preweaning lethality. To generate the compound MUTA-PED-
C3pde-205+/E884G mice were crossed to Lama5-tm1b+/- mice.  
 
2.2 Initial Identification 
2.2.1  Mapping and Next Generation Sequencing 
DNA from affected mice and littermate controls were extracted using a GE Healthcare 
Illustra BACC2 kit according to the manufacturer’s protocol and sent to GenProbe Life 
Sciences Ltd. to be tested in on the Illumina Golden Gate “Mouse MD Linkage Panel” 
(Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics). 
After identifying the candidate region that could contain the causative mutation, the 
DNA from the G1 founder of the pedigree was sent for whole genome sequencing (WGS) 
employing the Illumina HiSeq platform (Oxford Genomics Centre, Wellcome Trust 
Centre for Human Genetics). The sequence was then analysed by the Bioinformatics 
group based at the MRC-Harwell, highlighting the possible coding and non-coding 
mutations and the confidence in each mutation based on reading depth of the WGS. 
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2.2.2  Mutation Validation 
To confirm the mutation in Lama5, DNA samples from the tails of affected G3 animals 
and C57BL/6J control were extracted using GE Healthcare Illustra BACC2 kit according 
to the manufacturer’s protocol. The DNA was then amplified by polymerase chain 
reaction (PCR) using the following designed primers to amplify the relevant locus: 
Forward 5’-AAACTCCAGGGGGTTGAAGC-3’ 
Reverse 5’-AGCGAAGGACCACTACTTGC-3’ 
Phusion High-Fidelity PCR Kit (New England BioLabs) was used as the polymerase. The 
reaction conditions for a 50 μl reaction were 10 μl 5X HF Reaction Buffer, 1 μl (10 nM) 
dNTPs, 2.5 μl 10 μM Forward Primer, 2.5 μl 10 μM Reverse Primer, 2 μl DNA, 0.5 μl (0.8 
U) Phusion HiFi Polymerase, 31.5 μl of double-distilled water. Standard PCR settings 
were as follows: starting temperature 98°C for 30 seconds, then 40 cycles alternating at 
98°C for 10 seconds, 63°C for 30 seconds, 72°C for 20 seconds and final elongation at 
72°C for 10 minutes. Store at 8°C. 
PCR products were purified using QIAquick PCR Purification Kit (QIAGEN) according to 
the manufacturer’s instructions and sequenced with amplification primers using 
overnight Sanger sequencing by Source BioScience (UK). Results were analysed using 
Seqman pro (DNASTAR, USA).  
 
2.2.3  Genotyping 
The mice of the pedigree are routinely genotyped by performing LightScanner (Idaho 
Technology, USA) high-resolution DNA melting analysis with LCGreen and a LunaProbe 
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developed by the GEMS core facility using DNA extracted from ear biopsies. To 
distinguish between animals with different genotypes for the single point mutation, a 3’ 
blocked oligonucleotide (LunaProbe) was designed so that sits directly over the single 
nucleotide polymorphisms (SNP) and exhaustive asymmetric PCR was performed. This 
creates two products, one is the full PCR product between the normal primers, and the 
other is a hybridised product with the probe bound to the opposite strand. Hybridised 
products were then heated on a LightScanner and the and the fluorescence emitted by 
bound LCGreen was monitored using a high-resolution melting curve analysis performed 
with the manufacturer’s software. Because the probe matches the mutant sequence, it 
melts at a higher temperature than the wild-type (Figure 1.1). The result is a different 
shaped curve depending on the genotype.   
 
Figure 2.1. Example of a LightScanner output for the genotyping of the Lama5E884G lines. Depending on 
the genotype, the melting curve has a different shape (in red wild-type, in blue homozygote for the E884G 
mutation, and in grey homozygote for the E884G mutation). 
 
Primer pairs and probe are as follows: 
Forward 5’- GGGTTGAAGCCAAAGCGTA -3’ (highlighted in light blue) 
Reverse 5’- ATGCCTGTCCCACTCAGATA -3’ (highlighted in light red) 
Probe-FWD 5’- CTCCCCTAGTTCCAGCCGCATGTG -3’ (highlighted in light yellow) 
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Lama5 genomic sequence with primers and probe highlighted: 
AGCAGCTCCCATCTCTGCACCAAGCCCAGGGAGGGGGCAGCATGGTTCACCTGGATAGCCATCA
TGTGTGCGTAGCCTCTCCAGCTAAAGTTCTCAAACTCCAGGGGGTTGAAGCCAAAGCGTACAGC
GTGGCCCTCGGGAGTGGCCGCCTCC(T/C)CTAGTTCCAGCCGCATGTGGTGCAGGTCTGGCAA
GTAGTGGTCCTTCGCTGGCCTGCCATGAAACAGGTATCTGAGTGGGACAGGCATGGCCCTACAT
GGCC 
The reaction conditions for a 10 μl reaction were 5 μl of Hot Shot PCR master mix 
(Diamond, Clent Life Science, UK), 1 μl LCGreen, 0.5 μl reverse primer (20 ng/μl), 0.1 μl 
forward primer (20 ng/μl), 0.5 μl probe (20 ng/μl), and 0.9 μl double-distilled water. 
Standard PCR settings were as follows: starting temperature at 95oC for 2 min, then 55 
cycles alternating at 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds. The 
hybridisation step was at 95°C for 30 seconds, 25°C for 30 seconds and 15°C for 30 
seconds. 
 
2.3 C3pde-Lama5E884G Phenotyping and Characterization 
2.3.1 Metabolic Caging and Urinalysis 
A time course analysis using metabolic caging and terminal bleeds were performed on 
cohorts of homozygous and wild-type C3pde-Lama5E884G mice at 7, 12, 15, 20 and 22 
weeks of age. Mice were singly housed for overnight in metabolic cages (Techniplast) to 
collect urine for further analysis. 
Urine was diluted 1:10 with double-distilled water, 10 μl of the diluted urine are 
combined with 2.5 μl of sample buffer (NuPAGE, Invitrogen), 1 NuPAGE Antioxidant 
reducing agent. Samples of 5 μl from three male wild-types, three male homozygous 
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and three female homozygous, were loaded onto sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) precast gel (NuPAGE 4-12%  Bis-Tris). As 
controls, 1 μg/μl and 2 μg/μl bovine serum albumin (BSA) was prepared in the same way 
and loaded, as well as 5 μl of SeeBlue Plus2 Pre-stained Protein Standard (Invitrogen) as 
size ladder. The SDS-PAGE was run for 1 hour at 200 V with MOPS running buffer 
(NuPAGE MOPS SDS Running Buffer 20X). 
The gel was then stained with 25 ml of Quick Blue (Triple Red) on the shaker for 30 
minutes.  
 
2.3.2 Clinical Biochemistry Analysis of Plasma and Urine 
Blood samples were obtained through retro-orbital sinus with a prior intraperitoneal 
injection of euthatal. Plasma was collected by centrifuging at 8000g, for 10 minutes at 
4°C. Plasma was kept at °C and processed within a week. 
Plasma concentrations of albumin, urea, creatinine, total cholesterol, HDL and LDL were 
measured on an AU400 Olympus analyser by the clinical chemistry core team at MRC 
Harwell.   
 
2.3.3 Gene Expression Analysis 
RNA was extracted from ~30 mg of kidney cortex using RNeasy Mini Kit (QIAGEN) 
following the manufacturer’s protocol then the concentration was measured by using 
the NanoDrop (Thermo Fisher Scientific).  
cDNA was synthesised using high capacity cDNA reverse transcription kit (Thermo Fisher 
Scientific). The RNA was diluted to a concentration of 200 ng/µL to form a total volume 
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of 10 µL and mixed with 2 µL of 10X RT Buffer, 0.8 µL of 25x dNTP mix (100mM), 2 µL 
10x of RT random primers, 1 µL Multiscribe reverse transcriptase and 4.2 µL of Nuclease-
free water. The reagents so combined were run on a PCR block using the following 
program: 25°C for 10 minutes, 37°C for 120 minutes and 85°C for 5 minutes. Store at 
4°C.  
The cDNA synthesised was diluted 1:50 with double-distilled water to obtain 2ng/µL 
cDNA for TaqMan assay (Thermofisher). The reaction conditions for a 15 µL reaction 
were 10 µL of 2X TaqMan fast universal PCR master mixes, 1 µL of the target genes and 
reference genes 20x TaqMan Assay (Table 2.1), 4 µL of double-distilled water. The mix 
was dispensed in MicroAmp Fast Optical 96-Well Reaction Plate (Thermofisher) and 5 
µL of 2 ng/µL cDNA were added, three technical replicates for each sample to isolate 
sources of variation in measurements, and three biological replicates for each genotype 
were used. The plate was sealed with an optically clear adhesive lid and run on a 7500 
fast real-time PCR System (Applied Biosystems™). Results were analysed using Taqman 
7500 software. Alongside the gene of interested, three different housekeeping genes 
(Hprt1, Tbp and Gapdh) were assessed and the one with a more even expression across 
all the samples (Hprt1) was chosen to normalise the expression of the target genes. 
55 
 
 
Table 2.1. List of genes and associated Taqman probes used in the gene expression study. 
 
2.3.4 Immunoblotting 
Kidneys were obtained from terminal wild-type and Lama5E884G/E884G animals, snap 
frozen at the time of dissection and stored at -80°C until required.  
Proteins from a whole kidney were extracted by homogenising the tissue in RIPA buffer 
(150mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50mM Tris, pH 7.5) containing 
phosphatase (Roche) and protease (Roche) inhibitors in Precellys CK28 homogenisation 
tubes. Protein concentration was measured by Bradford assay and measured on a 96 
wells Nunc plate (Thermo Fisher). Bovine serum albumin (BSA) at a concentration of 1.4 
mg/mL, 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/mL and 0.06 mg/mL were used as 
standards.  
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LDS sample buffer (Invitrogen) and reducing agent (Invitrogen) were mixed to 20 μg of 
proteins and loaded in an SDS-PAGE 4-12% Bis-Tris gel (Invitrogen). Electrophoresis was 
performed for 200 V for 60 minutes at room temperature.  
The proteins were transferred to hybond polyvinylidene difluoride (PVDF) membrane 
(GE Healthcare) using an X-Cell Blot Module (Invitrogen). After the transfer, PVDF 
membranes were blocked in 5% w/v milk powder in phosphate buffered saline (PBS) 
with 0.1% Tween-20 (PBS-T) for 60 minutes with gentle shaking. Primary antibodies 
(Appendix 8.1.1), anti-integrin β1 (1:1000), anti-ILK (1:1000), anti-paxillin (1:5000), anti-
CDC42 (1:1000) and anti-RhoA (1:10000) were in 5% w/v milk powder in PBS-T for 60 
minutes with gentle shaking. The membranes were washed for 3 times in 0.1% PBS-T. 
Secondary antibodies (Appendix 8.1.2) diluted in 5% w/v milk powder in 0.1% PBS-T for 
60 minutes at room temperature, and then washed again in 0.1% PBS-T protected from 
light. The membranes were then dried in the dark.  
Fluorescent blots were scanned using a LI-COR Odyssey Cl-x or SA scanner (LI-COR 
Biosciences) to visualise bound antibodies. Image Studio Lite software (LI-COR 
Biosciences) is used for quantification and analysis (Median, 3-pixel border background). 
Protein expression target proteins has been normalised to the expression of wither α-
tubulin (1:2000) or β-actin (1:3000). 
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2.4 In Vitro Analysis of Laminin Assembly 
2.4.1 Laminin α5 Clone Propagation and Site-Directed Mutagenesis 
Full-length Lama5 clone in pSK+II vector, kindly gifted by Professor Jeff Miner, was 
transformed in XL-10 gold E.coli (Agilent) for 30 minutes and heat shocking at 42°C for 
30 seconds, plated on 100µg/mL ampicillin Luria-Bertani (LB) agar plates and incubated 
at 37°C overnight. Colonies were picked and grown overnight at 37°C with shaking in 
100µg/mL liquid LB broth. Colonies are picked and grown for a further 24 hours in LB 
broth. 
DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer’s protocol. Briefly, bacteria were pelleted, lysed and centrifuged to pellet 
cell membranes and organelles. The supernatant was applied to a spin column and DNA 
bound by centrifugation. Bound DNA was briefly washed before being eluted in 10mM 
Tris buffer.  
pSK+II-Lama5 has then used as a template for site-directed mutagenesis of the E884G 
mutation using Q5 site-directed mutagenesis kit (NEB) and the following primers to 
introduce the point mutation: 
Forward 5’-CTGGAACTAGgGGAGGCGGCC-3’ 
Reverse 5’-CCGCATGTGGTGCAGGTC -3’ 
PCR was performed according to manufacturer’s protocol with an initial denaturation of 
98°C followed by 25 cycles of 98°C for 10 seconds, 70°C for 30 seconds and 72°C for 2 
minutes. 
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Kinase, Ligase and DpnI (KLD) reaction were performed according to the kit instructions 
for 5 minutes at room temperature. Mutagenised vector was transformed into 50µL of 
NEB-5α competent cells. 950 µL of super optimal broth (SOC) was added to the bacteria 
and then incubated for 1 hour at 37°C with shaking. 100 µl were plated on 100µg/mL 
ampicillin LB agar plates overnight. DNA is again extracted using plasmid midi kit 
(Qiagen). Sanger sequencing using the following primers confirmed the presence of the 
mutation: 
Forward 5’-AAACTCCAGGGGGTTGAAGC-3’ 
Reverse 5’-AGCGAAGGACCACTACTTGC-3’ 
 
2.4.2 Cloning of the Laminin α5 Chain Short Arm 
2.4.2.1 Amplification, Insertion and Transformation 
Different fragments of the laminin α5 chain were cloned following the protocols of the 
OPPF (https://www.oppf.rc-harwell.ac.uk/OPPF/protocols/): LN-LEa, LN-L4a-LEb, LN-
L4a-L4b-LEc and L4a. 
pSK+II-Lama5 and pSK+II-Lama5-E884G vectors were used as template to amplify the 
targeted ORFs. Three different expression vectors were used: pOPINTTGneo, with a C-
terminus His tag and internal signal sequence, pOPINTTGneo-Fc, with a C-terminus His 
and FC tags and internal signal sequence, and pOPINEneo, with a C-terminus His tag. The 
sequence of the vectors can be found at https://www.oppf.rc-
harwell.ac.uk/OPPF/protocols/cloning.jsp.  
ORFs were amplified using Phusion Flash (Thermoscientific) or  KOD Xtreme™ Hot Start 
DNA Polymerase (Novagen). For Phusion Flash, a reaction of 50 µl  was set up as follows: 
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25 µl of Phusion Flash Master Mix, 3 µl of 10 µM of forward primer (Table 2.2), 3 µl of 
10 µM of reverse primer (Table 2.2), 2  µl of ~10-20 ng/ µl template plasmid, and 17 µl 
of sterile water. Standard PCR settings were as follows: starting temperature at 98°C for 
10 seconds, then 29 cycles alternating at 98°C for one second, 60°C for 5 seconds, 68°C 
for 15 seconds per kb, and then 68°C for 2 minutes.  
For KOD Xtreme™ Hot Start DNA Polymerase, a reaction of 50 µl  was set up as follows: 
25 µl of 2X KOD Hot Start Buffer, 10 µl of dNTP mix, 1 µl of KOD Hot Start, 3 µl of 10 µM 
of forward primer (Table 2.2), 3 µl of 10 µM of reverse primer (Table 2.2), 2  µl of ~10-
20 ng/ µl template plasmid, and 6 µl of sterile water. Standard PCR settings were as 
follows: starting temperature at 94°C for 2 min, then 29 cycles alternating at 98°C for 10 
seconds, 60°C for 30 seconds, 68°C for 1 minute per kb, and then 68°C for 2 minutes. 
Ligation in the destination vectors was carried out using the In-Fusion® HD EcoDry™ 
Cloning Plus (Takara). Briefly, 1µl (100ng) of the appropriate linearised pOPIN vector 
(provided by the OPPF) was added to a 10-250 ng of PCR product. The mix was incubated 
for 30 minutes at 42°C and the reaction stopped diluting the reaction with 40 µl of Tris 
EDTA (TE) buffer. The In-Fusion reaction was transformed into OmniMaxII competent 
cells (Thermofisher) heat shocking the cells for 30 seconds at 42°C. After being incubated 
for one hour in 1.2 mL of SOC medium, 20 µl of cells were plated on 50 mg/mL of 
carbenicillin LB agar plates and then incubated overnight at 37°C. The day after, colonies 
were picked and grown overnight at 37°C. The plasmid mini-preps were performed on 
the Bio-Robot 8000 (Qiagen). 
All experiments were performed in triplicates. 
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Table 2.2. List of primers used to amplify the different fragments of the LAMA5 short arm. 
 
2.4.2.2 Expression in Mammalian Cells for Immunoblotting 
HEK-293T (ECACC 12022001) cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM), supplemented with 10% foetal bovine serum (FBS) and 1x 
penicillin/streptomycin, and kept in a 5% CO2, 37°C environment. When required, cells 
are split 1:20-1:40 by first washing with pre-warmed PBS, and detached using 0.05% 
trypsin. 
OPPF transfection and immunoblotting protocol. HEK-293T cells were plated in 24-well 
plates at a concentration of 1.5-2*105 cells/ml, 16-24 hours prior transfection. DNA 
vectors were transfected using 2 µl of GeneJuice (EMD Millipore) per 1 µg of plasmid 
DNA, mixed with 60 µl serum-free DMEM. After 10 minutes incubation at room 
temperature, the DNA/GeneJuice cocktail was added to the cells and incubated at 37°C 
in a 5% CO2 environment. 
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After 72 hours, the conditioned medium was harvested and centrifuged for 15 minutes 
at 6000 g at 4°C, and then 20 µl were used for immunoblotting as previously described. 
In the meantime, cells were lysed with lysis buffer (NPI-10, DNase and protease 
inhibitors), and 20 µl used for immunoblotting as previously described.  
MRC Harwell transfection and immunoblotting. HEK-293T cells were plated in 6-well 
plates at a concentration of 2.5x105 cells/well, 16-24 hours prior transfection. DNA 
vectors were transfected using per ~1 µg of plasmid DNA, or in 6-well plates using 4 µl 
of jetPRIME (Polyplus) reagent per 2 µg of plasmid DNA, mixed with 200 µl of jetPRIME 
buffer. The mixture was incubated at room temperature for 10 minutes, then added 
dropwise to the cell medium and incubated at 37oC with 5% CO2 for 72 hours. 
Conditioned medium was harvested and clarified for 15 minutes at 6000 g at 4°C. A 20 
µl sample was mixed to LDS buffer and reducing agent and used for immunoblotting as 
previously described. The cells were lysed using x1 LDS buffer with added proteinase 
inhibitors, then 20 µl were loaded onto an SDS-PAGE gel and run as with 
immunoblotting. 
 
2.4.3 Cloning of the Full-Length Laminin α5 Chain  
2.4.3.1 Amplification, Insertion and Transformation 
Using pSK+II-Lama5 and pSK+II-Lama5-E884G vectors as templates, full-length laminin 
α5 chain was cloned into a pCMV6-AC-His vector. PCR was performed using Phusion 
polymerase with the following primers: 
Forward: 5’-AGATCTGCCGCCGCGATCGCATGGCGAAGCGCGGA-3’ 
Reverse 5’-GTTTCTGCTCGAGCGGCCGCTCAATGCCAAAGTAGCGGG -3’ 
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PCR is performed using a touchdown protocol with an initial denaturation of 95°C for 10 
minutes followed by cycles of 95°C for 10 seconds, 62°C (2x), 60°C (2x), 58°C (2x), 56°C 
(15x) for 20 seconds and 72°C for 8 minutes with a final elongation step of 10 minutes. 
PCR products were run of a 2% agar gel and the band of the right size (~11.3 kb) was 
purified using QIAquick gel extraction purification kit (Qiagen) according to 
manufacturer’s protocol of binding DNA to a spin column, washing briefly and finally 
eluting in 10mM Tris buffer. pCMV6-AC-His was linearised with a double digestion using 
SgfI (Promega) and MluI (Promega) restriction enzymes for four hours at 37°C. 
Purified PCR products were ligated onto linearised pCMV6-AC-His using Quick-Fusion 
cloning kit (Biotool). Briefly, a reaction of 10 µl with 20-100 linearised vector, 10-100 ng 
of the insert, 1 µl of fusion enzyme and 2 µl of 5X fusion buffer was set up and incubated 
for 30 minutes at 37°C. The resulting mix was transformed into NEB-5α competent cells 
as previously described.  
 
2.4.3.3 Expression in Mammalian Cells 
HEK-293 cells stably expressing human LAMB1 (HA-tagged) and human LAMC1 (FLAG-
tagged) were a kind gift of Prof Peter Yurchenco and Dr Karen McKee[223] and were 
maintained in DMEM, supplemented with 10% FBS, 500 µg/ml G418 (Sigma) and 100 
µg/ml zeocin (Invitrogen), and kept in a 5% CO2, 37°C environment. When required, cells 
are split 1:5-1:10 by first washing with pre-warmed PBS, and detached using 0.05% 
trypsin for a minute. 
Stable laminin β1γ1 HEK-293 cells were plated in 6-well plates at a concentration of 
5x105 cells/well, 16-24 hours prior transfection. pCMV6-AC-His-Lama5 and pCMV6-AC-
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His-Lama5-E884G were transfected using jetPRIME. After 72 hours, conditioned 
medium was harvested and cells lysed. Samples of medium and cell lysate were used for 
immunoblotting experiments.  
 
2.5 B6-Lama5E884G Phenotyping and Characterization 
2.5.1 Metabolic Caging and Urinalysis  
A time course analysis using metabolic caging and terminal bleeds were performed on 
cohorts of homozygous and wild-type LAMA5-E884G-B6-IC mice at 5, 15 and 25 weeks. 
Mice were singly housed for 24 hours in metabolic cages (Techniplast) to collect urine 
for analysis and to measure water intake and urine output.  
Urine creatinine was quantified using an AU400 Olympus analyser. Urinary protein 
concentration was quantified using Bradford protein assay (Biorad) using BSA at a 
concentration of 1.4 mg/mL, 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/mL and 0.06 
mg/mL as standards, and then normalised to urine creatinine. 
 
2.5.2 Clinical Biochemistry Analysis of Plasma  
Blood samples and plasma analysis were performed as described in 6.3.2 
 
2.5.3 Light and Electron Microscopy 
Kidneys were collected from male wild-type and male Lama5E884G/E884G mice at 5, 15 and 
25 weeks of age to investigate the progression of the glomerulopathy phenotype.  
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For light microscopy, kidneys fixed in 10% neutral buffered formaldehyde were 
embedded in paraffin wax and sectioned at 5 μm using a Finesse ME microtome (Thermo 
Electron). Kidney sections were stained with haematoxylin and eosin (H&E), periodic 
acid-Schiff (PAS) and Masson’s trichrome (MT) stain.  
For TEM, 1mm3 cubes of kidney cortex were fixed in 3% glutaraldehyde and 4% 
formaldehyde in 0.1 M PIPES and post-fixed with 1% osmium tetroxide in 0.1 PIPES. After 
serial dehydration in increasing concentration of ethanol, the blocks were stained with 
2% uranyl acetate for 20 minutes. The tissue was then embedded in epoxy resin (TAAB) 
and polymerised overnight at 60˚C. Semithin sections of 500 nm were cut and stained 
with toluidine blue staining to make sure of the presence of glomeruli in the tissue block 
(Figure 2.2). Golden ultrathin sections (70-80 nm) were cut with a diamond knife and 
collected them on copper/palladium grids. For better contrast, grids were stained with 
lead citrate. The ultrathin sections were visualised on a Hitachi HT7700 transmission 
electron microscope. 
 
Figure 2.2. Representative histology of a semithin section. Sections were cut and stained to make sure 
that at least four glomeruli (asterisk) were present in the block.  
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For SEM, 1mm3 cubes of kidney cortex were fixed in 3% glutaraldehyde and 4% 
formaldehyde in 0.1 M PIPES and post-fixed with 1% osmium tetroxide in 0.1 PIPES. 
Samples were then dehydrated through increasing strength of ethanol solutions and 
critical point dried using an Emitech K850 (EM Technologies LTD). Three specimens per 
animals were then mounted on stubs using silver paint (Agar Scientific) and sputter 
coated with platinum using a Quorum Q150T sputter coater (Quorum Technologies). 
The specimens were untimely visualised with a JEOL LSM-6010 (Jeol Ltd.). 
 
2.5.4 Immunofluorescence 
Primary antibodies (Appendix 8.1.1) rabbit anti-mouse laminin α5 (clone 1586) [224], 
rabbit anti-mouse laminin β1 (clone 1065) and rabbit anti-mouse laminin β2 (clone 
1117) [225] were generously provided by Prof Jeff Miner (Washington University, USA). 
Mouse anti-human active integrin β3 (clone WOW-1) [226] mouse anti-human active 
integrin β3 (clone AP5) [227] were a kind gift from Prof Sanford Shattil (UC San Diego, 
USA) and Dr Peter Newman (Blood Center of Wisconsin, USA) respectively. 
For immunofluorescence analysis, kidneys were fixed in Tissue-Tek® (Sakura) using 
isopentane on dry ice. Cryosections of 10 μm of different genotype were placed on the 
same slide kept at -20°C until needed. Sections were fixed with ice-cold acetone for 10 
minutes at 20˚C, then blocked using 5% goat serum (normal serum) in PBS for 30 minutes 
at room temperature. The sections were then stained with different primary antibodies 
at 4˚C overnight and Alexa-conjugated secondary antibody (Appendix 8.1.1) for 30 
minutes at room temperature. Images were taken using a Zeiss LSM 700 inverted 
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confocal microscope on the same day using the same pinhole, gain, offset and laser 
intensity using the 63x NA 1.4 plan-apochromat oil-immersion objective. 
 
2.5.5 Murine Glomeruli Isolation and Protein Extraction 
The glomeruli from 15 weeks (wild-type n= 5 and homozygotes n=5) and 25 weeks (wild-
type n= 5 and homozygotes n=4) old male mice were isolated following a modified 
Dynabeads-based protocol previously described [228]. The mice were perfused with 
Dynabeads® M-450 Tosylactivated (Thermofisher) diluted in PBS, the kidneys collected 
were then minced and the glomeruli were gathered by a Magnetic Particle Concentrator 
DynaMag™-2 (Thermofisher). For the glomeruli used for fractionated protein extraction, 
the incubation with collagenase I at 37˚C was skipped to avoid digestion of the ECM 
component of the glomerulus. 
The isolated glomeruli were incubated for one hour in ice-cold TB buffer (10 mM Tris, 
150 mM NaCl, 25 mM EDTA, 1%Triton X-100) then centrifuged at 14000x g for 10 
minutes to obtain cellular fraction 1. The remaining pellet was incubated for one hour 
in ice-cold EB buffer (20 mM ammonium hydroxide, 0.5% Triton X-100) then centrifuged 
at 14000x g for 10 minutes to obtain cellular fraction 2. The remaining pellet was 
incubated for 30 minutes in deoxyribonuclease-ribonuclease buffer (25 μg/mL DNase, 
25 μg/mL RNase) to degrade DNA and RNA, then centrifuged at 14000x g for 10 minutes 
to obtain nuclear fraction. The final ECM enriched pellet was resuspended in sample 
buffer (7% SDS, 30% glycerol, 0.2 M Tris-HCl pH 6.8, 0.01% bromophenol blue, 10% β-
mercaptoethanol) to obtain the ECM fraction [229]. All the steps were carried on ice or at 
4˚C. 
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2.5.6 Mass Spectrometry Analysis 
The samples obtained by protein extractions were prepared for liquid chromatography-
tandem MS analysis. The two cellular component fractions were combined and run, 
along with the ECM fraction, on a Bis-Tris 4-12% SDS-PAGE for 3 minutes at 200 V. The 
gels were then stained with Coomassie staining to visualise the protein samples. After 
washing with double-distilled water, the “gel top” proteins were cut into slices and then 
in 1 mm3 pieces, and then given to the MS facility core at the University of Manchester 
for in-gel proteolytic digestion, offline peptide desalting and actual MS run. All the 
samples were run blindly, in a random sequence of genotype and age. 
Quantitative analysis was carried out using the software using Progenesis LCMS (Non 
Linear Dynamics Ltd) in association with the use of Mascot (Matrix science) used to 
identify the proteins. Statistical analysis was performed on proteins identified by at least 
three unique peptides.  
2.5.7 Immunoblotting 
Immunoblotting was performed as described in 6.3.4. 
For rat anti-mouse integrin β1 clone 9EG7 (1:100, BD Pharmingen) proteins were run on 
SDS-PAGE under non-reducing conditions. 
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CHAPTER 3 
Identification of Chronic Renal Disease Resulting 
from a Mutation in Lama5  
69 
 
3. Identification of Chronic Renal Disease Resulting 
from a Mutation in Lama5 
3.1 Initial Identification 
3.1.1 The Harwell Ageing Screen  
MRC Harwell has been a pioneer of ENU-based phenotype-driven screens since the 
1990s [211]. To study recessive mutations causing age-related or late-onset diseases, a 
large-scale mouse screen, the Harwell ageing screen, was established at MRC Harwell 
Institute. A total of 157 pedigrees, each comprising around 100 mice, entered the 
phenotyping pipeline and a total of 105 distinct mutant lines were identified in 72 of the 
pedigrees [222]. The G3 mice were periodically put through a variety of phenotyping 
procedures to assess vision, hearing, behaviour, body composition, musculoskeletal 
abnormalities, defects in heart conduction and different organ profiles by clinical 
chemistry analysis (Figure 3.1). The pipeline ran from 12 weeks to 18 months of age. 
After being euthanized and terminally bled, selected mice were sent for a complete 
pathological examination of tissues to assist in the confirmation or determination of a 
phenotype [222]. 
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Figure 3.1. Graphic display of the Ageing Screen pipeline: the mice were phenotyped at the time points 
outlined in the figure (circles). In addition to the tests of the phenotype pipeline, mice are weighed every 
3 months up until 12 months of age and then monthly from 12 months onwards. Image adapted from 
Potter et al. [222]. 
 
3.1.2 Pedigree MUTA-PED-C3pde-205 
During the analysis of the clinical chemistry data from the pedigree MUTA-PED-C3pde-
205 (MPC-205) at 6 months of age, six mice out of 70 were identified with higher levels 
of urea, creatinine and amylase and lower levels of albumin than their littermates 
(Figure 3.2 A and D). Based on the breeding scheme used to generate the G3 screening 
pedigrees (described in chapter 2, section 2.1), the expected ratio of homozygous mice 
for the causative mutation is 1:8 mice. Chi-square test was used to establish whether a 
normal Mendelian inheritance was conserved. Chi-squared equals 0.988 with one 
degrees of freedom and a two-tailed P value of 0.03203, indicating a normal ratio 
between observed (6 putative homozygotes and 64 heterozygotes/wild types) and 
expected mice (8.75 homozygotes and 61.25 heterozygotes/wild types). The clinical 
chemistry results indicated kidney impairment but the mice did not show any other signs 
of poor health or any other abnormal readings on the parameters analysed during the 
routine panel. Total lactate dehydrogenase (LDH) plasma levels, a marker of tissue 
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damage, appeared to be normal. Parameters such as alkaline phosphatase (ALP), alanine 
transaminase (ALT) and aspartate aminotransferase (AST) were within the normal range, 
suggesting that liver function is maintained at normal levels. As liver function appears 
to be normal, decreased plasma albumin was attributed to kidney impairment.  
 
Figure 3.2. Clinical chemistry analysis of the pedigree MUTA-PED-C3pde-205 at 6 months of age. 
Outliers (in red) exhibit higher levels of urea, creatinine (A) and amylase (E), and lower levels of albumin 
(D) when compared to the other mice of the pedigree. The same mice also exhibit hypercalcemia (D), the 
common secondary effect of kidney impairment due to an abnormal phosphorus/calcium metabolism. 
The mice did not show altered liver function or tissue damage (B and C). 
 
The affected mice did gradually deteriorate and were eventually culled at 9 months of 
age for welfare concerns, including loss of weight and piloerection, or died suddenly. 
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The bodies were potted in 10% formalin and sent for a default post-mortem analysis. 
The resident pathologist could not see any histopathological lesion in any organs but the 
kidneys, which exhibited signs of CKD (Figure 3.3).  
 
Figure 3.3. H&E stained sections of kidneys of one of the outliers identified in the pedigree MPC-205. 
The affected mice showed typical lesion of CKD: fibrosis of the Bowman’s capsule (black arrow), dilated 
tubules (green arrows) with protein casts (red arrows). Scale bar represents 1 mm (A) and 100 µm (B). 
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Using the elevated kidney markers and the CKD histological lesions as the affected traits, 
samples of five affected mice and a control littermate were sent for mapping using the 
Illumina Golden Gate “Mouse Medium Density (MD) Linkage Panel” [230]. This panel 
includes 1,449 SNPs to have a uniform distribution across the mouse genome with a 
density of around three SNPs per five megabases, of which at least one is informative 
for crosses involving C57Bl/6J mice [230]. Since the ENU treatment is firstly carried out on 
the C57BL/6J G0, the region(s) carrying the causative mutation should be either 
homozygous (for recessive alleles) or heterozygous (for dominant alleles) for C57BL/6J 
when compared with C3H-C3pde SNPs in the same region. The chromosomal region 
containing the possible causative mutation was mapped to chromosome 2, in a region 
between 171 Mb and the end of the chromosome (Figure 3.4), as this was the only 
region where all the affected were homozygous for C57BL/6J. This region, of 
approximately 10 Mb, contains 242 genes (Appendix 8.2). The best candidate was 
identified in the gene coding for laminin α5 chain, Lama5, a major component of the 
GBM involved in both glomerular development and preservation of the GFB.  
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Figure 3.4. Graphic display of the candidate region on chromosome 2. DNA from five affected mice and 
one unaffected control was sent for mapping: ENU treatment is carried out on the male G0 C57BL/6J 
hence the region carrying the causative mutation is homozygous for C57BL/6J when compared with C3H-
C3pde6b+ (C3H) SNPs. 
 
To identify the mutation underlying the observed phenotype, WGS analysis performed 
by Wellcome Trust Centre for Human Genomics sequencing facility and analysed by the 
MRC Harwell bioinformatics team on the DNA from the G1 pedigree founder. Using a 
scoring system based the read depth, a high confidence score was given to variants 
observed in a number of reads, on the contrary variants that were only found in a one 
or low numbers of reads was assigned a low confidence score (meaning that the variant 
is more likely to represent an error rather than a real mutation). This analysis identified 
23 mutations in the candidate region, five of which were high confidence. Four of the 
high confidence mutations were intragenic variants, the fifth mutation was a coding 
mutation in Lama5 mutation (Table 3.1).  
The candidate mutation, in exon 22, resulted in a missense variant consisting of an A to 
G transition at nucleotide 2651. The nucleotide change results in a glutamic acid (E) to a 
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glycine (G) substitution at amino acid 884 in the LAMA5 protein. Sanger sequencing of 
DNA from an affected mouse and C57BL/6J wild-type control confirmed the A to G 
transition (Figure 3.5 A). 
 
Table 3.1. List of the mutations included in the candidate region on chromosome 2. In light grey are 
shown the mutations with a low confidence score, in dark grey the mutations with a medium confidence 
score, in yellow the mutation with a high confidence score. Lama5E884G missense variant is the only coding 
high confidence mutation resulting from the WGS analysis. 
 
The glutamic acid residue is well conserved back to Drosophila (Figure 3.5 B) and is part 
of the L4a domain on the short arm of the laminin α5. 
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Figure 3.5. Result of the Sanger sequencing of C57BL/6J control and an affected mouse from the MPC-
205 mouse line used to validate the mutation in Lama5 (A). Comparison between the amino acid sequence 
of different species shows how the E884 residue is conserved down to Drosophila (B).  
 
In order to assess the effect of this amino acid substitution, different web-based protein 
prediction algorithms were consulted through their online interfaces for in silico 
analysis. The software predicted the mutation to be deleterious for the function or 
structure of the protein (Table 3.2). 
 
Table 3.2. Protein prediction software PROVEAN, SIFT, SNAP, Meta-SNP and PhD-SNP described the 
Lama5E884G mutation as deleterious. 
 
Given the close association of Lama5 with renal development and function, I worked on 
the hypothesis that the missense variant was the causative mutation for the renal 
phenotype observed in the MPC-205 pedigree. 
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A LightScanner assay [231] was set up to genotype retrospectively the whole pedigree 
analysing the DNA extracted from the tails of the MPC-205 mice.  Genotyping results 
demonstrated only mice homozygous for the Lama5E884G mutation exhibited a 
phenotype (Figure 3.6). Furthermore, there was no detectable phenotype in the 
heterozygous mice.  
 
Figure 3.6. Results of the clinical chemistry analysis of the pedigree MUTA-PED-C3pde-205 at 6 months 
of age, with the animals grouped according to their genotype. The homozygous mice are the only ones 
showing alteration in the concentration of kidney markers (urea, A and creatinine, B), albumin(C) and 
amylase (D). The values shown are means ± SEM. One-way ANOVA **** p<0.0001.  
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3.2 Gene Validation 
To confirm the causative mutation, we ordered a Lama5 global knock-out, the Lama5-
tm1b line, from the IMPC. Tm1b alleles are produced by the deletion of a critical exon 
and the neomycin cassette using a Cre recombinase that recognises loxP sites flanking 
the critical exons, resulting in a null allele. In the case of Lama5, the deleted critical exons 
are exons 4, 5 and 6 (Figure 3.7 A). As in the previously described Lama5 knockout line 
[103], Lama5-tm1b-/- died between E14.5 and E18.5 (Figure 3.7 B and C) with complete 
penetrance. No phenotype was observed in heterozygous mice. 
 
Figure 3.7. A: Graphic representation of the Lama5-tm1b allele. Critical exons 4, 5 and 6 are deleted 
and result in a null allele. The LacZ cassette expresses LacZ in tissues where Lama5 is knocked out. Image 
adapted from http://www.mousephenotype.org/. B-C: Microtomography (µCT – far left) images of 
Lama5-tm1b-/- embryos and wild-type controls. Lama5-tm1b-/- showed preweaning lethality due to a 
strong phenotype of exencephaly, dying between E14.5 and E18.5. The image was taken by Zsombor 
Szoke-Kovacs (team LacZ, MRC Harwell Institute). 
79 
 
To validate the link between the phenotype and the mutation in Lama5, a cross between 
Lama5 knockout mice line (Lama5-tm1b) and the line carrying the E884G mutation was 
set up to generate compound heterozygotes (Lama5E884G/-). Since heterozygous 
Lama5E844G/+ mice and Lama5+/- mice did not show any kidney impairment, the 
phenotype should be present only in mice carrying the E884G mutation inherited from 
the MPC-205 line and the Lama5-tm1b allele. 
As expected, compound heterozygous mice (Lama5E884G/-) developed the same 
phenotype as the original phenotype, but with a more rapid progression. At 22 weeks 
of age, the mice had to be culled due to welfare concerns and analysis of plasma 
confirmed ESRD (Figure 3.8). The littermates used as controls (Lama5+/+, Lama5+/-, 
Lama5E844G/+) did not show any sign of proteinuria or variation in renal function markers 
in the plasma analysis, confirming the Lama5E884G as the causative mutation underlying 
the observed nephrotic syndrome phenotype. 
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Figure 3.8. The clinical chemistry analysis of plasma confirmed kidney insufficiency (A and B) and 
hypoalbuminaemia (C) in Lama5E884G/- mice. The values shown are means ± SEM. One-way ANOVA **** 
p<0.0001. Coomassie blue stained gel shows the presence of albumin in the urine of Lama5E884G/- mice at 
21 weeks of age (D). 
 
3.3 C3pde-Lama5E884G Phenotyping and Characterization 
3.3.2 Phenotyping 
To establish the experimental cohorts, the line was rederived by in vitro fertilization (IVF) 
using the sperm from the G1 male founder of the MPC-205 pedigree, and backcrossed 
for one generation onto C3H-C3pde6b+ and then intercrossed.  Since the heterozygous 
mice of the original MPC-205 pedigree did not show any phenotype, the time course 
analysis was performed on cohorts of wild-type (C3pde-Lama5+/+) and homozygous 
(C3pde-Lama5E884G/E884G) mice to identify the earliest time point where kidneys start to 
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lose their normal function and also to study disease progression. At 7, 12, 15, 20 and 22 
weeks of age, mice of both sexes were put through metabolic cages to collect urine, 
were terminally bled to collect plasma, and tissue was harvested for further analysis. 
Interestingly, after the first backcross, the disease became more severe and aggressive, 
with the mice reaching the humane endpoint around 26 weeks of age instead 9 months 
as in the original pedigree.  
 
3.3.2.1 Inheritance  
Given the pre-weaning lethality found in Lama5 null mice, it could be possible that the 
mutation E884G had some effect on embryonic development. To exclude the possibility 
of embryonic lethality, the total number of genotyped mice of the C3pde-Lama5 line 
(hence all the mice that made it to weaning) was compared with the expected 
Mendelian inheritance from a heterozygous intercross (1 wild type: 2 heterozygotes: 1 
homozygote). Based on 291 genotyped mice with a ratio of 91:121:79, the chi-square 
value obtained was 0.0099 with an expected Mendelian ration of 72.75:145.5:72.75 
(Figure 3.9). This value indicates that the E884G mutation does not result in a loss of 
mice before weaning (72.75 expected mice versus 79 observed) and that its inheritance 
follows the Mendelian ration. However, there was a reduction in the number of 
heterozygous mice (145 expected mice versus 121 observed) in favour of wild types 
(72.75 expected mice versus 91 observed). This could be due to the effect of additional 
mutations still present in the one generation C3H-C3pde6b+ backcross mice, such as the 
identified donor splice in the gene Ptprq (encoding protein tyrosine phosphatase, 
receptor type Q) [222] also identified in the pedigree MPC-205. 
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Figure 3.9. Total numbers of mice from each genotype from the C3pde-Lama5 line. 
 
3.3.2.2 Clinical Chemistry and Urinalysis Time Course Analysis of the C3pde-
Lama5E884G/E884G Phenotype  
Blood samples were collected from wild-type and homozygous mice at each time point 
by puncture of the retro-orbital sinus as a terminal procedure. The analysis of plasma 
from cohorts of control and homozygous C3pde-Lama5E884G/E884G showed a progressive 
deterioration of the renal function (Figure 3.10 A, B and C) with age-related increased 
levels of urea and creatinine. Albumin levels were decreased before signs of kidney 
impairment (at 12 weeks).   
Before being culled, the mice were singly housed in metabolic cages overnight and urine 
was collected. To assess the presence of proteinuria, the same amount of urine sample 
was run on a SDS-PAGE gel and stain with Coomassie blue stain. After staining, a large 
band of the same size as BSA was apparent in all C3pde-Lama5E884G/E884G samples at all 
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ages but was absent in samples from Lama5+/+ mice (Figure 3.10 D). Hence, the analysis 
of urine showed a severe proteinuria as early as 7 weeks. 
 
Figure 3.10. Clinical chemistry analysis of plasma shows worsening of renal function with high urea (A) 
and creatinine (B) levels and a low level of albumin (C). Hypoalbuminaemia seems to be one of the earliest 
changes. Coomassie blue-stained SDS-PAGE gels at different time points. A band of the same size of the 
BSA controls is present in all homozygous mice, both males and females, at all time points including at 7 
weeks of age when the clinical chemical plasma did not show alteration in the renal markers (D). The 
values shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test *p<0.05, **** p<0.0001. 
 
Because the mice showed two of the fundamental symptoms of nephrotic syndrome, 
analysis of lipid metabolism was added to the clinical chemistry panel. Homozygous mice 
at 12, 20 and 22 weeks of age indeed showed significantly increased levels of total 
cholesterol, LDL and HDL indicating an abnormal lipoprotein homeostasis (Figure 3.11).  
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Figure 3.11. Abnormal lipid metabolism indicated by higher plasma concentration of total cholesterol 
(A), HDL (B) and LDL (C), which is a classic symptom of nephrotic syndrome. The values shown are means 
± SEM. Two-way ANOVA with Bonferroni post-hoc test ***p<0.001, **** p<0.0001.  
 
3.3.2.3 Histological Analysis 
The clinical chemistry and urinalysis data suggested that Lama5E884G/E884G mice were 
affected by a progressive nephrotic syndrome, so histological analysis of the kidneys was 
carried out to further characterise the pathology development. The H&E stained kidney 
slides from mice of different ages showed the typical lesions of CKD from 12 weeks of 
age. The kidneys were globally compromised and the glomeruli presented with sclerotic 
Bowman’s capsules and obliteration of the Bowman’s space. The tubules were dilated 
and often contained protein casts (Figure 3.12).  
Giving the vital role of the laminin α5 chain in murine development and formation of a 
functional vascularised glomerulus, histological analysis was also performed at 
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additional earlier time points. No lesions or signs of abnormal development were 
observed at 7 or 14 days suggesting a normal kidney growth. 
 
Figure 3.12. Time course of histology on wild-type and Lama5E884G/E884G kidneys. Kidneys from 
homozygotes did not differ from the wild-type controls at 1 and 2 weeks: the glomeruli (black stars) are 
surrounded by the Bowman space and the tubules do not appear enlarged, indicating normal kidney 
development. At 12 and 22 weeks of age, the kidneys from Lama5E884G/E884G mice showed abnormal 
glomeruli (red starts) with sclerosis of the Bowman capsule with obliteration of the Bowman space, and 
enlarged tubules with protein casts, in comparison with wild type controls. Scale bar represents 100 µm. 
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3.3.2 Possible Mechanisms Involved in the Development of Nephrotic 
Syndrome in Lama5E884G/E884G Mice 
 
3.3.2.1 Gene Expression Analysis 
As a first approach to study the possible mechanisms involved in the pathogenesis of 
the Lama5-releted nephrotic syndrome, the expression of a set of genes involved in the 
composition of different structures of the glomerular filtration barrier was assessed by 
quantitative reverse transcription PCR (RT-qPCR) on three biological replicates per time 
points. The genes chosen encode proteins expressed in the apical domain of the 
podocyte body (podocalyxin and podoplanin), in the slit diaphragm (nephrin and 
podocin), in the GBM (laminin α5, laminin α2, laminin α1 and agrin) and laminin α5 
receptors (integrin α3, integrin β1 and Lutheran body).  
In general, mRNA levels of genes coding for some proteins of the slit diaphragm (nephrin 
and podocin) and of the apical domain of the podocyte body (podocalyxin) in C3pde-
Lama5E884G/E884G samples did not show any difference when compared with wild types 
of the same age after disease onset (at 15 and 22 weeks). However, both nephrin and 
podocin were upregulated at 7 weeks (Figure 3.13 A and B). The mRNA levels of the gene 
coding for podoplanin, another protein expressed in the apical domain and upregulated 
in the course of inflammation [232], were overexpressed in C3pde-Lama5E884G/E884G and 
the increase in expression was elevated further with the age of the mice (Figure 3.13 D).  
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Figure 3.13. Results of the gene expression of some genes encoding proteins of the slit diaphragm 
(nephrin, Nphs1 - A, and podocin, Nphs2 - B) and the apical domain of the podocyte body (podocalyxin, 
Podx1 - C, and podoplanin, Pdpn - D). The mRNA level of Pdpn is upregulated and increased as the mice 
aged (relative expression normalised to Hprt1). The values shown are means ± SEM. Two-way ANOVA 
with Bonferroni post-hoc test * p<0.05, ** p<0.01, *** p<0.001. 
 
For the ECM component, the expression of all the laminin α chains (Lama5, Lama2 and 
Lama1) was assessed, in addition to agrin (Agrn) since the agrin protein is associated 
with the laminin-521 trimer (Figure 3.14). In a normal fully developed glomerulus, the 
laminin α5 chain is the only α chain present in the GBM. Lama2 and Lama1 are only 
expressed in the mesangial matrix or, in the case of Lama1, as during embryonic renal 
development.  
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Figure 3.14. Results of the gene expression of some genes encoding proteins of the GBM. The mRNA 
levels of Lama5 (A), Lama2 (B) and Agrn (D) appear to be upregulated and increased as the mice aged 
(relative expression normalised to Hprt1). The values shown are means ± SEM. Two-way ANOVA with 
Bonferroni post-hoc test * p<0.05, ** p<0.01 * p<0.05, ** p<0.01, *** p<0.001. 
 
The mRNA levels of the genes coding for the main LAMA5 receptors, integrin α3β1 and 
Lu/BCAM, were also elevated (Figure 3.15).  
The upregulation of laminin α5 chain receptors, in particular, integrin α3β1, could 
suggest an abnormal signalling is being sent from the LAMA5-receptor interaction. 
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Figure 3.15. Results of the gene expression of some genes encoding proteins of the main LAMA5 
receptors, integrin α3 (Itga3, A), integrin β1 (Itgb1, B) and Lutheran body (Lu, C). The mRNA levels of all 
the receptors appear to be upregulated after disease onset (relative expression normalised to Hprt1). The 
values shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test * p<0.05, ** p<0.01, *** 
p<0.001. 
 
Once LAMA5 and integrins are bound, the signals travel through mechanical mediators, 
such as α-actinin4 (Actn4), talin-1 (Tln1) and kindlin-2 (Fermt2), and chemical mediators 
like paxillin (Pxn), ILK (Ilk), FAK (Fak) and Src (Src) (Figure 3.16), forming focal adhesions 
and maintaining the actin cytoskeleton. In cells like podocytes, which present a large 
number of interdigitating processes, it is critical to their function maintain cell 
morphology. I, therefore, looked at the gene expression of some of these molecules to 
explore the possible effect on the integrin signalling. The mRNA levels of most of the 
genes encoding for the chemical signal mediators (paxillin, ILK, FAK and Src) were 
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increased in the C3pde-Lama5E884G/E884G samples, especially at 22 weeks. These results 
strengthened the hypothesis that the mutation in laminin α5 resulted in an abnormal 
signal though integrins.  
 
Figure 3.16. Results of the gene expression of some genes coding for proteins of the LAMA5-ITGB1 
mediators in wild-type and mutant mice. Mechanical mediators (α-actinin 4 - A, talin-1 – B, and kindilin - 
C) are not different but all the genes, but genes involved in chemical signalling (paxillin –D, ILK – E, and 
Src -G) appeared to be upregulated at 22 weeks. Relative expression normalised to Hprt1. The values 
shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test * p<0.05, *** p<0.001, **** 
p<0.0001. 
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3.3.2.2 Protein Expression Study 
To investigate in more thoroughly the role of focal adhesion proteins in the pathogenesis 
of nephrotic syndrome in the C3pde-Lama5E884G/E884G mice, the protein expression of 
some of the integrin signalling mediators was assessed by immunoblotting on whole 
kidneys.  
Proteins expression of the integrin β1 correlated with the mRNA levels being increased 
at 22 weeks of age in kidney samples from Lama5E884G/E884G animals (Figure 3.17).  
 
 
Figure 3.17. Results of the protein expression of integrin β1. At 22 weeks At 22 weeks, the ITGB1 protein 
levels resulted upregulated in homozygotes compared to wild-type controls. Relative expression 
normalised to β-tubulin. The values shown are means ± SEM. Unpaired parametric T-test * p<0.05. 
 
Paxillin and ILK are major components of two different pathways of the ECM-integrin 
axis. Paxillin is activated by phosphorylation by the FAK-Src complex, while ILK is part of 
the ILK/PINCH/parvin complex. The mRNA levels of the genes encoding for these 
proteins, Pxn and Ilk, were both upregulated in homozygous mice at 22 weeks, but the 
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protein levels in C3pde-Lama5E884G/E884G were normal when compared with wild-type 
(Figure 3.18).  
 
Figure 3.18. Results of the protein expression of paxillin (A-C) and ILK (B-D) in wild-type and mutant 
mice. Although the equivalent genes were upregulated in homozygous mice at 22 weeks, the protein 
levels at the same point were unchanged. HEK293T cell lysate was used as positive control to demonstrate 
antibody specificity. Relative expression normalised to β-actin. The values shown are means ± SEM. 
 
Chemical signalling mediators like paxillin and ILK also regulate the activities of small 
GTPases, like CDC42 and RhoA. Immunoblotting analysis was therefore performed to 
study the downstream effect of chemical mediators (Figure 3.19). The total protein 
levels of CDC42 were unchanged, but there was an approximately three-fold increase in 
total RhoA in homozygous mice.  
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Figure 3.19. Results of the protein expression of CDC42 (A-C) and RhoA (B-D) in wild-type and mutant 
mice. CDC42 protein levels of C3pde-Lama5E884G/E884G do not differ from the wild-type controls, however, 
RhoA expression is significantly increased. HEK293T cell lysate was used as positive control to 
demonstrate antibody specificity. Relative expression normalised to β-actin. The values shown are means 
± SEM.  Unpaired parametric T-test *** p<0.001. 
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3.4 Chapter 3 Summary and Discussion 
Employing a combination of SNP mapping and WGS analysis, a single coding mutation 
was identified in the gene encoding laminin α5 chain, a major component of the GBM 
and necessary for normal glomerular development, as responsible for a nephrotic 
phenotype in a pedigree of mice arising from the Harwell ageing screen. 
The mutation, resulting in the substitution of a glutamic acid to a glycine at amino acid 
884, lies in the L4a domain, one of the globular domains of the protein short arm the 
function of which is still unknown. However, the deleterious effect of the E884G 
mutation was been predicted by five different protein prediction software packages. 
After retrospectively genotyping all the mice of the MPC-205 pedigree, no phenotype 
could be observed in heterozygous animals indicating that Lama5 is haplosufficient.  
When rederived and backcrossed for one generation onto C3H.Pde6b, the homozygous 
animals exhibit an earlier onset of disease and progressed to ESRD much quicker than 
the homozygotes in the original MPC-205 pedigree. The Lama5E884G/E884G mice of the 
original pedigree were indistinguishable from their littermates and could only be 
identified at 6 months because of altered clinical chemical kidney markers. On the 
contrary, C3pde-Lama5E884G/E884G showed histological signs of CKD from 12 weeks of age, 
and hypercreatinemia and hyperazotemia from 15 weeks of age. This difference in onset 
and progression is probably due to the mixed background of the mice, with the mice 
being approximately 81.25% C3H.Pde6b versus 18.75% C57BL/6J after one backcross 
onto C3H.Pde6b while in MPC-205 the percentages are respectively 62.5% versus 37.5%. 
C57BL/6 is well known to be less susceptible to fibrosis in different organs including renal 
fibrosis [233], an important factor in the progression of kidney disease and ESRD. Several 
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studies have compared renal disease progression in C57BL/6J versus other strains such 
as 129/Sv and FVB [157, 234-236] and found that C57BL/6J develop a renal related phenotype 
either much slower or if challenged (for example with induced hypertension [236]).  
Since one of the limitations of using ENU as mutagenesis is the presence of numerous 
random mutations, the pathogenicity of E884G had to be proven by a genetic 
complementation with a knock out allele. Indeed, only the animals carrying the E884G 
allele and the null allele developed the expected nephrotic phenotype. 
Preliminary results on the possible pathways involved using gene expression analysis 
and suggested that there might be some specific response to the Lama5 mutation 
resulting in the alteration of the constituency of the GBM and the interaction between 
LAMA5 and the podocytes. The change in mRNA levels of integrin α1β3 and protein 
levels of integrin β1, and mRNA levels of integrin signal mediators suggested a 
perturbation of focal adhesion pathway that maintains actin cytoskeleton stability, but 
at the protein level, the only significantly upregulated protein was RhoA. This result 
would not exclude a change of this pathway since most of the elements involved have 
to be phosphorylated to be activated. It is, therefore, possible that the total protein is 
normal but specific amino acid residues are more phosphorylated.  
Although these preliminary results looked promising, the study presented has some 
weaknesses. Glomeruli represent a minimal part of the kidney mass. Podocytes, for 
example, make up less than 2% of the kidney mass [228]. Both gene expression and 
protein expression studies were carried using renal cortex or whole kidney, this means 
that other renal structure could mask upregulation or downregulation of mRNA and 
protein levels of target gene/proteins, resulting in false positive or false negative. 
Moreover, the mixed background could also have an effect on the pathways since the 
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C3H.Pde6b are more prone to develop kidney lesion and because of the possible effect 
of other mutations co-inherited. Therefore, the changes observed may be secondary to 
disease as they only occur at later time points.  
To overcome the limitations in this preliminary characterization of the phenotype, all 
further experiments have been carried on a congenic C57BL/6J background so to avert 
the additional effect of possible concomitant ENU mutations and the susceptibility of 
C3H.Pde6 mice to accelerated renal disease. 
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CHAPTER 4 
In Vitro Analysis of Laminin Assembly 
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4. In Vitro Analysis of Laminin Assembly 
 
In order to be delivered into the extracellular space, proteins enter the secretory 
pathways, compromised of the rough ER, ER exit sites (ERESs), the ER-to-Golgi 
intermediate compartment (ERGIC), the Golgi complex and the post-Golgi, to carry the 
proteins to their final destination [237]. To be able to enter this pathway, the proteins 
contain an ER signal sequence (generally at the N-terminus) to translocate them into the 
ER and that is cleaved by a signal peptidase following co-translational processing [238]. 
Once the proteins are folded in the ER, they are incorporated into COPII (membrane-
coating coat protein II) vesicles and exit the ER to be transported to the Golgi cisternae, 
and from there, the secretory vesicles take them to the cell surface. 
Several studies have been carried out to characterise the function of the main binding 
domains (NH2-terminal LN domain and COOH-terminal LG domains) but not much is 
known about the function of the other domains, in particular L4a. To characterise the 
mutated L4a domain and its role in cell binding, I submitted a proposal to the Oxford 
Protein Production Facility (OPPF) for access to their facilities and expertise. The aim of 
the proposed study was to express different fragments of the LAMA5 short arm in vitro 
and purify the secreted proteins from conditioned medium, with the intent being to 
generate an adhesion assay to investigate the effect of the mutation on the primary role 
of laminin α5 chain on cell-adhesion.  
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4.1 Cloning and Expression Screening of the Laminin α5 
Chain Short Arm  
 
Each of three different short arm fragments (LN-LEa, LN-L4a-LEb, LN-L4a-L4b-LEc) were 
cloned at the OPPF using three different vectors, two with an internal signal and one 
that uses the native signal sequence. The fragment containing only the L4a domain was 
inserted only in the two vectors with the internal signal sequence since it lacks a native 
one (Table 4.1). Site directed mutagenesis was employed to introduce the E884G point 
mutation into each of the fragments. Because of the lack of a crystal structure of the L4a 
domain, the OPPF offered their help to obtain a crystallised form of the wild type and 
mutated fragments to look at the effect of the mutation on the three-dimensional 
structure of the LAMA5 short arm. 
The experiment had to be carried out in two rounds of cloning and expression screening 
to be sure that all the fragments were correctly inserted into the vectors. 
After two rounds, the wild-type fragments were secreted, whilst none of the mutated 
proteins were detected in the conditioned medium but could be detected in the cell 
lysate (Figure 4.1). 
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Table 4.1. Cloning plan of the experiment carried out at the OPPF. Each row corresponds to the 
fragment cloned, the vector used, the amino acidic position of the N and C terminus of the open reading 
frame (ORF) and the expecting molecular weight of the fragment. The well position identified the 
fragment in the immunoblotting experiment (Figure 4.1). 
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Figure 4.1. Images of the two rounds of cloning and screening of the LAMA5 short arm fragments. In 
both rounds (A and B “secreted”) 293T did not secrete the E884G mutated proteins, but they appended 
to be expressed in the whole cell lysate (B “whole lysate). 
 
Since the experiments at OPPF were carried out in a high throughput manner, I scaled 
up the reaction and re-screened the fragment that gave the most consistent results 
being secreted in both runs, LN-L4a-LEb. I, therefore, cloned the fragment in the 
pOPINGTTneo vector (N-terminal his tag and internal signal sequence), scaled up the 
volumes of cells and transfections and used wet protein transfer method to validate 
previous results. Again, the fragments containing the mutation were not secreted, 
although a band of the right size product was found in the cell lysate (Figure 4.2), 
suggesting that the mutant protein is misfolded and not secreted. 
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Figure 4.2. Confirmation of the impaired secretion of the mutated LN-L4a-LEb 6xHis-tagged fragment 
(expected band size: 175 kDa, primary antibody anti-6xHis tag). In the conditioned medium of 293T cells 
wildtype LN-L4a-LEb is normally expressed (lanes 1 and 2), but completely absent when the E884G 
mutation is present (lanes 3 and 4). However, the protein is present in the cell lysate of both conditions 
(lanes 9, 10, 11 and 12). Medium (lane 5 and 6) and cell lysate (lanes 13 and 14) from untransfected cells 
were used as negative controls. Lane 7 and 8 are empty.  
 
4.2 Cloning and Expression Screening of the Full Length 
Laminin α5 Chain Full Length 
 
The complete absence of laminin α5 protein results in embryonic lethality between 12.5 
and 18.5 days due to incomplete neural tube closure and placental vascular defect [103]. 
All mice homozygous for the E884G mutation survived until adulthood, and hence the 
mutant laminin α5 must be incorporated into the ECM for the animals to develop 
normally and age, even though the short arm fragments were not secreted.  
Working on this hypothesis, I examined the in vitro expression and secretion of the full-
length protein. Laminin alpha 5 was amplified and inserted into a pCMV6 vector with a 
6xHis tag at the C-terminal. The insertion of the ORF was confirmed by Sanger 
sequencing and revealed the presence of the stop codon (TGA) and an extra base (G). 
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Since the 6xHis tag is expressed at the C-terminal end, the stop codon had to be deleted 
for LAMA5 to be expressed with the tag. Moreover, the presence of the extra base 
resulted in the 6X His tag being out of frame. To correct the sequence, site directed 
mutagenesis primers were designed to delete the additional TGAG.  
After confirming the TGAG deletion and the correct insertion of Lama5, site directed 
mutagenesis was used to introduce the E884G point mutation. The two pCMV6-LAMA5 
constructs were transfected into HEK293T and after, 72 hours, the medium and the 
whole cell lysate were screened as previously described to assess secretion and cell 
expression. Results showed expression of the wild-type and mutated LAMA5 in the cell 
lysate, confirming correct transfection of the pCMV6-LAMA5 constructs, but the 
absence of secreted protein, even in the case of control constructs (Figure 4.3). 
 
Figure 4.3. Screening of secreted and cell expressed full-length 6xHis-tagged laminin α5 transfected in 
HEK293T cells. The protein (arrow, expected size 404 kDa, primary antibody anti 6xHis tag) could be 
detected neither in the medium of the cells transfected with control protein (lane 1 and 2) nor in the one 
of the cells transfected with the mutated protein (lane 3 and 4). On the contrary, normal cell expression 
was found in wild-type (lane 7 and 8) and mutant (lane 9 and 10). Untransfected cells (lane 11) and their 
medium (lane 5) were used as negative control. Lane 6 is empty. 
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This negative result was probably due to the absence of a laminin β and γ chain since 
the laminin monomers are not secreted. Therefore, the experiment was repeated using 
a HEK293 cell line stably expressing human laminin β1 and human laminin γ1 (kind gift 
of Prof P. Yurchenco and Dr K. McKee[223]), which have more than 90% homology with 
the corresponding mouse proteins (Appendix 8.3).  
The contemporary expression of the three-laminin chains allowed the secretion of both 
wild-type and mutant laminin α5, confirming that the mutant protein is excreted from 
the cell. Nonetheless, in the presence of the E884G mutation, laminin α5 protein 
secretion was greatly reduced (Figure 4.4 A). With the aim of quantifying the ability of 
HEK293 cells to secrete the transfected constructs, the amount of secreted laminin α5 
protein detected in the medium was normalised to the amount of laminin α5 protein 
detected in the corresponding cell lysate. Considering the highest ratio found in the 
controls to be equal to 100%, the secretion of the other samples were expressed as a 
percentage of the control sample secretion. Indeed, the secretion of the mutant protein 
was reduced by 67.9% ±7.9 (Figure 4.4 B).  
The findings support the hypothesis that the mutation E884G affects protein folding and 
results in a hypomorph.  
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Figure 4.4. Screening of secreted and cell expressed full-length 6xHis-tagged laminin α5 transfected in 
HEK293 cells stably expressing human laminin β1 and human laminin γ1. A: Control pCMV6-LAMA5 
construct (arrow, expected size 404 kDa, primary antibody anti-6xHis tag) could be detected as secreted 
protein in the medium (lane 1, 2 and 3) and expressed in the cell lysate (lane 8, 9 and 10). In presence of 
the E884G mutation, protein abundance in the medium was dramatically reduced (lane 4, 5 and 6), even 
though LAMA5 is expressed in cell lysate (lane 11, 12 and 13). Untransfected 293 cells (lane 14) and their 
medium (lane 7) were used as negative control. B: Graphical representation of the relative protein 
secretion. The values shown are means ± SEM. Unpaired parametric T-test ** p<0.01.  
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4.3 Chapter 4 Summary and Discussion 
 
The production and purification of laminin fragments is a well described method to 
study the function and the crystal structure of the different laminin chains [120, 124, 125, 128]. 
With this approach, it was possible to perform adhesion assays to identify laminin α5 
binding partners and peptides with amino acidic active sequences with specific functions 
such as promotion of neurite elongation. This methodology was not applicable because 
screening of laminin α5 short arm fragments showed that those carrying the E884G 
mutation were not secreted in vitro. This also limited the possibility of obtaining the 
crystal structure of the LAMA5 short arm and in particular, of the yet uncrystallised and 
characterised L4a domain. 
Similar results were observed in in vitro studies of mutations in the laminin β2 found in 
nephrotic syndrome patients. The mutations LAMB2R246Q, LAMB2R245W and LAMB2C321R 
all result in impaired secretion of the short arm fragment screened [89]. Moreover, 
HEK293 cells stably transfected with a construct carrying the C321R mutation and 
transgenic mice expressing full-length rat laminin β2 cDNA with an engineered C321R 
mutation, showed ER stress suggesting an accumulation of unfolded or unsecreted 
proteins in the ER [90]. 
Even though the screening of protein fragments give an indication of the effect of the 
mutation on the structure/function of the laminins under investigation, the complete 
absence of secreted protein it is not compatible with embryonic development, in the 
case of laminin α5, or leads to a short lifespan, in the case of laminin β2. This limitation 
is evident by studying in vitro the mutated full length laminin α5 chain. In fact, even 
though the secretion is dramatically reduced, the secreted mutant protein is detectable 
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in three days conditioned medium of HEK293 cells expressing three laminin chains 
(human laminin β1, human laminin γ1, and transfected murine laminin α5). This result 
provides insight into two aspects of the mechanism for disease in Lama5E884G/E884G 
animals. Firstly, Lama5E884G is capable of interacting with other laminin chains, allowing 
for trimer formation and explaining why embryonic lethality was not seen in 
Lama5E884G/E884G mice. On the other hand, this suggests that Lama5E884G secretion is 
significantly reduced in comparison to wild types and it is this reduction in protein and 
hence trimer levels that likely leads to disease.   
Whether the rescue of the in vitro secretion depends on a higher stability of the full-
length protein or it is due to a stabilising effect of the other laminin chains might have 
formed the mature heterotrimer.  
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CHAPTER 5 
Analysis of the Lama5E884G mutation congenic on a 
C57BL/6J background   
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5. Analysis of the Lama5E884G mutation congenic on a 
C57BL/6J background 
 
5.1 B6-Lama5E884G Phenotyping 
To study the effecte of the E884G mutation on disease progression on a C57L/6J 
congenic background, B6-Lama5+/E884G were intercrossed and I time course study was 
set up phenotyping wild-type (B6-Lama5+/+) and homozygous mice (B6-Lama5E884G/E884G) 
at 5, 15 and 25 weeks of age.  
For each time point, samples have been collected to characterize the pathology and the 
molecular changes that occur at the very early time points of disease. Mice were 
individually housed for 24 hours in metabolic cages to measure water intake and urine 
production, and to collect urine for further analysis. Mice were then terminally bled and 
kidneys were harvested with different techniques depending on the experiments that 
followed. To keep the experiment as consistent as possible, kidneys harvested from 
male animals have been used for histology, electron microscopy, and 
immunofluorescence, whilst the females have been perfused with Dynabeads M450 
tosylactivated and the kidneys harvested to isolate the glomeruli for immunoblotting. A 
second cohort of male mice aged 15 and 25 weeks was bred and perfused with 
Dynabeads to isolate the glomeruli for mass spectrometry analysis. 
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5.1.1 Metabolic Cages and Urinalysis 
After 24 hours in singly housed in metabolic cages, the water intake and the urine 
production did not show any difference between homozygous mutant mice and wild-
type controls (Figure 5.1 A and B) excluding polydipsia and polyuria at any of the time 
points. The urine was tested for the presence of erythrocytes and leukocyte with 
dipsticks. Although the presence of red blood cells was not detected in any of the 
samples, all the 25 weeks old B6-Lama5E884G/E884G mice and some of the 15 weeks old 
B6-Lama5E884G/E884G mice showed some degree of leukocyturia (Figure 5.1 C). To assess 
the levels of proteinuria, instead of using the SDS-PAGE method as with the C3pde-
Lama5 cohorts, a quantitative approach was taken calculating the urinary protein-
urinary creatinine ratio. Results showed mild proteinuria at 15 weeks and severe 
proteinuria at 25 weeks in the homozygotes (Figure 5.1 D).  
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Figure 5.1. Results from metabolic caging studies showed that polydipsia (A) and polyuria (B) are absent 
in homozygous mice as indicated by the normal levels of water intake and urine production, however, 
urine dipstick and urinalysis showed leukocyturia (C) and proteinuria (D) at 15 and 25 weeks. The values 
shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test * p<0.05, **** p<0.0001. 
 
5.1.2 Clinical Chemistry Analysis 
The plasma from blood collected by retro-orbital sinus puncture was analysed to 
measure urea and creatinine as the main markers for kidney function, with albumin, 
total cholesterol, LDL and HDL (Figure 5.2). The levels of plasma albumin mirrored the 
proteinuria results, with the B6-Lama5E884G/E884G mice showing mild hypoalbuminaemia 
at 15 weeks of age and more severe hypoalbuminaemia at 25 weeks (Figure 5.2 C). 
Homozygous mice also exhibited altered lipid metabolism with increased levels of total 
cholesterol, LDL and HDL (Figure 5.2 D, E and F). Markers of kidney functions were either 
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slightly elevated at 25 weeks (urea), or normal (creatinine) in comparison with wild-type 
controls (Figure 5.2 A and B).  
Creatinine clearance is the volume of plasma that is cleared of creatinine per unit time 
and it is often used as an indicator of glomerular filtration rate (GFR), the flow rate of 
filtered fluids through the glomeruli, and hence of kidney function. It is calculated using 
the formula (UxV)/P with U= urinary creatinine in umol/L, V= urinary flow rate in 
ml/minute, P= plasma creatinine in umol/L. No difference between wild-types and 
homozygotes was detected at any age (Figure 5.2 C). 
These results, in combination with the urinalysis data, suggest that even if the B6-
Lama5E884G/E884G are nephrotic from 15 weeks of age, they conserve a normal renal 
function at all ages investigated, even in presence of severe proteinuria. 
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Figure 5.2. Results of the clinical chemistry analysis. B6-Lama5E884G/E884G exhibited a nephrotic 
phenotype with hypoalbuminaemia starting from 15 weeks (C) and hypercholesterolaemia at 25 weeks 
(D, E and F). Even though urea is slightly more elevated in homozygous plasma compared to wild-type 
samples (A), there is no difference in creatinine levels (B). Creatinine clearance, an indicator of GFR and 
its normal values confirm that the homozygous mice have a well-functioning kidney at all ages. The values 
shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test * p<0.05, **p<0.01, *** p<0.001, 
**** p<0.0001. 
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5.1.3 Histopathological Analysis and Glomerular Ultrastructure 
Kidneys from mutant mice and wild-type controls were processed to look at possible 
histopathological features and ultrastructure of the glomerulus, and to determine the 
correlation of gross histopathology with the urine and plasma analysis. 
For light microscopy analysis, kidney sections were stained with three different stains: 
H&E as routine stain, PAS to delineate glomerular cells, mesangial matrix changes of the 
GBM, and MT to highlight possible fibrosis. Kidneys of affected animals did not show any 
glomerular (Figure 5.3) or tubular (data not shown) lesions compared with unaffected 
controls, even at 25 weeks of age when the same B6-Lama5E884G/E884G exhibited severe 
proteinuria, leukocyturia, hypoalbuminaemia and hypercholesterolaemia.  
115 
 
 
Figure 5.3. Results of the histological time course study. H&E (first column), PAS (middle column) and 
MT (right column) stains were used to study kidney architecture. No difference was identified between 
affected mice and wild-type controls. Scale bar represents 20 µm. 
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To look at the glomerular ultrastructure, samples from the same kidneys assessed by 
histology were processed for TEM at 5, 15 and 25 weeks, and for SEM at 15 and 25 
weeks. TEM showed a normal renal ultrastructure at 5 and 15 weeks, but irregular 
subepithelial GBM and podocyte foot process effacement at 25 weeks. Podocyte 
invasion of the GBM also appears to be present, a feature identified by Randles et al. in 
a number of glomerular diseases, the implication of which remains unclear [239]. The 
subendothelial GBM and the glomerular endothelium remain normal (Figure 5.4).   
The foot process effacement was confirmed by SEM (Figure 5.5). At 25 weeks, the foot 
processes from homozygotes appeared completely flattened. No difference was seen at 
15 weeks with either TEM and SEM although B6-Lama5E884G/E884G mice of this age were 
mildly proteinuric. 
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Figure 5.4. Results of TEM time course study on wild type and B6-Lama5E884G/E884G kidneys. The GBM 
maintains its ribbon-like appearance, and podocyte foot processes are clearly distinguishable in both wild 
type (A and C) and homozygous mice at 5 and 15 weeks (B and D). At 25 weeks of age mutant mice (F) 
developed irregular GBM (red stars), loss of foot process definition and partial fusion (foot process 
effacement) and what appears to be podocyte foot process invasion of the GBM (arrows), while aged 
matched wild type maintain a normal appearance of the GFB (E). Scale bar represents 2 µm. 
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Figure 5.5. Results of SEM time course study on wild-type and B6-Lama5E884G/E884G kidneys. A normal 
podocyte body, primary processes and interdigitate foot processes can be observed in wild type mice at 
15 (A and B) and 25 weeks (E and F), and in homozygous mice at 15 weeks (C and D). Foot process 
effacement, with loss of any interdigital structure, is present in homozygotes at 25 weeks of age, 
confirming the TEM data (G and H).  
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5.2 Laminin Distribution in the Glomerular Basement 
Membrane  
The presence of LAMA5 is essential for the normal development and function of the 
glomerulus. In vitro analysis of laminin α5 expression showed that the E884G mutation 
affected the ability of HEK293 cells stably expressing LAMB1 and LAMC1 to secrete 
normally LAMA5. Indeed, the amount of mutated construct was dramatically reduced 
of almost fourfold (WT 90.6% ± 7.9 vs E884G 22.7% ± 0.9).  
Since the B6-Lama5E884G/E884G mice are viable and develop normally, I investigated the 
expression of the laminin α5 chain and its trimer partner laminin β2 chain in the kidneys 
of affected mice and unaffected controls at 15 and 25 weeks (Figure 5.6 A and B). Both 
expression and distribution of LAMA5 and LAMB2 did not vary between in samples 
collected from homozygous and littermate control mice at 15 and 25 weeks. This 
confirms that the point mutation results in a hypomorphic allele.  
As mutations in other components of the GBM such as collagen type IV proteins and 
laminin β2 chains result in the aberrant expression and localization of other laminin 
chains, I also looked at the expression of LAMB1, which can form a trimer with laminin 
α5 chain and laminin γ1 chain (laminin-511), but its expression is limited to the 
mesangium. The expression of LAMB1 in the mutants did not differ from the wild-type 
controls (Figure 5.6 C). 
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Figure 5.6. Representative immunofluorescence images of wild-type and homozygous mice, at 15 and 
25 weeks, stained with anti-LAMA5 (A). anti-LAMB2 (B) and anti-LAMB1 (C). The mutant LAMA5 protein 
and its trimer partner LAMB2 are normally distributed in the homozygous sample suggesting a normal 
secretion and incorporation into the GBM. LAMB1 is expressed solely in the mesangium, demonstrating 
the absence of aberrant localization.   
 
These immunofluorescence results are in contrast with the in vitro analysis of laminin 
α5 secretion and a different approach would be then needed to confirm the expression 
of laminin α5 in the GBM. 
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5.3 Protein Studies 
The complex composition of the GBM (insoluble and highly cross-linked) represents a 
challenge for routine biochemical analysis. Given the nature of its protein, normal 
biochemical analysis such as immunoaffinity-based approaches is very complicated, 
time-consuming and likely to be inconclusive as they rely on the antibody affinity and 
antigen accessibility. Transcriptome analysis with RNA sequencing gives a global 
quantification of the gene expression. Nevertheless, mRNA quantification cannot be 
always used as a substitute for protein expression, especially in the case of ECM proteins 
that have a long half-life. Proteomics analysis is, therefore, the best option to study the 
GBM composition and identify possible pathways involved. Mass spectrometry (MS) is 
a technique that enables a global protein analysis.  
As a result of their complexity and protein-rich nature, biological samples are often 
analysed with tandem MS (MS/MS), since peptides derived from protein digestion have 
more chance to have assigned a unique identification for an easier detection and 
quantification. In MS/MS the peptides are first selected and analysed to determine their 
exact mass. Then the peptides are fragmented into ions so the final mass spectrometric 
measurements are carried out in the gas phase on ionized analytes to generate fragment 
ion spectra [240].  
I carried out an extensive proteomics analysis in collaboration with the Wellcome Trust 
Centre for Cell-Matrix Research (University of Manchester) to study the GBM 
composition and signalling in B6-Lama5E884G/E884G. The experiment has been carried at 
15 weeks, when proteinuria is detectable but very mild and there is no presence of foot 
processes effacement or irregular GBM, and at 25 weeks, when the mice exhibit severe 
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proteinuria, foot processes effacement and focal thickening of the GBM. In choosing 
these two time points, I hoped to be able to detect early changes and determine if 
additional changes occurred once the disease is established. 
 
5.3.1 Glomerular Isolation and Protein Extraction 
To study protein composition and molecular bases of disease, glomeruli were isolated 
to avoid contamination from other renal structures.  
Sieving techniques have been successfully used to isolate human and rat glomeruli, but 
it has been difficult to adapt this procedure in mice because of the small diameter of 
murine glomeruli, very similar to their tubules. I, therefore, used dynabeads containing 
iron which accumulate in the glomerular vessels and collected the pure B6-Lama5+/E884G 
and B6-Lama5E884G/E884G glomeruli with a magnet. The original published protocol [228] 
was modified to exclude the incubation step with collagenase A, to preserve the 
composition of the GBM.  
Proteins from the isolated glomeruli were extracted using a fractionation approach to 
enrich the otherwise insoluble ECM component, and preparing protein fractions of the 
different cell structures (i.e. cellular components and nuclear protein). Immunoblotting 
confirmed the ECM enrichment and absence of the proteins from another compartment 
in the ECM fraction (Figure 5.7). 
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Figure 5.7. A, B: Glomeruli isolated with Dynabeads perfusion and magnetic collection. Dynabeads are 
visible inside the glomerular tufts as small brown dots (A and B). Scale bar represents 20 µm. C: The 
successful protein fractionation extraction was confirmed by immunoblotting: nephrin (in red, observed 
band size: ~85 kDa) is enriched in the two cellular fractions (lane 1 and lane 2); pan-collagen type IV (in 
green) is only expressed in the ECM enriched fraction (lane 4). An unspecific band (in red) is present in the 
nuclear fraction (lane 3) and the first cellular fraction (lane 1). 
 
The samples so obtained were prepared for proteomics analysis by the service core of 
the Wellcome Trust Centre for Cell-Matrix Research. 
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5.3.2 Renal Extracellular Matrix Proteomics 
The abundance of the ECM proteins identified by MS was quantified using Progenesis 
LCMS (Non Linear Dynamics Ltd) and calculated form the sum of all unique normalised 
peptide ion abundance for a specific protein on each run. Of all the 1141 proteins 
identified in all samples, quantification analysis was only carried out on the ones with at 
least three unique peptides (485). 
To highlight the possible different ECM composition in a genotype- and time-dependent 
manner, a two network maps (one for each time point) were generated. The nodes of 
the network represent the proteins identified and the different colours represent a 
protein that is enriched in control samples (blue) or in mutated samples (red) (Figure 
5.8).
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Figure 5.8. Protein interaction network constructed from enriched glomerular ECM proteins identified by MS. The nodes, circles, represent the proteins identified 
and the edges, lines, represent a reported protein-protein interaction. Nodes are coloured according to the protein abundance, blue if enriched in the wild-type 
samples and red if enriched in the mutant samples. Darker circles around the nodes indicate statistical significance (two-way ANOVA with Bonferroni post-hoc test p 
<0.05). Netrin-4 and agrin are enriched in wild-type samples at 25 weeks, laminin α5 is enriched in wild-type samples at 25 weeks, peroxidasin is enriched in mutant 
samples at 25 weeks. Quantification and network analysis performed by Dr Michael Randles. 
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Network analysis showed a statistically significant reduction of the abundance of the 
laminin alpha α5 chain in B6-Lama5E884G/E884G samples at 25 weeks. Other laminins that 
form a trimer with laminin α5 such as laminin β2, laminin β1 and laminin γ1 seem to be 
more abundant in the wild-type samples meaning that there is a reduction of the laminin 
networks as a whole. The lower expression of laminin-521 corroborates the hypothesis 
that the mutation results in a hypomorphic protein since the complete absence of 
laminin alpha 5 would have resulted in a lethal phenotype. 
In addition to the reduced laminin-521, I found a decreased expression at 25 weeks of 
proteins strictly related to this network: agrin (AGRN) and netrin-4 (NTN4). Agrin, the 
most abundant HSPG in the GBM [27], is expressed in its full length only in the GBM while 
isoforms lacking the C-terminal epitopes are localised in the other kidney BMs [241]. Agrin 
N-terminal end binds laminin γ1 coiled coil via hydrophobic and ionic interactions, while 
its C-terminal end binds to cell surface receptor-like integrin [242-245]. Although neither 
agrin nor the other HSPGs of the GBM is essential to maintaining a normal renal function 
[246], their role is essential for the normal activity of factor H which inactivates the bound 
of C3b to the GBM [247]. The absence or reduction of HSPGs triggers the local 
amplification of the C3 activation worsening or exacerbating glomerular lesions, as in 
glomerulopathies mediated by immunocomplexes (i.e. membranous nephritis and lupus 
nephritis) or FSGS, where glomerular deposition of C3 and IgM are a common finding [59, 
247]. Segmental and reduced expression or absence of HSPGs is reported in several 
kidney diseases such as membranous nephropathy, minimal change disease and diabetic 
nephropathy, but not in Alport syndrome or IgA nephropathy [248, 249]. 
Netrin-4 is a protein of the laminin-related netrin family, with a structure related to 
laminin β chains and expressed widely especially in the kidney [250]. As agrin, netrin-4 
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interacts with laminin γ1 forming a high-affinity complex: the strong bond between the 
LN domains of both proteins prevents the polymerization of the laminin trimers and 
disrupts the pre-existing laminin network in a non-enzymatic manner [251]. 
In addition to GBM components, the ECM also contains a number of enzymes required 
for the post-translational modification of said components [252]. Peroxidasin, enriched in 
the mutants at 25 weeks, stabilises the collagen IV network catalysing the formation of 
a sulfilimine bond between the alpha chains [253]. Increased peroxidasin expression is 
been found in a mouse model of renal fibrosis suggesting that it promotes the formation 
of ECM during injury, but its role in pathogenesis remains unknown [254].  
Lastly, vitronectin (VTN), an ECM glycoprotein also known as complement S protein, is 
more abundant in homozygous ECM at 25 weeks. Vitronectin is synthesized mostly in 
the liver and circulates in the bloodstream, however controversial production by the 
podocytes has been also reported [255, 256]. In the kidney, vitronectin is expressed in the 
glomerulus and an increased accumulation is detected in many patients with glomerular 
diseases in both glomeruli [257] and urine [258] suggesting a deleterious role in the 
progression of glomerulopathies. Indeed, Vtn-/- mice showed less glomerular fibrosis and 
milder proteinuria in a model of experimental nephrotoxic nephritis, possibly due to a 
decreased deposition of plasminogen activator inhibitor-1 (PAI-1) leading to a more 
facilitated fibrin clearance because of a greater activation of plasminogen activator 
activity [259]. The major vitronectin receptor is integrin αVβ3, expressed on the podocyte 
cell surface and the activation of which has been reported to be the cause of proteinuria, 
especially when acting as a mediator of the urokinase receptor (uPAR) and soluble 
urokinase receptor (suPAR) (Nature Medicine papers). Therefore, the role of vitronectin 
in the pathogenesis of glomerular diseases is still poorly understood.  
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5.3.3 Renal Cellular Component Proteomics 
A similar analysis performed on the glomerular matrisome was also performed to 
investigate the expression of the proteins involved in focal adhesion (Figure 5.9).  
Most of the adhesion proteins expressed in the cellular fractions did not show any 
significant difference. The only two proteins whose expression were significantly 
downregulated are kindlin-2 (FERMT2) and integrin α6 (ITGA6).  
Integrin α6 forms a heterodimer with integrin β4 and integrin β1 and together they are 
expressed in podocytes. Indeed, laminin α6 can bind integrin β4 and β1 through binding 
site present in the LG C-terminal domains and LN n-terminal domain. Although integrin 
α6 is expressed in the kidney, Itga6 knockout mice do not show any renal phenotype 
and double Itga3/Itga6 knockout mice showed the same phenotype of Itga3-/- mice 
meaning that integrin α6 is dispensable for a proper kidney function [146, 260, 261]. 
Nonetheless, integrin α6β4 plays a role in regulating the anchoring of the podocytes to 
the GBM and it is possible that integrin containing the α6 subunit are associated with 
the development of fibrotic kidney disease [262]. 
Kindlin-2 is one of the proteins that mediate mechanical signals through the integrin-
laminin pathway. In vivo and in vitro studies have shown that its role is crucial for the 
normal architecture of podocytes and their foot processes indirectly promoting the 
activation of Rac1.  
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Figure 5.9. Protein interaction network constructed from enriched glomerular cellular proteins identified by MS. The nodes, circles, represent the proteins identified 
and the edges, lines, represent a reported protein-protein interaction. Nodes are coloured according to the protein abundance, blue if enriched in the wild-type 
samples and red if enriched in the mutant samples. Darker circles around the nodes indicate statistical significance (two-way ANOVA with Bonferroni post-hoc test p 
<0.05). Kindlin-2 and integrin α6 are enriched in the wild-type samples. Quantification and network analysis performed by Dr Michael Randles.
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Since adhesion proteins can be still present in an insoluble state, their abundance was 
analysed in the ECM fraction as well (Figure 5.10). Again, all the proteins analysed at 15 
weeks and most of the ones analysed at 25 weeks did not show any statistically 
significant difference, with the exception of supervillin (SVIL) and integrin β1 (ITGB1). 
Not much is known about supervillin, especially in relation to its role in maintaining GFB 
architecture. However, it is known that SVIL modulates focal adhesion involving thyroid 
receptor–interacting protein 6 (TRIP6) and lipoma-preferred partner (LPP). Expression 
of LPP was detected in both the cell fraction and ECM fraction but its abundance was 
not different in B6-Lama5E884G/E884G samples compared to wild types. 
Integrin β1 is possibly the most important laminin-binding integrin in regards to kidney 
disease. Increased abundance of ITGB1 at 25 weeks coincides with the previous mRNA 
expression results carried out on the C3H-Lama5 line. However, the protein abundance 
gives an indication of the total protein expression. More analysis would be needed to 
look at the level of activation of integrin β1.  
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Figure 5.10. Protein interaction network constructed from enriched glomerular ECM proteins identified by MS. The nodes, circles, represent the proteins identified 
and the edges, lines, represent a reported protein-protein interaction. Nodes are coloured according to the protein abundance, blue if enriched in the wild-type 
samples and red if enriched in the mutant samples. Darker circles around the nodes indicate statistical significance (two-way ANOVA with Bonferroni post-hoc test p 
<0.05). Integrin β1 and supervillin are enriched in the mutant samples at 25 weeks. Quantification and network analysis performed by Dr Michael Randles.
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The abundance of other proteins involved in focal adhesion complexes but not included 
in the network analysis, such as ILK, FAK and talin1, was also analysed and no difference 
was detected between wild-type and B6-Lama5E884G/E884G (Figure 5.11). 
 
Figure 5.11. Results of the protein abundance of ILK (A), FAK (B) and talin1 (C) in wild-type and B6-
Lama5E884G/E884G mice. The expression of these proteins, involved in the formation of focal adhesion 
complexes, in homozygotes appears to be normal when compared to littermate controls. 
 
Lastly, abundance of the protein endoplasmin, also known as heat shock protein 90β1 
(HSP90B1) and glucose-regulated protein 94 (GRP94), was increased in homozygous 
samples at 25 weeks (Figure 5.12). Endoplasmin is the most abundant glycoprotein in 
the ER, it participates in chaperoning the folding of proteins and it is involved in the ER-
associated degradation (ERAD) assisting the targeting of misfolded proteins [263]. 
Endoplasmin is a selective chaperon and has as clients proteins such as 
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histocompatibility class I (MHC-I), insulin-like growth factor (IGF) II and integrins [263, 264], 
but it has also affinity to laminin chains and it has been indicated as a possible chaperone 
involved in chain assembly [265].  
In case of abnormal protein misfolding and/or accumulation of unfolded proteins, ER 
stress occurs triggering the activation of an adaptive mechanism, the unfolded protein 
response (UPR), in the patent of increasing the folding capacity and degrading misfold 
proteins so to restore homeostasis. Endoplasmin is involved in UPR response and it is 
upregulated during ER stress to increase the efficiency of the folding preventing the 
activation of apoptotic pathways by the UPR [263, 264].  
 
Figure 5.12. Results of the protein abundance of endoplasmin in wild-type and B6-Lama5E884G/E884G 
mice. Mutant samples showed increased abundance at 25 weeks suggesting ER stress and activation of 
the UPR. The values shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test *p <0.05. 
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5.4 Integrin Activation 
Integrin α3β1 is the most highly expressed integrin in the podocytes and binds directly 
laminin α5. Its importance it has been described in several studies on both laminins and 
integrins. Up- and downregulation during kidney diseases have both been reported. In 
models and studies of diabetic nephropathy, downregulation of integrin α3β1 
expression in podocytes is thought to be associated with podocyte detachment [266-268]. 
However, upregulation of α3β1 in podocytes in early stages of diabetic nephropathy has 
also been reported, as well as in case of reduction of laminin α5 expression [107, 269]. The 
latter seems to be the case also in this model of Lama5-related nephrotic syndrome 
since the reduction of laminin α5 results in increased expression of integrin β1 in 
homozygous mice. Moreover, the upregulation of ITGB1 was detected in both C3pde-
Lama5E884G and B6-Lama5E884G lines. 
Integrin αVβ3 is not a laminin-binding integrin, it binds vitronectin and fibronectin and 
it is expressed on the podocyte foot process surface [262]. The αVβ3 dimer, and in 
particular of integrin β3, has been associated with damage pathway leading to 
proteinuria and FSGS. In particular, integrin β3 is a mediator of the urokinase receptor 
(uPAR) and soluble urokinase receptor (suPAR), through its activation [256, 270-272]. MS 
analysis revealed that in 25 weeks old B6-Lama5E884G/E884G mice abundance of 
vitronectin was increased. Since vitronectin binds integrin β3, and that the activation of 
the latter leads to proteinuria and FSGS, it could be possible that the more abundant 
vitronectin in mutant mice activates integrin β3, helping to exacerbate the nephrotic 
phenotype. 
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When activated, integrins physically change their conformation and it is possible to 
measure their activation using specific antibodies that detect epitopes exposed only 
after the conformational change. The antibody clones 9EG7[273] and HUTS-4[274] for 
integrin β1, and clones AP5[227] and WOW-1[226] for integrin β3, have been often been 
used in renal field to look at the activation of these integrins [163, 166, 256, 270, 271, 275-278].  
Immunoblotting using the 9EG7 clone antibody was used to assess the activation of 
integrin β1 (Figure 5.13).  
 
Figure 5.13. Results of the protein expression of active integrin β1 in wild-type and B6-Lama5E884G/E884G 
mice. Mutant samples showed reduced expression at 25 weeks suggesting decreased activation of ITGB1. 
The values shown are means ± SEM. Two-way ANOVA with Bonferroni post-hoc test *p <0.05. 
 
This result would suggest that although total integrin β1 protein expression in increased 
in 25 weeks old B6-Lama5E884G/E884G, the amount of protein that is activated changing its 
conformation is reduced. 
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Since vitronectin, increasingly abundant in homozygotes at 25 weeks of age, activates 
integrin β3, and that integrin β1 seems to be less activated, I decided to investigate 
whether an integrin signalling switch was occurring in B6-Lama5E884G.E884G mice. Using 
the antibody WOW-1 (kindly gifted by Prof S. Shattil), I looked at integrin β3 activation 
with immunofluorescence (Figure 5.14). In case of abnormal podocyte activation of 
integrin β3, WOW-1 should colocalise with slit diaphragm markers such as podocin. In 
B6-Lama5E884G/E884G samples, WOW-1 localisation does not vary from wild-type controls, 
remaining expressed in the mesangium. Same results were obtained using the antibody 
AP5 (kindly gifted by Dr P. Newman), another antibody that recognises integrin 
activation (data not shown).  
Results on integrin activation seem to indicate that even if there is a downregulation of 
active integrin β1, a switch in integrin activation is not present. 
 
Figure 5.14. Representative immunofluorescence images of wild-type and homozygous mice, at 1 25 
weeks, stained with anti-WOW-1 (red) anti-Podocin (green). WOW-1 is expressed solely in the mesangium 
in both wild-type and homozygotes, as demonstrated in the merge panel, suggesting the absence of 
abnormal activation of integrin β3 in the podocyte. 
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5.5 Kindlin-2 Downregulation 
Kindlin -2 is one of the components of the focal adhesion of the podocytes. In vitro and 
in vivo studies have confirmed the importance of kindlin-2 expression in podocytes for 
normal cell attachment to the GBM and cell morphology, however, not much it is known 
about how its specific role. In podocyte-specific knockout mice, the lack of kindlin-2 
results in a higher activation of Rac1 due to the reduced expression of one of its 
inhibitors, RhoGDIα [168]. In a very recent in vitro study associated with in vivo zebrafish 
and Drosophila models, the loss of kindlin-2 resulted in cortex destabilization and 
membrane blebbing due to a re-distrubution of actin filaments [167]. The expression of 
coronin-1C (CORO1C) and filamin A (FLNA), proteins of the cortical actin cytoskeleton, 
was reduced in knockout cells and RhoA more active (no difference was found in the 
activation of Rac1) [167]. 
Because kindlin-2 was less abundant in 25 weeks B6-Lama5E884G/E884G samples analysed 
by MS, I have looked at the expression of the proteins reported to be related with its 
decreased expression: coronin-1C, filamin A and RhoGDIα. No difference was detected 
in the abundance of these proteins between homozygous or control samples at both 15 
and 25 weeks (Figure 5.15).  
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Figure 5.15. Results of the protein abundance of RhoGDI (A), filamin A (B) and coronin 1C (C) in wild-
type and B6-Lama5E884G/E884G mice. Downregulation of these proteins has been reported in podocytes 
lacking kindlin-2, but in Lama5E884G/E884G mice, their expression did not differ from wild-type glomeruli. 
 
Expression of downstream proteins could exclude a role of kindlin-2 in the pathogenesis 
of Lama5-related nephrotic syndrome. Nonetheless, it could still possible that the 
decreased expression of kindlin-2 could have an effect on activation of GTPases. 
Unfortunately, given the high protein concentration needed for to perform the assay, 
the activation of the GTPases Rac1 and RhoA, could not be measured. 
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5.6 Chapter 5 Summary and Discussion 
Congenic B6 mice homozygous for the E884G mutation still developed a nephrotic 
phenotype although much later than the original pedigree MPC-205 and C3pde-
Lama5E884g/E884G. If at 6 months of age, the MPC-205E884/E884G mice showed increased 
levels of urea and creatinine in plasma and C3pde-Lama5E884g/E884G had to be culled for 
welfare concerns, at the same age B6-Lama5E884G/E884G mice showed severe proteinuria, 
hypoalbuminaemia and hypercholesterolaemia but no elevated creatinine or 
histological lesions by light microscopy. Glomerular ultrastructure assessed by TEM 
revealed no foot process effacement and a normal-looking GBM at 5 and 15 weeks, but 
foot process fusion and irregular GBM at 25 weeks. Samples of 15 and 25 weeks old mice 
were also processed for SEM analysis confirming the healthy aspect of the podocytes at 
15 weeks and the complete loss of the interdigitated appearance of the foot processes 
at 25 weeks.  
Even though severe proteinuria correlates with foot process effacement as expected, at 
15 weeks B6-Lama5E884G/E884G exhibited mild proteinuria but no difference in the 
podocyte or GBM appearance. Similar results were observed in Lamb2 knockout mice, 
a murine model of Pierson syndrome. although the phenotype exhibited by these mice 
is much more aggressive, with homozygotes dying at one month of age from ESRD, P2 
and P5 Lamb2-/- animals showed detectable proteinuria but no sign of foot process 
effacement [85]. The Lamb2-null model and now the results of the B6-Lama5E884G/E884G, 
implicate a more active role of the GBM in acting as a barrier for albumin.  
Proteomics analysis is particularly indicated to study large insoluble proteins such the 
ones that make up the GBM. Using this approach, I was able to look at the glomerular 
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GBM composition and a large number of proteins involved in focal adhesion. Indeed MS 
analysis detected reduced abundance of laminin α5 in mutant samples at 25 weeks that 
immunofluorescence analysis cannot reveal. Other proteins related to the laminin-521 
trimer, such as agrin and netri-4, were less abundant in B6-Lama5E884G/E884G glomeruli at 
25 weeks of age, while vitronectin abundance was increased in mutants at the same 
time point.  
Proteomics studies on components of the focal adhesion complex revealed an 
upregulation of integrin β1 in 25 weeks mutant samples, backing up the results seen in 
the C3pde-Lama5E884G/E884Gsamples, and a downregulation of kindlin-2 (FERMT2).  
The expression of the RhoGDI, filamin and coronin 1C, reported to be downregulated in 
the podocyte lacking kindlin-2, maintained a normal level of abundance at both 15 and 
25 weeks when compared to wild-type littermates. This result suggests that kindlin-2 is 
not involved in the mechanism of the pathogenesis of the nephrotic syndrome resulting 
from the E884G mutation, at least not through the pathways previously described. Both 
mechanisms suggested result in the over-activation of a GTPase protein, either RhoA or 
Rac1. The assessment of GTPases activation in B6-Lama5E884G/E884G mice could answer 
the question of a possible involvement of this pathway. Unfortunately, the technicality 
of the assay does not allow it to be performed on protein isolated from glomeruli.  
Integrin β1 was upregulated in homozygous mice of both C3pde-Lama5E884G and B6-
Lama5E884G lines. Nonetheless, the integrin activation was reduced in B6-Lama5E884G. 
Considering the increased abundance of vitronectin, and that the activation of integrin 
β3, binding partner of vitronectin, is deleterious in podocytes, I have looked at its 
activation. The localization and expression of active β3 did not differ between controls 
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and affected, therefore switching in integrin activation seems not to be a factor in the 
pathogenesis of disease.  
Focal adhesion proteomics analysis also indicated an increased abundance of supervillin, 
a protein member of the villin/gelsolin family that binds F-actin [279]. Overexpression of 
supervillin decreases cell adhesion to fibronectin and induces redistribution of 
lamellipodial increasing the numbers of F-actin punctae [280, 281]. Supervillin has not be described 
in relation to podocyte physiology or to foot process effacement. 
Lastly, the reduced abundance of laminin α5 (and in minor extent of the other laminin 
of the trimer) in the ECM enriched fraction, correlates with the increased expression of 
the chaperone endoplasmin, or GPR94, a marker of UPR activation.   
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6. Discussion and Conclusion 
6.1 Discussion 
As part of a large-scale ENU mutagenesis program focused on identifying genes involved 
in age-related diseases, the Harwell ageing screen, a mutant line with a mutation in the 
gene coding laminin α5 chain showed kidney impairment and classic histological lesions 
attributable to CKD. Laminin α5 is a major component of the GBM and it is indispensable 
for a normal embryonic development.  
The causative point mutation was identified as a change of a glutamic acid residue into 
a glycine in the globular L4a domain. Glutamic acid is a polar acidic amino acid while 
glycine is a non-polar amino acid, meaning that the mutation results in the change from 
a hydrophilic amino acid to a hydrophobic one.  Moreover, glycine differs greatly in size 
being the smallest amino acid. In silico analysis, using a number of protein prediction 
algorithms indicated the missense variant as deleterious and likely resulting in disease. 
In vitro study showed that the E884G mutation results in a hypomorph that seems to 
affect protein secretion. Expression of mutated fragments of the short arm of laminin 
α5 chain in HEK293T cells resulted in complete absence of secretion, whilst expression 
of the full-length protein in association with other laminin chains partially rescued the 
phenotype, reducing the secretion by about 67%.  
Phenotypically, homozygous mice showed typical signs of nephrotic syndrome such as 
severe proteinuria, hypoalbuminaemia and hypercholesterolaemia. The expression of 
the laminin α5 chain is necessary for a normal embryonic development. LAMA5 is the 
most abundant laminin α chain of the body and it is expressed almost ubiquitously, 
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hence the dramatic phenotype displayed by Lama5 knockout mice. Even given this 
crucial role, the mutation E884G of laminin α5 ultimately leads only to nephrotic 
syndrome, without the presence of other obvious phenotypes. Similarly, mutation in 
collagen IV and laminin β2 sometimes only cause a renal symptomatology.  
Kidneys, and in particular glomeruli, are subjected to a series of forces resulting from 
the filtration of the pre-urine that continuously apply pressure to the GFB. This alone 
could be the reason why mutations in widely expressed ECM proteins manifest with only 
kidney disease. Another explanation could lie in the strict composition of the GBM: some 
organs, such as lungs, express similar laminin and collagen networks to the GBM. 
However, in lungs, laminin-521 and collagen α3α4α5 are expressed concomitantly with 
other networks, therefore the lack of one of the components could be compensated 
with protein already normally present in the ECM. In the case of the GBM, the networks 
present are the only possible combination. Compensation for loss of one component 
could lead to the retention of embryonic forms of the given protein (such as collagen 
α1α1α2 or laminin β1) or to the accumulation of ectopic proteins (like laminin α2) that 
can change the resistance of the GBM to filtration forces and/or the signalling to the 
podocytes. 
Nonetheless, disease progression was greatly affected by genetic background. 
Homozygous mice of the original MPC-205 pedigree that entered the pipeline of the 
Harwell Ageing Screen exhibited signs of kidney impairment at 6 months and had to be 
culled due welfare concerns around 9 months of age, presumably because of ESRD. 
C57BL/6J-C3H-C3pde6b+ mixed background mice exhibited proteinuria as early as 7 
weeks of age, signs of kidney impairment at 15 weeks and eventually developed ESRD 
around 25 weeks. On the contrary, Lama5E884G/E884G congenic C57BL/6J mice developed 
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mild proteinuria at 15 weeks and severe proteinuria at 25 weeks, but this was not 
associated with impaired kidney function. The difference in disease progression is more 
than likely attributable to the different strain backgrounds of the lines. It is well reported 
that C57BL/6J is a protective strain for the development of fibrosis [233] and this greatly 
influences the progression of kidney diseases and hypertension. The percentage of 
C57BL/6J component in the different lines varies from 18.75% in the C3pde-Lama5 line, 
to 62.5% in the original MPC-205 pedigree, and 100% in the congenic B6-Lama5 line. 
The progression of the nephrotic phenotype was increasingly more severe in presence 
of the lower percentage of C57BL/6J.  
The effect of different strains influences the onset and progression also of Alport 
syndrome, another GBM disease. The cause of Alport syndrome is mutations in the 
genes coding for the α3α4α5 collagen type IV network. In C57BL/6J mice, the 
upregulation of Col4a6 and the expression of the α5α5α6 network has been identified 
as a possible mechanism to compensate the loss of the α3α4α5 network ameliorating 
disease in models of autosomal recessive Alport syndrome [235]. However, in a more 
recent study the role of the α5α5α6 as compensatory role has been disproved 
suggesting the existence of other genes that act as modifiers [282]. In an attempt to 
determine possible modifiers, Andrews et al. used age at ESRD as a quantitative trait to 
map the modifier as a quantitative trait loci (QTL), identifying possible markers on 
chromosomes 9 and 16  [283]. Unfortunately, no follow up studies have been carried out 
to confirm or disprove the presence of a modifier in these two chromosomes.  
The reason why C57BL/6J are less susceptible to the development of proteinuria, 
glomerulosclerosis and hypertension is not clear yet. The activation of the renin-
angiotensin-aldosterone system (RAAS) is an important factor in the onset of CKD. Mice 
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are polymorphic for the number of renin genes, some murine strains such as C57BL/6J, 
only have one gene (Ren-1), while other strains more susceptible to develop renal 
phenotypes such as 129SvJ have two genes (Ren-1 and Ren-2) [284, 285]. The presence of 
only one renin gene leads to a decreased activation of the RAAS, slowing down the 
development of CKD, as demonstrated in a study of glomerularsclerosis and 
hypertension induced by deoxycorticosterone acetate salt [234]. However, if the 
difference in the number of renin genes can be a factor in C57BL/6J vs 129SvJ 
comparison, it should not influence the development of CKD on C3H-C3pde6b+mice, 
that have only one gene like C57BL/6J mice [285]. Using a model of albumin overload, 
Ishola et al. observed a strain difference in proteinuria and renal inflammatory response 
which were not due to a difference in renal morphology after the BSA treatment, but 
more likely due to differences in glomerular protein permeability [286]. Indeed, protein 
composition and organization of the glomerular ECM varies depending on the genetic 
background. Global proteomics analysis on the glomerular matrisome found that 
proteins such as netrin-4 and fibroblast growth factor 2 were enriched in FVB glomeruli 
(susceptible strain) and proteins such as tenascin C and type I collagen enriched in 
C57BL/6J glomeruli. 
The effect of the susceptible/protective mouse strain disruption of different 
components of the GFB seems to be consistent, independent of whether mutations 
affect the GBM, as in the case of Alport syndrome [235] or laminin-521 [105], or by 
mutations in genes associated with focal adhesion complexes, such as CD151 [157].  
The strain effect on renal phenotypes should be considered when choosing the mouse 
as a model of kidney diseases. C57BL/6 mice are widely used as the background for 
murine models of disease, but kidney phenotypes might be mild and with late onset 
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because of the slow development of renal fibrosis or complete absence. Renal 
phenotypes could be exacerbated by challenging C57BL/6 mice through the 
administration of deoxycorticosterone acetate/high-salt treatments [236] or by unilateral 
nephrectomy [287]. On the contrary, susceptible murine strains such as 129SvJ develop a 
more aggressive phenotype, making dissection of the disease progression challenging.  
In humans, studies on the epidemiology of CKD revealed a prevalence of disease varies 
by sex, race and age [288]. For example, two risk alleles in APOL1 found in individuals of 
West African descent have been identified as being a modifier that increases the risk of 
developing CKD of 3-5 fold [72]. The identifications of modifiers in murine models of renal 
diseases and their possible translation to patients could be a useful tool to identify new 
risk alleles deleterious to human health. 
More in-depth histological and ultrastructural studies on B6-Lama5E884G/E884G revealed 
the absence of lesions by light microscopy. On electron microscopy, both TEM and SEM, 
foot process effacement was visible at 25 weeks but not at 15 weeks, the time of 
proteinuria onset. Given these findings and based on histopathological criteria of 
classification of nephrotic syndrome, B6-Lama5E884G/E884 seem to develop MCD since 
they showed normal-appearing glomeruli on light microscopy but foot process fusion on 
electron microscopy. Severe proteinuria is the cornerstone symptom of nephrotic 
syndrome and it is usually the first manifestation of disease and triggers most of the 
other nephrotic symptoms such as hypoalbuminaemia, oedema and 
hypercholesterolaemia.  
In vitro studies have shown the toxic effect of albumin on both podocytes, inducing 
inflammatory response [289], and tubular cells, with upregulation of TGF-β1 and inducing 
ER stress [290, 291]. The effect of albumin overload is reproducible in vivo, where it causes 
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foot process effacement, upregulation of TGF-β1 and COX-2, and reorganization of the 
actin cytoskeleton [292-295]. In a model of Alport syndrome, the lack of circulating albumin 
(obtained by generating a Col4a3 and albumin -Alb- double knockout) dramatically 
improved lifespan of Col4a3-/- mice, that developed elevated urea just around one year 
of age [296]. Mice lacking Lamb2, used as model of Pierson syndrome, develop proteinuria 
before any sign of foot process effacement [85]. B6-Lama5E884G/E884G mice exhibit the 
same phenotype showing proteinuria at 15 weeks but maintaining a normal glomerular 
ultrastructure until 25 weeks of age. This result suggests a much more active role of the 
GBM in preventing the passage of albumin through the GFB to the pre-urine. How the 
GBM plays a role in the filtration of plasma is still unclear. A popular hypothesis is that 
the deposition of ectopic laminins such as LAMA1, LAMA2 and LAMB1 leads to a change 
of the usual gel properties and porosity of the GBM [85]. Accumulation of ectopic laminins 
indeed occurs not only in the case of LAMB2-related disease, but also in Alport 
syndrome, where deposition of the laminin α2 chain in GBM causes an increased 
phosphorylation of FAK [194]. However, B6-Lama5E884G/E884G samples did not show 
increased abundance or staining of ectopic laminins suggesting that the filtration role of 
the GBM does not depend solely on the aberrant presence of constituent proteins. 
Nonetheless, proteinuria is unlikely to be the only cause of podocyte effacement. The 
absence of albumin in Col4a3-Alb double knock out mice did not completely rescue the 
phenotype, and there is evidence that podocyte morphology can be maintained in the 
presence of proteinuria [296, 297]. How much proteinuria affects podocyte health is a 
causality dilemma very hard to solve. Unfortunately, due to time constrictions, it was 
not possible to age the B6-Lama5E884G/E884G mice long enough to establish the possible 
onset of kidney impairment, or if these mice would not show any signs of reduced GFR 
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at all. However, they could prove a very useful tool to study the effect of proteinuria on 
podocyte health and physiology. 
With the aim to dissect the possible pathways and mechanisms of diseases, molecular 
studies have been performed on both C3pde-Lama5E884G and B6-Lama5E884G mouse 
lines. The ultimate role of laminin α5 is to maintain and stabilise the F-actin bundles that 
make up the cytoskeleton of the foot processes, providing scaffolding and signalling to 
the podocytes. Laminin α5 regulates actin cytoskeleton through two pathways: integrin, 
mainly α3β1, signalling pathway and agrin-utrophin pathway. Integrin α3β1 is the main 
receptor of the laminin α5 chain, its activation leads to clustering and a change of 
conformation of the dimer, and the recruitment of proteins to form focal adhesion 
complexes. The podocyte-specific knockout of integrin α3 or β1 results in proteinuria in 
mice [146]. In addition, reduced activation of integrin β1, but not reduction of total 
integrin β1 protein,  has been reported after lipopolysaccharide-induced podocytopathy 
and overexpression of B7-1 (also known as CD80) induction of which is associated with 
nephrotic syndrome by preventing the binding of talin with integrin β1 [298, 299]. 
Agrin binds laminin-521 coiled coil[245] and together they interact with α and β 
dystroglycans stabilising the actin cytoskeleton via utrophin [300, 301]. Although the 
importance of this pathways in podocytes has not been a focus of studies yet, it is very 
well described in muscles in relation to congenital muscular dystrophy resulting from 
mutations in LAMA2 [302]. Interestingly, LAMA2 mutations found in patients affected by 
congenital muscular dystrophy are clustered in the short arm [303], just like the ones 
identified patients affected by LAMB2- and LAMA5-related nephrotic syndrome and the 
one described in this thesis. In fact, both pathways seems to be involved in the 
pathogenesis of the Lama5E884G phenotype.  
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Preliminary study on mixed background mice was performed using gene expression and 
protein expression analysis. Upregulation of mRNA levels of integrin α3 and β1 and 
protein levels of integrin β1 suggested a possible response to Lama5E884G that 
compromises the interface podocyte-GBM via the regulation of focal adhesion 
complexes. This theory was corroborated by the upregulation of genes coding chemical 
mediators of integrin signals, such as ILK and paxillin, however, protein levels remained 
unchanged with the only exclusion of total RhoA.  
Even though preliminary data looked promising, a better approach to study GBM 
composition and possible pathways involved was needed. Analysis of the matrisome on 
ECM fractions extracted from isolated glomeruli was chosen as the best tool to look at 
the ECM composition, and proteomics analysis of cellular fractions was used to look at 
any possible variation in cell response between homozygotes and wild-type controls at 
15 and 25 weeks of age. This methodology allowed the study of scaffolding proteins that 
are otherwise very difficult to approach given the complexity of their structure and their 
limited solubility.  
Matrisome analysis confirmed a reduction in laminin α5 protein abundance at 25 weeks 
of age, backing up the in vitro experiment results. Decreased concentration of laminin 
α5 was not visible with immunofluorescence (possibly due to the position of the epitope 
or because insufficient sensitivity) proving that MS is a much more sensitive and precise 
technique. Reduction of wild-type laminin α5 has previously been investigated by 
Shannon et al. who described a more severe phenotype than the one outlined in this 
thesis [104]. The compound heterozygous animals, used to validate the causative 
mutation in this thesis, displayed a more severe phenotype than the Lama5E884G/E884G 
animals, although milder than the one described by Shannon et al.  In addition, Lama5+/- 
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animals, with a theoretical 50% reduction in protein levels, do not develop any 
phenotypes. Taken together, these results produce an allelic series demonstrating 
various degrees of reduction in LAMA5 and suggests that there may be a threshold level 
for reduced protein levels before renal phenotypes are observed, and below which there 
is a relationship between level of LAMA5 and severity of disease.  
Reduced secretion has been observed in laminin β2-related nephrotic syndrome, in 
particular due to mutations, such as R246Q [89] and C321R [90],  causing mild symptoms 
of the Pierson syndrome-spectrum (i.e. milder nephrotic syndrome and absence of 
extra-renal manifestations). The authors of the in vitro studies on and mouse models of 
Lamb2C321R attributed the nephrotic phenotype to the ER stress resulting from the 
retention of unfolded laminin β2 and did not explore other modifications that could take 
part in disease pathogenesis. Similar to Lamb2C321R, Lama5E884G causes retention of 
unfolded/misfolded laminin α5 that results in activation of the UPR, as demonstrated by 
the increased protein abundance of endoplasmin in 25 weeks old homozygotes detected 
with MS analysis, but the disease mechanism seems to be much more complex than just 
ER stress.  
In addition to the direct effect that unfolded/misfolded laminin α5 has on the activation 
of the UPR and ER stress, there seem to be two possible pathways involved in the 
pathogenesis of Lama5E884G-dependent nephrotic syndrome which result in actin 
cytoskeleton regulation. 
Laminin α5-binding integrin β1 signalling is a well-characterised pathway since through 
the activation of ITGB1 focal adhesion complexes are formed. Upregulation of integrin 
β1 gene and protein was found in both mouse lines under study, but its activation was 
reduced in B6-Lama5E884G/E884G mice. Similar results were seen in a talin 1 knockout 
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model [163] but no difference in talin 1 abundance was detected in this study. Whether 
the reduced activation of integrin β1 depends directly on the mutation or just on the 
reduction of specific substrate, is hard to tell and further investigation would be needed 
to answer these questions. 
Laminin α5 regulates actin cytoskeleton also through the interaction with agrin via 
dystroglycans-utrophin. Indeed, agrin concentration is reduced in 25 weeks old B6-
Lama5E884G/E884G, concomitant with the reduction of laminin α5. As for integrin β1 
activation, it is difficult to attribute the lower protein abundance directly to the effect 
of E884G on the structure of LAMA5, or if it is simply due to less available trimer available 
for agrin to interact with. In conclusion, we can, therefore, hypothesise that the 
mutations affect the actin cytoskeleton regulation through disruption/misregulation of 
both possible pathways. 
Lastly, this study has identified a potential novel role of the protein supervillin in 
maintaining a stable actin cytoskeleton in podocytes. Podocytes extend numerous 
lamellipodia that branch into the primary, secondary and foot processes [304], so the 
redistribution triggered by the overexpression of supervillin seen in vitro could have a 
role in the pathogenesis of foot process effacement [281].  
In summary, this study helped to characterise the effect of a deleterious point mutation 
in a domain with an unknown function of the protein laminin α5. The mutation results 
in a reduction of laminin α5, reduced activation of integrin β1 and reduction of agrin, as 
well as upregulation of supervillin, a possible novel protein involved in podocyte 
pathophysiology. Phenotypically, homozygous mice for the E884G mutation showed 
nephrotic syndrome, onset and progression of which was greatly modified by the 
genetic background of the lines under investigation. 
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6.1.1 Implications for the Field of Renal Research 
Recent identification of mutations in LAMA5 in paediatric patients affected by nephrotic 
syndrome indicated that this gene is indeed important in human health and it should be 
screened as a candidate in case of nephrotic patients with no other diagnosis. 
Two of the three families understudy carried mutations in the laminin α5 short arm, one 
of which resulted in the change of a glutamic acid into a glycine in the L4a domain. 
Although it is not in the exact same position, the mutation identified in the Harwell 
Ageing Screen it is the first murine model of a point mutation in laminin α5. It could 
serve as a useful tool to dissect disease mechanisms and could be a good line to test 
new treatments to alleviate symptoms.  
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6.2 Future Directions 
Even if this study gives an insight into the effect of the mutation on the laminin α5 
protein, the work completed so far raises many questions, which could not be answered 
given time and technical limitations.  
Firstly, I demonstrated that the E884G mutation affects laminin α5 secretion but it is not 
clear whether the phenotype results from the overall reduction of LAMA5 in the GBM 
or if it is due to the direct effect of the mutation on cell binding or cell signalling.  
Secondly, different approaches could be used to try to rescue the phenotype possibly to 
eventuality identify treatments that could be applicable to humans. 
 
6.2.1  The effect of Lama5E884G on the Actin Cytoskeleton 
The ECM is not just an agglomeration of scaffold proteins that support cells, it is instead 
an active component of the GFB involved in pathway signalling.  
The laminin α5 chain regulates the actin cytoskeleton of the podocyte foot processes 
through the integrin α3β1 pathway or the agrin-dystroglycan pathway. The study of 
actin cytoskeleton in tissues is very challenging, so I suggest two approaches, in vitro and 
ex vivo, to study the effect of the E884G mutation. The ultimate aim of the experiments 
would be to assess the shape and distribution of F-actin bundles and shape/distribution 
of focal adhesion complexes in a similar fashion to the study of Tian et al. on talin 1 [163].  
Both approaches would require the use of cultured podocytes, which are a notoriously 
hard to culture cell line. Human [305] and murine [306] immortalised cell lines are available, 
and widely used, and should provide consistency for technical and biological replicates. 
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Moreover, the use of exclusively wild-type cells would eliminate the ER stress factor 
resulting from the retention of unsecreted LAMA5, so any eventual result would be 
depending solely on the effect of the E884G mutation on signalling. 
In vivo approach. Even in presence of the E884G mutation, LAMA5 is still secreted in 
vivo, although to a severely reduced extent. The protein could therefore be purified and 
adhesion assays and assessment of the actin cytoskeleton performed by growing 
podocytes on recombinant LAMA5-coated coverslips.  
Since to be secreted laminin α5 has to be part of a trimer, a cell line expressing a β and 
γ chain is necessary. HEK293 cells stably transfected with laminins are a popular option 
and have already been used in this project. Another option would be the use of cells that 
produce their own ECM such as the PFHR-9 cell line, an epithelial adherent line isolated 
from mouse embryonal carcinoma [307], and already used to study another component 
of the GBM, collagen type IV [308, 309]. PFHR-9 cells are not easy to transfect, so the 
CRISPR-Cas9 gene editing technology could be used to induce the E884G to create a cell 
line stably expressing mutated laminin α5.  
Even though in vitro production of recombinant proteins does not include the 
complexity of the components of the GBM, especially after the modifications occurring 
during disease, this approach is relatively quick and could be used to screen different 
mutations found in patients in both LAMA5 and LAMB2. Moreover, the coverslips could 
be coated with the same concentration of wild-type and mutant laminin α5, in this way 
I could distinguish between the effect of the mutation and the reduced expression of 
LAMA5. If the actin cytoskeleton and/or the focal adhesion complexes looked variated, 
the phenotype could be ascribed to the direct effect of E884G. 
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Ex vivo approach. Multiples studies have demonstrated the possibility of using ECM from 
organs as a scaffold for downstream applications. Methods of decellularization have 
been described using organs from animals and humans, and with regards to renal 
diseases, kidneys have been used to create ECM scaffold to study Alport syndrome or to 
find new approaches for renal transplant [310-312]. Following published protocols [312], it is 
possible to decellularise and isolate glomeruli. Podocytes can then be seeded on the 
glomeruli, which work as a new scaffold since they maintain the same intricate 
architecture of macromolecules [313].  
This approach would be more laborious and animals carrying the E884G mutation would 
be required. However, the podocyte response would be a better representation of what 
happens in vivo with the benefit of allowing study of the actin cytoskeleton more easily. 
Other interesting measurements, such as time of colonization of the scaffold glomeruli 
and cell binding and proteomics analysis, could also help to elucidate the direct effect 
that this point mutation has on podocytes.  
 
6.2.2  Rescue of the Phenotype  
Considering that the effect of the ENU-induced E884G mutation on the laminin α5 
structure leads to a defect in secretion, probably resulting in protein misfolding, a way 
to facilitate LAMA5 release from the cell could be a target to ameliorate disease. 
Chemical chaperones, in particular tauroursodeoxycholic acid (TUDCA), have been used 
in vitro and in vivo to rescue defective trafficking of potentially functional proteins. 
TUDCA treatment has been successfully used in nephrogenic diabetes insipidus [314], 
Fabry’s disease [315], cystic fibrosis [316], and proved to protect the kidney in a model of 
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ischaemia/reperfusion-induced acute kidney injury [317]. The use of TUDCA also 
enhanced the secretion of LAMB2C321R in vitro [90].  
Consequently, the treatment of Lama5E884G/E884G mice with TUDCA could be a good trial 
to attempt rescue of the nephrotic phenotype or at least delay the disease onset. 
It remains unclear whether the phenotype is the direct result of the E884G mutation on 
the function of the L4a domain, or a result of decreased deposition of laminin α5 in the 
GBM. It may be possible to determine which of these is the cause of the phenotype by 
transgenically overexpressing LAMA5E884G in podocytes. This would be done by 
pronuclear injection of a vector containing the laminin α5 gene under the control of the 
podocin promoter (Nphs2), resulting in podocyte specific overexpression of LAMA5E884G. 
Theoretically this method would restore laminin α5 protein in the GBM to levels 
comparable to, or greater than, wild-type animals. If the phenotype is a result of reduced 
laminin α5 protein levels in the GBM, this approach should rescue it. However, if the 
phenotype is a direct result of the E884G mutation on the function of the L4a domain, 
overexpression of LAMA5 is unlikely to significantly alter the development of disease. A 
considerable caveat to this is that it does not take into account the effect of the 
misfolded protein on the ER. If the overexpressed protein is unable to be secreted from 
the podocytes it may lead to a more severe phenotype due to ER stress.  
 
6.2.3  Murine Models of LAMA5 Mutations Found in Patients 
The use of CRISPR-Cas9 technology based on the adaptive immune system that 
prokaryotic cells use against plasmids and phage, has recently revolutionised gene-
editing techniques [318]. This technique uses RNA-guides and the Cas9, an RNA-guided 
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DNA endonuclease to edit DNA target sequence complementary to the RNA-guides and 
recognised by a nucleotide motif (PAM – protospacer adjacent motif) downstream of 
the target sequence [319]. The gene editing so described can be used on cells for in vitro 
studies, or to create animal models injecting the RNA guides and Cas9 in embryos [320, 
321]. 
CRISPR-Cas9 technology can be used to generate animals carrying disease-causing point 
mutation, it could be then used to create murine models of the mutations recently 
identified in laminin α5 [118]. The study of different mutations could help to confirm the 
pathogenicity of the mutations as cause of the nephrotic syndrome. Models of different 
mutations can also help elucidate the role of laminin α5 and the function of 
uncharacterised domains in kidney diseases, especially of L4a domain that carries the 
mutation described in this thesis and one of the disease-causing mutation described by 
Braun et al. 
 
6.3 Concluding Remarks 
Using the combination of ENU-mutagenesis and extensive phenotyping pipeline across 
18 months, I have been able to identify the first point mutation (E884G) in the gene 
Lama5 encoding laminin α5, a major and vital component of the GBM. The mutation 
results in nephrotic syndrome and is the first model of Lama5-related dysfunction where 
the animals survive to adulthood.  
The data I have generated leads me to suggest that defect in protein folding and 
secretion resulting from the mutation described leads to disease not just triggering ER 
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stress and UPR, but also influencing the regulation of the actin cytoskeleton via 
downregulation of agrin and reduced activation of integrin β1.  
In conclusion, Lama5E884G represents not only a novel mouse model of LAMA5 related 
nephrotic syndrome, recently identified also in paediatric patients, but could also work 
as a tool to investigate the role of the entire laminin-521 network, as mutations in 
LAMB2 lead to Pierson Syndrome and congenital nephrotic syndrome. 
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8. Appendix 
8.1  Antibody List 
8.1.1 Primary Antibodies 
 
WB: Western blot, IF: immunofluorescence. 
 
8.1.2 Secondary Antibodies 
 
WB: Western blot, IF: immunofluorescence. 
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8.2 Gene list 
Gene Name Description 
Arfrp1 ADP-ribosylation factor related protein 1  
Zgpat zinc finger, CCCH-type with G patch domain  
Lime1 Lck interacting transmembrane adaptor 1  
Zbtb46 zinc finger and BTB domain containing 46  
Abhd16b abhydrolase domain containing 16B  
Tpd52l2 tumor protein D52-like 2  
Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5  
Uckl1 uridine-cytidine kinase 1-like 1  
Znf512b zinc finger protein 512B  
Prpf6 PRP6 pre-mRNA splicing factor 6 homolog (yeast)  
Bhlhe23 basic helix-loop-helix family, member e23  
Ythdf1 YTH domain family 1  
Birc7 baculoviral IAP repeat-containing 7 (livin)  
Nkain4 Na+/K+ transporting ATPase interacting 4  
Arfgap1 ADP-ribosylation factor GTPase activating protein 1  
9230112E08Rik RIKEN cDNA 9230112E08 gene  
Col20a1 collagen, type XX, alpha 1  
Chrna4 cholinergic receptor, nicotinic, alpha polypeptide 4  
Kcnq2 potassium voltage-gated channel, subfamily Q, member 
2  
Eef1a2 eukaryotic translation elongation factor 1 alpha 2  
Ppdpf pancreatic progenitor cell differentiation and proliferation 
factor homolog (zebrafish)  
Ptk6 PTK6 protein tyrosine kinase 6  
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Srms src-related kinase lacking C-terminal regulatory tyrosine 
and N-terminal myristylation sites  
BC051628 cDNA sequence BC051628  
Helz2 helicase with zinc finger 2, transcriptional coactivator  
Gmeb2 glucocorticoid modulatory element binding protein 2  
Stmn3 stathmin-like 3  
Rtel1 regulator of telomere elongation helicase 1  
Adrm1 adhesion regulating molecule 1  
Lama5 laminin, alpha 5  
Rps21 ribosomal protein S21  
Cables2 CDK5 and Abl enzyme substrate 2  
Rbbp8nl RBBP8 N-terminal like  
Gata5 GATA binding protein 5  
Slco4a1 solute carrier organic anion transporter family, member 
4a1  
Ntsr1 neurotensin receptor 1  
Mrgbp MRG/MORF4L binding protein  
Ogfr opioid growth factor receptor  
Col9a3 collagen, type IX, alpha 3  
Tcfl5 transcription factor-like 5 (basic helix-loop-helix)  
Dido1 death inducer-obliterator 1  
Gid8 GID complex subunit 8 homolog (S. cerevisiae)  
Slc17a9 solute carrier family 17, member 9  
Osbpl2 oxysterol binding protein-like 2  
Hrh3 histamine receptor H3  
Gtpbp5 GTP binding protein 5  
Ss18l1 synovial sarcoma translocation gene on chromosome 18-
like 1  
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Psma7 proteasome (prosome, macropain) subunit, alpha type 7  
Lsm14b LSM14 homolog B (SCD6, S. cerevisiae)  
Taf4a TAF4A RNA polymerase II, TATA box binding protein 
(TBP)-associated factor  
Gm10711 predicted gene 10711  
Gm14403 predicted gene 14403  
Gm14406 predicted gene 14406  
Gm14322 predicted gene 14322  
Gm14325 predicted gene 14325  
Gm14327 predicted gene 14327  
C330013J21Rik RIKEN cDNA C330013J21 gene  
Gm14326 predicted gene 14326  
Etohi1 ethanol induced 1  
Zfp931 zinc finger protein 931  
Phactr3 phosphatase and actin regulator 3  
Sycp2 synaptonemal complex protein 2  
Ppp1r3d protein phosphatase 1, regulatory subunit 3D  
Fam217b family with sequence similarity 217, member B  
Cdh26 cadherin-like 26  
Cdh4 cadherin 4  
Gm14420 predicted gene 14420  
Gm14418 predicted gene 14418  
Gm14412 predicted gene 14412  
Gm14409 predicted gene 14409  
Gm20721 predicted gene, 20721  
Nelfcd negative elongation factor complex member C/D, Th1l  
Ctsz cathepsin Z  
Tubb1 tubulin, beta 1 class VI  
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Atp5e ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit  
Slmo2 slowmo homolog 2 (Drosophila)  
Zfp831 zinc finger protein 831  
Edn3 endothelin 3  
Gm14444 predicted gene 14444  
Gm14393 predicted gene 14393  
Gm14399 predicted gene 14399  
Gm14443 predicted gene 14443  
Gm14391 predicted gene 14391  
Gm14440 predicted gene 14440  
Gm4631 predicted gene 4631  
Gm4723 predicted gene 4723  
Gm4724 predicted gene 4724  
Gm8923 predicted gene 8923  
Gm11007 predicted gene 11007  
Gm4245 predicted gene 4245  
Gm2007 predicted gene 2007  
Gm14288 predicted gene 14288  
Gm6710 predicted gene 6710  
Gm8898 predicted gene 8898  
Gm2026 predicted gene 2026  
Gm2004 predicted gene 2004  
2210418O10Rik RIKEN cDNA 2210418O10 gene  
Gm11009 predicted gene 11009  
Gm14435 predicted gene 14435  
Gm14434 predicted gene 14434  
Gm14431 predicted gene 14431  
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Gm14308 predicted gene 14308  
Gm14306 predicted gene 14306  
Gm14305 predicted gene 14305  
Gm14295 predicted gene 14295  
Gm14408 predicted gene 14408  
Gm14296 predicted gene 14296  
Gm14419 predicted gene 14419  
Gm14401 predicted gene 14401  
Gm14410 predicted gene 14410  
Cbln4 cerebellin 4 precursor protein  
Mc3r melanocortin 3 receptor  
Fam210b family with sequence similarity 210, member B  
Aurka aurora kinase A  
Cstf1 cleavage stimulation factor, 3' pre-RNA, subunit 1  
Cass4 Cas scaffolding protein family member 4  
Rtfdc1 replication termination factor 2 domain containing 1  
Gcnt7 glucosaminyl (N-acetyl) transferase family member 7  
Fam209 family with sequence similarity 209  
Tfap2c transcription factor AP-2, gamma  
Bmp7 bone morphogenetic protein 7  
Spo11 SPO11 meiotic protein covalently bound to DSB homolog 
(S. cerevisiae)  
Rae1 RAE1 RNA export 1 homolog (S. pombe)  
Rbm38 RNA binding motif protein 38  
Ctcfl CCCTC-binding factor (zinc finger protein)-like  
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic  
Zbp1 Z-DNA binding protein 1  
Pmepa1 prostate transmembrane protein, androgen induced 1  
182 
 
1700021F07Rik RIKEN cDNA 1700021F07 gene  
Ankrd60 ankyrin repeat domain 60  
Rab22a RAB22A, member RAS oncogene family  
1700010B08Rik RIKEN cDNA 1700010B08 gene  
Vapb vesicle-associated membrane protein, associated protein 
B and C  
Stx16 syntaxin 16  
Npepl1 aminopeptidase-like 1  
Gnas GNAS (guanine nucleotide binding protein, alpha 
stimulating) complex locus  
Samd10 sterile alpha motif domain containing 10  
Gm22502 predicted gene, 22502  
Mir298 microRNA 298  
Sox18 SRY-box containing gene 18  
Mir124a-3 microRNA 124a-3  
Tcea2 transcription elongation factor A (SII), 2  
Gm25184 predicted gene, 25184  
Mir1a-1 microRNA 1a-1  
BX284639.1 
 
Gm25879 predicted gene, 25879  
Gm22842 predicted gene, 22842  
Rgs19 regulator of G-protein signaling 19  
Mir133a-2 microRNA 133a-2  
4930526D03Rik RIKEN cDNA 4930526D03 gene  
Oprl1 opioid receptor-like 1  
Myt1 myelin transcription factor 1  
Pcmtd2 protein-L-isoaspartate (D-aspartate) O-methyltransferase 
domain containing 2  
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Polr3k polymerase (RNA) III (DNA directed) polypeptide K  
Gm14496 predicted gene 14496  
1700028P15Rik RIKEN cDNA 1700028P15 gene  
Gm14272 predicted gene 14272  
Gm14641 predicted gene 14641  
Gm14271 predicted gene 14271  
Gm14274 predicted gene 14274  
Gm14275 predicted gene 14275  
Gm14273 predicted gene 14273  
Gm14455 predicted gene 14455  
Gm14303 predicted gene 14303  
Gm20490 predicted gene 20490  
Gm14453 predicted gene 14453  
1300015D01Rik RIKEN cDNA 1300015D01 gene  
Gm14454 predicted gene 14454  
Gm14642 predicted gene 14642  
Ppp4r1l-ps protein phosphatase 4, regulatory subunit 1-like, 
pseudogene  
Gm14371 predicted gene 14371  
Gm14336 predicted gene 14336  
Gm14337 predicted gene 14337  
Vamp7-ps vesicle-associated membrane protein 7, pseudogene  
Gm10714 predicted gene 10714  
Nespas neuroendocrine secretory protein antisense  
Rpl30-ps5 ribosomal protein L30, pseudogene 5  
Gm14385 predicted gene 14385  
Vmn1r-ps1 vomeronasal 1 receptor, pseudogene 1  
Gm14617 predicted gene 14617  
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Gm14618 predicted gene 14618  
Gm14616 predicted gene 14616  
Gm16354 predicted gene 16354  
Gm14445 predicted gene 14445  
Gm14439 predicted gene 14439  
Gm14387 predicted gene 14387  
Gm14392 predicted gene 14392  
Gm16355 predicted gene 16355  
Gm14442 predicted gene 14442  
Gm14438 predicted gene 14438  
Gm14298 predicted gene 14298  
Gm14297 predicted gene 14297  
Gm16359 predicted gene 16359  
Gm16358 predicted gene 16358  
Rps8-ps2 ribosomal protein S8, pseudogene 2  
Gm2020 predicted gene 2020  
Gm16356 predicted gene 16356  
Gm11008 predicted gene 11008  
Gm16357 predicted gene 16357  
Gm6182 predicted gene 6182  
Gm17258 predicted gene, 17258  
Gm1980 predicted gene 1980  
Gm16362 predicted gene 16362  
Gm14307 predicted gene 14307  
Gm14301 predicted gene 14301  
Gm14390 predicted gene 14390  
Gm14405 predicted gene 14405  
Gm14296 predicted gene 14296  
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Gm14417 predicted gene 14417  
Gm14402 predicted gene 14402  
Gm14421 predicted gene 14421  
Gm14407 predicted gene 14407  
Gm14415 predicted gene 14415  
Gm14411 predicted gene 14411  
Gm14416 predicted gene 14416  
Gm14413 predicted gene 14413  
Gm14400 predicted gene 14400  
Gm14404 predicted gene 14404  
Gm14414 predicted gene 14414  
Gm16363 predicted gene 16363  
Gm14324 predicted gene 14324  
Gm14429 predicted gene 14429  
Gm14323 predicted gene 14323  
Gm14428 predicted gene 14428  
Gm14314 predicted gene 14314  
Gm14292 predicted gene 14292  
Gm14293 predicted gene 14293  
Gm14294 predicted gene 14294  
4930591A17Rik RIKEN cDNA 4930591A17 gene  
Gm14300 predicted gene 14300  
4921531C22Rik RIKEN cDNA 4921531C22 gene  
Gm14299 predicted gene 14299  
Gm17180 predicted gene 17180  
Gm14318 predicted gene 14318  
B230312C02Rik RIKEN cDNA B230312C02 gene  
Gm14343 predicted gene 14343  
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Gm14340 predicted gene 14340  
Gm14342 predicted gene 14342  
Gm14344 predicted gene 14344  
Gm14339 predicted gene 14339  
RP23-
359C15.10 
 
Gm14341 predicted gene 14341  
Gm14398 predicted gene 14398  
Gm7645 predicted gene 7645  
Slc2a4rg-ps Slc2a4 regulator, pseudogene  
Gm16119 predicted gene 16119  
Gm14489 predicted gene 14489  
Gm5466 predicted gene 5466  
Gm22773 predicted gene, 22773  
Gm24892 predicted gene, 24892  
Mir3091 microRNA 3091  
Mir296 microRNA 296  
Gm22708 predicted gene, 22708  
Gm22071 predicted gene, 22071  
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8.2  Gene homology 
8.2.1  Laminin β1 chain alignment  
 
 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXMGL L QXXAF XXL AL XXXRVXAQEPEF SYGCAEMajority
10 20 30 40 50 60 70 80
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - MGL L QL L AF SF L AL CRARVRAQEPEF SYGCAE 32H.sapiens
MEGPL SSL PT F AF SPRYL SRKEDPKKRQAACL L RPPSRAASPRL RGL DMGL L QVF AF GVL AL WGT RVCAQEPEF SYGCAE 80M.musculus
GSCYPAT GDL L I GRAQKL SVT ST CGL HKPEPYCI VSHL QEDKKCF I CXSXDPYHET L NPDSHL I ENVVT T F APNRL KI WWMajority
90 100 110 120 130 140 150 160
GSCYPAT GDL L I GRAQKL SVT ST CGL HKPEPYCI VSHL QEDKKCF I CNSQDPYHET L NPDSHL I ENVVT T F APNRL KI WW 112H.sapiens
GSCYPAT GDL L I GRAQKL SVT ST CGL HKPEPYCI VSHL QEDKKCF I CDSRDPYHET L NPDSHL I ENVVT T F APNRL KI WW 160M.musculus
QSENGVENVT I QL DL EAEF HF T HL I MT F KT F RPAAML I ERSSDF GKXWGVYRYF AYDCEXSF PGI ST GPMKKVDDI I CDSMajority
170 180 190 200 210 220 230 240
QSENGVENVT I QL DL EAEF HF T HL I MT F KT F RPAAML I ERSSDF GKT WGVYRYF AYDCEASF PGI ST GPMKKVDDI I CDS 192H.sapiens
QSENGVENVT I QL DL EAEF HF T HL I MT F KT F RPAAML I ERSSDF GKAWGVYRYF AYDCESSF PGI ST GPMKKVDDI I CDS 240M.musculus
RYSDI EPST EGEVI F RAL DPAF KI EDPYSPRI QNL L KI T NL RI KF VKL HT L GDNL L DSRMEI REKYYYAVYDMVVRGNCFMajority
250 260 270 280 290 300 310 320
RYSDI EPST EGEVI F RAL DPAF KI EDPYSPRI QNL L KI T NL RI KF VKL HT L GDNL L DSRMEI REKYYYAVYDMVVRGNCF  272H.sapiens
RYSDI EPST EGEVI F RAL DPAF KI EDPYSPRI QNL L KI T NL RI KF VKL HT L GDNL L DSRMEI REKYYYAVYDMVVRGNCF  320M.musculus
CYGHASECAPVDGXNEEVEGMVHGHCMCRHNT KGL NCEL CMDF YHDL PWRPAEGRNSNACKKCNCNEHSXSCHF DMAVXLMajority
330 340 350 360 370 380 390 400
CYGHASECAPVDGF NEEVEGMVHGHCMCRHNT KGL NCEL CMDF YHDL PWRPAEGRNSNACKKCNCNEHSI SCHF DMAVYL  352H.sapiens
CYGHASECAPVDGVNEEVEGMVHGHCMCRHNT KGL NCEL CMDF YHDL PWRPAEGRNSNACKKCNCNEHSSSCHF DMAVF L  400M.musculus
AT GNVSGGVCDXCQHNT MGRNCEQCKPF YXQHPERDI RDPNXCEXCT CDPAGSXNXGI CDXYT DF SXGL I AGQCRCKL XVMajority
410 420 430 440 450 460 470 480
AT GNVSGGVCDDCQHNT MGRNCEQCKPF YYQHPERDI RDPNF CERCT CDPAGSQNEGI CDSYT DF ST GL I AGQCRCKL NV 432H.sapiens
AT GNVSGGVCDNCQHNT MGRNCEQCKPF YF QHPERDI RDPNL CEPCT CDPAGSENGGI CDGYT DF SVGL I AGQCRCKL HV 480M.musculus
EGEXCDVCKEGF YDL SXEDPXGCKSCACNPL GT I PGGNPCDSET GXCYCKRL VT GQXCDQCL PXHWGL SNDL DGCRPCDCMajority
490 500 510 520 530 540 550 560
EGEHCDVCKEGF YDL SSEDPF GCKSCACNPL GT I PGGNPCDSET GHCYCKRL VT GQHCDQCL PEHWGL SNDL DGCRPCDC 512H.sapiens
EGERCDVCKEGF YDL SAEDPYGCKSCACNPL GT I PGGNPCDSET GYCYCKRL VT GQRCDQCL PQHWGL SNDL DGCRPCDC 560M.musculus
DL GGAL NNSCXXXSGQCSCXPHMI GRQCNEVEXGYYF XT L DHYXYEAEEANL GPGVXXVERQYI QDRI PSWT GXGF VRVPMajority
570 580 590 600 610 620 630 640
DL GGAL NNSCF AESGQCSCRPHMI GRQCNEVEPGYYF AT L DHYL YEAEEANL GPGVSI VERQYI QDRI PSWT GAGF VRVP 592H.sapiens
DL GGAL NNSCSEDSGQCSCL PHMI GRQCNEVESGYYF T T L DHYI YEAEEANL GPGVI VVERQYI QDRI PSWT GPGF VRVP 640M.musculus
EGAYL EF F I DNI PYSMEYXI L I RYEPQL PDHWEKAVI T VQRPGXI PXSSRCGNT XPDDDNQVVSL SPGSRYVVL PRPVCFMajority
650 660 670 680 690 700 710 720
EGAYL EF F I DNI PYSMEYDI L I RYEPQL PDHWEKAVI T VQRPGRI PT SSRCGNT I PDDDNQVVSL SPGSRYVVL PRPVCF  672H.sapiens
EGAYL EF F I DNI PYSMEYEI L I RYEPQL PDHWEKAVI T VQRPGKI PASSRCGNT VPDDDNQVVSL SPGSRYVVL PRPVCF  720M.musculus
EKGXNYT VRL EL PQYT XSXSDVESPYT XI DSL VL MPYCKSL DI F T VGGSGDGXVT NSAWET F QRYRCL ENSRSVVKT PMTMajority
730 740 750 760 770 780 790 800
EKGT NYT VRL EL PQYT SSDSDVESPYT L I DSL VL MPYCKSL DI F T VGGSGDGVVT NSAWET F QRYRCL ENSRSVVKT PMT  752H.sapiens
EKGMNYT VRL EL PQYT ASGSDVESPYT F I DSL VL MPYCKSL DI F T VGGSGDGEVT NSAWET F QRYRCL ENSRSVVKT PMT  800M.musculus
DVCRNI I F SI SAL XHQT GL ACECDPQGSL SSVCDPNGGQCQCRPNVVGRT CNRCAPGT F GF GPXGCKPCXCHL QGSXXAFMajority
810 820 830 840 850 860 870 880
DVCRNI I F SI SAL L HQT GL ACECDPQGSL SSVCDPNGGQCQCRPNVVGRT CNRCAPGT F GF GPSGCKPCECHL QGSVNAF  832H.sapiens
DVCRNI I F SI SAL I HQT GL ACECDPQGSL SSVCDPNGGQCQCRPNVVGRT CNRCAPGT F GF GPNGCKPCDCHL QGSASAF  880M.musculus
CXXXT GQCHCF QGXYARQCDRCL PGXWGF PSCQPCQCNGHAXDCDXVT GECL XCQDYT XGHNCERCL AGYYGDPI I GSGDMajority
890 900 910 920 930 940 950 960
CNPVT GQCHCF QGVYARQCDRCL PGHWGF PSCQPCQCNGHADDCDPVT GECL NCQDYT MGHNCERCL AGYYGDPI I GSGD 912H.sapiens
CDAI T GQCHCF QGI YARQCDRCL PGYWGF PSCQPCQCNGHAL DCDT VT GECL SCQDYT T GHNCERCL AGYYGDPI I GSGD 960M.musculus
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T GQHCERCEXNHF GF GPEGCKPCDCHXEGSL SL QCKXDGRCECREGF VGNRCDQCEENYF YNRSWPGCQECPACYRL VKDMajority
970 980 990 1000 1010 1020 1030 1040
T GQHCERCEVNHF GF GPEGCKPCDCHPEGSL SL QCKDDGRCECREGF VGNRCDQCEENYF YNRSWPGCQECPACYRL VKD 1040H.sapiens
T GQHCERCET NHF GF GPEGCKPCDCHHEGSL SL QCKEDGRCECREGF VGNRCDQCEENYF YNRSWPGCQECPACYRL VKD 1038M.musculus
KVAXHRVKL QEL ESL I ANL GT GDXMVT DQAF EDRL KEAEREVXDL L REAQXVKDVDQNL MDRL QRVNXXL XSQI SRL QNIMajority
1050 1060 1070 1080 1090 1100 1110 1120
KVADHRVKL QEL ESL I ANL GT GDEMVT DQAF EDRL KEAEREVMDL L REAQDVKDVDQNL MDRL QRVNNT L SSQI SRL QNI  1120H.sapiens
KVAEHRVKL QEL ESL I ANL GT GDDMVT DQAF EDRL KEAEREVT DL L REAQEVKDVDQNL MDRL QRVNSSL HSQI SRL QNI  1118M.musculus
RNT I EET GXL AEXARXXVEXT EXL I EI ASREL EKAKXAAANVSXT QPEST GXPNNMT L L AEEARKL AERHKQEADDI VRVMajority
1130 1140 1150 1160 1170 1180 1190 1200
RNT I EET GNL AEQARAHVENT ERL I EI ASREL EKAKVAAANVSVT QPEST GDPNNMT L L AEEARKL AERHKQEADDI VRV 1200H.sapiens
RNT I EET GI L AERARSRVEST EQL I EI ASREL EKAKMAAANVSI T QPEST GEPNNMT L L AEEARKL AERHKQEADDI VRV 1198M.musculus
AKT ANXT SXEAYNL L L RT L AGENQT AXEI EEL NRKYEQAKNI SQDL EKQAARVHEEAKRAGDKAVEI YASVAQL XPXDSEMajority
1210 1220 1230 1240 1250 1260 1270 1280
AKT ANDT ST EAYNL L L RT L AGENQT AF EI EEL NRKYEQAKNI SQDL EKQAARVHEEAKRAGDKAVEI YASVAQL SPL DSE 1280H.sapiens
AKT ANET SAEAYNL L L RT L AGENQT AL EI EEL NRKYEQAKNI SQDL EKQAARVHEEAKRAGDKAVEI YASVAQL T PVDSE 1278M.musculus
XL ENEANXI KXEAXXL XXL I DQKL KDYEDL REDMRGKEXEVKNL L EKGKXEQQT ADQL L ARADAAKAL AEEAAKKGRXT LMajority
1290 1300 1310 1320 1330 1340 1350 1360
T L ENEANNI KMEAENL EQL I DQKL KDYEDL REDMRGKEL EVKNL L EKGKT EQQT ADQL L ARADAAKAL AEEAAKKGRDT L  1360H.sapiens
AL ENEANKI KKEAADL DRL I DQKL KDYEDL REDMRGKEHEVKNL L EKGKAEQQT ADQL L ARADAAKAL AEEAAKKGRST L  1358M.musculus
QEANDI L NNL KDF DRRVNDNKT AAEEAL RXI PAI NXT I XEANEKT REAQXAL GXAAADAT EAKNKAHEAERI ASAVQKNAMajority
1370 1380 1390 1400 1410 1420 1430 1440
QEANDI L NNL KDF DRRVNDNKT AAEEAL RKI PAI NQT I T EANEKT REAQQAL GSAAADAT EAKNKAHEAERI ASAVQKNA 1440H.sapiens
QEANDI L NNL KDF DRRVNDNKT AAEEAL RRI PAI NRT I AEANEKT REAQL AL GNAAADAT EAKNKAHEAERI ASAVQKNA 1438M.musculus
T ST KAXAERT F XEVT DL DNEVNXML XQL XEAEXEL KXKQDDADQDMMMAGMASQAAQEAEXNARKAKNSVXSL L SXXNXLMajority
1450 1460 1470 1480 1490 1500 1510 1520
T ST KAEAERT F AEVT DL DNEVNNML KQL QEAEKEL KRKQDDADQDMMMAGMASQAAQEAEI NARKAKNSVT SL L SI I NDL  1520H.sapiens
T ST KADAERT F GEVT DL DNEVNGML RQL EEAENEL KKKQDDADQDMMMAGMASQAAQEAEL NARKAKNSVSSL L SQL NNL  1518M.musculus
L XQL GQL DT VDL NKL NEI EGXL NKAKDEMKXSDL DRKVSDL EXEAXKQEAAI MDYNRDI XEI XKDI XNL EDI XKT L PXGCMajority
1530 1540 1550 1560 1570 1580 1590 1600
L EQL GQL DT VDL NKL NEI EGT L NKAKDEMKVSDL DRKVSDL ENEAKKQEAAI MDYNRDI EEI MKDI RNL EDI RKT L PSGC 1600H.sapiens
L DQL GQL DT VDL NKL NEI EGSL NKAKDEMKASDL DRKVSDL ESEARKQEAAI MDYNRDI AEI I KDI HNL EDI KKT L PT GC 1598M.musculus
F NT PSI EKPMajority
F NT PSI EKP                                                                        1609H.sapiens
F NT PSI EKP                                                                        1607M.musculus
